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9General introduction
1GEnEral introDuction
Tumors that originate in the human brain are called primary brain tumors. Distinct 
subtypes are recognized by the World Health Organization (WHO), as distinct types 
of brain tissue or anatomic location can give rise to specific tumors. One of them 
is called glioma, named so as it is hypothesized that this type of tumor arises from 
glial cells (supporting tissue of the brain). Although it is the most common type of 
primary malignant brain tumors in human, it is a rare disease with an incidence rate 
of approximately 6 per 100.000 persons annually in Europe and the United States.1, 2 
Extrapolated to the Dutch situation, this means approximately 1000 persons per year 
in the Netherlands are newly diagnosed with a glioma.
claSSification anD ProGnoSiS of DiffuSE GlioMaS
Diffuse gliomas have a variable prognosis with overall survival rates ranging from only 
several months to more than 20 years, depending on the subtype.3, 4 It is clear that 
very aggressive tumors with an overall survival of only a few months need a different 
treatment strategy than more indolent tumors with an overall survival of multiple 
years. Therefore, classifying gliomas into different subtypes that reflect their clinical 
behavior, prognosis and/or response to treatment is essential.
Gliomas are classified according to the WHO classification of tumors of the central 
nervous system and traditionally this was based on histological features.5 However, 
differences between histological subtypes on microscopic level can be very subtle, and 
therefore this classification was subject to substantial interobserver variability.6-8 This 
potentially results in suboptimal treatment of some patients which is undesirable. The 
WHO classification scheme was updated in 2016 following many observations that 
showed better discrimination of clinically relevant subclasses of glioma by classify-
ing on the molecular background of brain tumors.5 The updated WHO classification 
now consists of both histologic and molecular features and this has led to marked 
improvement of objectivity and prognostic significance. Cornerstone of the WHO 
2016 classification is testing for presence of mutations in isocitrate dehydrogenase 
gene 1 or 2 (IDH1/2) and presence of a combined deletion (co-deletion) of chromo-
somal arms 1p and 19q. Based on just these two markers, three subtypes of diffuse 
lower grade glioma can be recognized; 1) Oligodendroglioma, IDH1/2 mutant and 
1p/19q co-deleted (IDH1/2 mutation in combination with presence of a co-deletion of 
the entire 1p and 19q chromosomal arms); 2) Astrocytoma, IDH1/2 mutated (IDH1/2 
mutation without 1p19q co-deletion); and 3) Astrocytoma, IDH1/2 wildtype. The 
highest grade of glioma, glioblastoma, is separated in IDH1/2 mutated and IDH1/2 
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wildtype (most common form).5, 9 Molecular aberrations described in IDH wildtype 
glioblastoma are generally equal to the aberrations described in IDH wildtype astrocy-
tomas and the outcome is similarly poor (median survival approximately 15 months). 
Hence, low-grade and anaplastic IDH wildtype astrocytomas are often considered 
as misdiagnosed glioblastoma. Oligodendrogliomas and IDH mutated astrocytomas 
have a much better prognosis with a median overall survival of 12-14 years and 3-8 
years respectively. Next to IDH gene mutations and 1p19q co-deletion, there are many 
other frequently reported genetic changes in glioma that are not used for classifica-
tion criteria, but which can support the diagnosis. For example, TP53 and ATRX muta-
tions are frequently reported in IDH mutated astrocytoma. These two mutations are 
mutually exclusive with 1p/19q co-deletions in glioma. CIC and FUBP1 mutations are 
frequently reported in IDH mutant 1p19q co-deleted oligodendroglioma, but almost 
never in IDH mutated or wildtype astrocytoma. TERT promotor mutations are present 
in almost all IDH mutant 1p19q co-deleted oligodendrogliomas and are frequently 
reported in IDH wildtype astrocytoma and glioblastoma, but in principle not in IDH 
mutated astrocytoma.9-12 Also, mutations or amplifications of the EGFR gene are fre-
quently reported, mostly in IDH wildtype glioblastoma. Observation of this aberration 
can support diagnosis, but is not related to prognosis. For a detailed description of the 
WHO 2016 classification scheme, see Figure 1.
Apart from classification of diffuse gliomas into histomolecular subgroups, diffuse 
gliomas are also graded (grade II, III, or IV) to further stratify the aggressiveness of the 
tumors. This is currently still based on the presence of the following histopathological 
features: nuclear atypia, mitotic activity, microvascular proliferation, and necrosis.13 
Unfortunately, grading of glioma is subject to interobserver variability as scoring of 
these histological criteria may be difficult due to tumor heterogeneity, small sample 
volumes, and different interobserver judgement. Therefore, although the updated 
classification outflanks the previous version for prognosis estimation, there is still 
variation in prognosis of patients within the major glioma groups. Further improve-
ment and refinement of the classification would be very welcome, especially with 
markers that reflect aggressiveness/grade within the current WHO subgroups, but so 
far no molecular markers have been identified that aid in objective grading. chapter 2, 
3, and 4 of this thesis focus on the efforts to further refine the WHO classification and 
are described briefly in the last paragraph of this chapter.
GlioMa trEatMEnt
Diffuse gliomas have an infiltrative growth pattern and are often located in or near 
eloquent areas of the brain (i.e. the sensory cortex, motor cortex, basal ganglia, and 
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language/speech area).4 Therefore it is impossible to fully resect a glioma. As our 
knowledge on the molecular background of glioma improves, much research nowa-
days focusses on targeting glioma specifi c mutations and developing glioma specifi c 
immunotherapies. So far this has not led to new standard therapies in daily clinical 
setting. Therefore, the common available modalities for glioma treatment still are (a 
combination of) surgical resection, chemotherapy, and radiotherapy.3, 4, 14-18 How to 
best employ these different treatment modalities remains a matter of controversy. 
In individual patients the combination, timing, and sequence is often decided based 
upon the perception of prognostic factors within a specifi c patient, such as the clinical 
condition, location and size of the tumor, and the integrated WHO 2016 diagnosis 
which is assessed following surgery. The intent of surgery is threefold; to provide 
tissue for diagnostic purposes (histology and molecular testing), to remove as much 
tumor as possible to relieve symptoms and to improve survival. Whether that latter 
objective is actually realistic in low grade glioma has been a topic of debate for years. 
In the past a so called wait-and-scan approach was the common strategy to treat a 
lesion suspected for low-grade glioma.19, 20 This strategy consists of monitoring tumor 
behavior over time with regular interval MRI scans, with the intention to start active 
treatment once signifi cant growth of the lesion, clinical deterioration or malignant 
transformation (signs of contrast enhancement on brain imaging) has occurred. The 
rationale behind this was the incurable nature of these tumors, the low growth rates 
and the fact that patients usually present with minor symptoms, such as controllable 
seizures. Furthermore, the fear for inducing neurological defi cits by a neurosurgical 
procedure withheld many neurosurgeons from aggressive surgical treatment. Per-
forming early surgery on these lesions was therefore generally seen as inappropriate, 
Histology Astrocytoma OligodendrogliomaOligoastrocytoma Glioblastoma Multiforme
IDH status
1p/19q and 
other genetic 
parameters
IDH mutant IDH wild-type IDH mutant IDH wild-type
ATRX loss*
TP53 mutation*
1p/19q co-deletion
Diffuse astrocytoma, IDH mutant 
After exclusion of other entities:
Diffuse astrocytoma, IDH wild-type
oligodendroglioma, NOS 
Glioblastoma, IDH mutant
Glioblastoma, IDH wild-type
Oligodendroglioma, IDH 
mutant and 1p/19q codeleted
Molecular 
subgroups of 
glioma Diffuse astrocytoma, NOS
Oligodendroglioma, NOS
Oligoastrocytoma, NOS
Glioblastoma, NOS
* : Characteristic but not required for diagnosis
NOS: not otherwise specified
Genetic testing not 
done or inconclusive
figure 1. 2016 WHO classifi cation scheme of diffuse glioma. Figure adapted (with permission) from 
Louis et al.5
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as surgery comes with these risks and is not curative. This consensus on treatment of 
low-grade glioma patients gradually changed in the past decade towards a standard 
of care where clinicians aim for aggressive resections as early as possible when this 
is safely possible. This was due to the growing evidence that early and extensive 
resections are associated with a better clinical outcome (longer overall survival) and 
the improvement of surgical techniques that allow more safe and extensive resec-
tions.21-26 However, all studies investigating the role of surgery for low grade glioma 
are retrospective, and are therefore exposed to certain indication and selection bias. 
Nonetheless, as a prospective study to answer this question is generally considered not 
feasible for various reasons, retrospective evidence for early and extensive resections 
is the best option and over time early resection has become part of the international 
guidelines on glioma treatment. Nevertheless, the timing and extent of resection re-
main topics of debate in the field. in chapter 5 and 6 we focus on this still timely topic.
ScoPE of thiS thESiS
This thesis mainly focusses on lower grade diffuse gliomas (grade II and III). Although 
the objectivity and prognostic value of glioma classification have improved with the 
updated WHO classification, further refinement in order to achieve more efficient 
treatment strategies is mandatory. In chapter 2 we analyze the publically available 
whole exome sequencing data of The Cancer Genome Atlas (TCGA) of both low and high 
grade glioma, to find additional prognostic markers within WHO recognized glioma 
subgroups. In chapter 3 we report the prognostic relevance of additional mutations 
and copy number alterations in IDH mutated grade II glioma, using a targeted next 
generation sequencing panel that is also used in routine diagnostic setting. In chapter 
4 we report on a relatively large group of IDH-wildtype gliomas, and show this is in fact 
a molecular and clinical heterogeneous group of tumors. As mentioned above, the role 
of surgery for lower grade gliomas has been controversial in the past. Consensus in the 
field shifted from a wait-and-scan approach to early and aggressive resection during 
the last decade. As the WHO classification of gliomas has been completely revised and 
is now predominantly based on molecular criteria, the impact of extent of resection 
needed to be re-evaluated in molecularly defined low grade glioma which we describe 
in chapter 5. In chapter 6, we focus on the timing of surgery and the impact on out-
come in presumed low-grade glioma, but with a set-up wherein we tried to minimize 
the above mentioned indication and selection bias as much as possible. In chapter 7, 
we provide insight in the location distribution of specific WHO molecular subgroups of 
glioma in the human brain. Finally, chapter 8 discusses the main findings of chapters 2 
to 7 and puts this in perspective with recent literature and opinions in the field.
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abStract
Recent advances in molecular diagnostics allow diffuse gliomas to be classified based 
on their genetic changes into distinct prognostic subtypes. However, a systematic 
analysis of all molecular markers has thus far not been performed; most classifica-
tion schemes use a predefined and select set of genes/molecular markers. Here, we 
have analyzed the TCGA dataset (combined GBM and LGG datasets) to identify all 
prognostic genetic markers in diffuse gliomas in order to generate a comprehensive 
classification scheme. Of the molecular markers investigated (all genes mutated at 
a population frequency >1.7% and frequent chromosomal imbalances) in the entire 
glioma dataset, 57 were significantly associated with overall survival. Of these, IDH1 
or IDH2 mutations are associated with lowest hazard ratio, which confirms IDH as the 
most important prognostic marker in diffuse gliomas. Subsequent subgroup analysis 
largely confirms many of the currently used molecular classification schemes for dif-
fuse gliomas (ATRX or TP53 mutations, 1p19q codeletion). Our analysis also identified 
PI3-kinase mutations as markers of poor prognosis in IDH-mutated +ATRX/TP53 mu-
tated diffuse gliomas, median survival 3.7 v. 6.3 years (P=0.02, Hazard rate (HR) 2.93, 
95% confidence interval (CI) 1.16 – 7.38). PI3-kinase mutations were also prognostic 
in two independent datasets. In our analysis, no additional molecular markers were 
identified that further refine the molecular classification of diffuse gliomas. Interest-
ingly, these molecular classifiers do not fully explain the variability in survival observed 
for diffuse glioma patients. We demonstrate that tumor grade remains an important 
prognostic factor for overall survival in diffuse gliomas, even within molecular glioma 
subtypes. Tumor grade was correlated with the mutational load (the number of non-
silent mutations) of the tumor: grade II diffuse gliomas harbor fewer genetic changes 
than grade III or IV, even within defined molecular subtypes (e.g. ATRX mutated diffuse 
gliomas). The increase in mutational load may partially explain the increased aggres-
siveness of higher grade diffuse gliomas when a subset of the affected genes actively 
contributes to gliomagenesis and/or progression.
19
Prognostic markers in TCGA dataset
2
introDuction
Gliomas are the most common primary malignant brain tumors in adults.1,2 Diffuse 
gliomas are classified into different subtypes according to their histological features 
into astrocytomas, oligodendrogliomas and mixed oligoastrocytomas.3 These subtypes 
are further divided into various tumor grades (grade II-IV) depending on the number of 
malignant features present in the tumor (nuclear atypia, mitoses, endothelial prolif-
eration and necrosis). The WHO classification, in combination with clinical parameters 
such as age and Karnofsky Performance Status (KPS), guides treatment decisions and 
provides prognostic information for patients and clinicians.
Unravelling the causal genetic changes of diffuse gliomas has been the focus 
of extensive research in the past decade4-6 and it is now possible to classify diffuse 
gliomas based on their molecular characteristics.7-11 For example, IDH1 mutations are 
frequent events in all grade II and III gliomas and in secondary glioblastomas (sGBM, 
glioblastomas that progress from lower grade gliomas) whereas primary GBMs 
(pGBM) are usually IDHwt and frequently have genetic changes involving the EGFR 
locus, PTEN deletions and TERT promoter mutations.4,6,12 In addition, CIC, FUBP1, TERT 
promoter mutations and 1p/19q codeletion are observed more frequently in oligoden-
drogliomas than in astrocytic tumors13-15 whereas ATRX and TP53 mutations are seen 
more frequently in grade II/III astrocytic tumors.16-18 The importance of this molecular 
information is widely acknowledged and guidelines have been made to incorporate 
them in the WHO classification of gliomas.19
Although the genetic changes are used to classify diffuse gliomas into distinct prog-
nostic subtypes9,10,16,20-23, a systematic analysis of all available molecular prognostic 
markers has thus far not been performed. In fact, most classification schemes use only 
a few high frequent genes or molecular markers. It is therefore possible that addi-
tional and/or stronger prognostic markers are present that can improve the molecular 
classification of diffuse gliomas. Furthermore, while the prognostic molecular markers 
may refine (or even replace) the histological classification of diffuse gliomas, there are 
thus far no genetic changes that can discriminate between grade II and III tumors. 
This is remarkable as tumor grade is a strong prognostic marker in diffuse gliomas3 
(although some reports found little prognostic value for tumor grade within defined 
glioma subtypes).24,25
In this study we therefore have analyzed the publicly available TCGA dataset in 
order to identify additional prognostic molecular markers in diffuse gliomas. Since 
diffuse gliomas can be classified solely based on molecular markers9,20, we also evalu-
ated whether tumor grade remains relevant after the molecular classification and/
or whether there are genetic markers that can distinguish between tumor grades in 
diffuse gliomas. Our analysis confirms many of the currently used molecular classifica-
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tion schemes for diffuse gliomas: gliomas are first separated based on IDH-mutation 
status and a further stratification is based on ATRX/TP53 mutation status or 1p19q 
codeletion. We show that PI3-kinase mutations are associated with poor prognosis 
in molecular astrocytomas (i.e. diffuse gliomas that are IDH-mutated and 1p19q 
intact (or ATRX/TP53 mutated)) and that no other marker investigated in this study 
appears to further refine this molecular/prognostic classification of diffuse gliomas. 
Our analysis also shows that, for most driver mutations investigated here (IDH1/2, 
ATRX, TP53), tumor grade remains a prognostic factor in diffuse gliomas with identical 
driver mutations. This indicates that IDH-mutated glioblastomas behave significantly 
more aggressive than IDH-mutated grade III gliomas. Although no single molecular 
marker was associated with tumor grade, we find that tumor grade is correlated 
with the overall mutational load: grade II gliomas harbor fewer genetic changes than 
grade III or IV, even within defined molecular subtypes (e.g. ATRX mutated gliomas). 
The increased mutational load may partially explain the increased aggressiveness 
of higher grade gliomas when a subset of the affected genes actively contributes to 
gliomagenesis and/or progression.
MEthoDS
For this study, we have used publicly available data from the TCGA, both lower grade 
glioma and glioblastoma datasets. Data include mutation status, copy number 
variations and clinical data, only cases with complete data were included in current 
analysis (n=542). All data analyses were based on overall survival (OS). Survival data for 
patients that are listed as <30 days were omitted from the survival analysis; the cause 
of death for such patients may not be tumor-related (but e.g. related to complications 
occurring after surgery). EGFR amplification status and CDKN2A deletions data were 
downloaded from the cbioportal site.26 Although such data could be extracted from 
the copynumber data (see below), we used cBioportal data to ensure identical thresh-
olds were used to define amplification and allelic loss. All mutation data were filtered 
for those that result in a change in the primary amino acid sequence. We focused on 
all genes that are mutated in more than ten samples of the entire study population. 
We also included the copy number alterations 1p19q codeletion (loss of heterozygos-
ity (LOH) of the 1p and 19q chromosome arms) and trisomy of chromosome 7 and LOH 
of chromosome 10 (alt 7/10). Combined, we analyzed 128 genetic alterations in 542 
samples.
Genome wide SNP 6 Copynumber data was downloaded from the TCGA data portal. 
This data gives a value per chromosomal region (segment) where values deviating 
from 0 likely correspond to regions with chromosomal losses (<0) or gains (>0). From 
21
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the segment values, we calculated the average an entire chromosome/chromosomal 
arm and defined 1p19q codeletion as averages over both arms -0.3 or less. When 
values were discordant between 1p and 19q or values were between 0 and -0.3 (which 
can occur in tumors with a high content of non-neoplastic tissue), we determined 
1p19q codeletion based on visualization of the copynumber plot. This visualization 
was performed blinded to the patient outcome. Alt 7/10 was determined by a value of 
0.3 or higher for chromosome 7 and a value of -0.3 or lower for chromosome 10. When 
values were either discordant between chromosomes 7 and 10, or were between 0 and 
0.3 for chromosome 7 and/or between 0 and -0.3 for chromosome 10, we determined 
alt 7/10 based on visualization of the copynumber plot (blinded to patient outcome). 
Because IDH1 and IDH2 mutations are mutually exclusive and play an identical role 
in tumor pathogenesis, we have combined mutation data into an additional single 
IDH-mutations variable. Similarly, we combined EGFR-mutations and EGFR gene am-
plifications into a single additional EGFR-alteration variable. As PIK3CA and PIK3R1 are 
highly related (and mutually exclusive) genes within the same PI3-kinase pathway, we 
also combined mutation data into an additional single PI3-kinase mutations variable.
To validate the prognostic value of identified genes, we performed survival analysis 
on two additional datasets containing mutation and survival data.6,17 Hazard ratios 
(HR) and survival differences were calculated using a cox proportional hazard model 
in R (survival CRAN package), unless specifically indicated otherwise. Differences in 
mutation frequencies were calculated using an ANOVA (3 groups) or T-Test (2 groups). 
Bonferroni correction was done by using a P value cut-off of 0.0004 (0.05 divided by 
the total number of calculations (128 genes and copy number changes)). Chi square 
tests were performed using an online calculator (www.quantpsy.org/chisq/chisq.htm), 
Graphpad Prism (version 5.00) was used to perform log-rank tests.
Because a large number of genes were tested to determine association with survival, 
we corrected for multiple testing by estimating the false positive rate. This was done 
by an in-silico analysis in which a set of 100 genes were randomly mutated across 
542 samples (at a population frequency between 2.5-10%) and we then calculated 
how many of those were associated with survival using the Cox proportional hazards 
method. These false positive estimations were made using three different population 
mutation frequencies (2.5%, 5% and 10%) and were done 50 times for each popula-
tion mutation frequency. In such analysis, we identified between 1-12 genes that were 
significantly associated with outcome. For all calculations, P<0.05 was considered 
statistically significant.
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rESultS
Prognostic classification of diffuse gliomas
We analyzed the combined GBM and LGG (low grade glioma) datasets from the TCGA 
(n=542 samples) and identified 128 genes that are mutated (non-silent mutations 
only) in ten or more samples, consistent with a population frequency >1.7% (i.e. 
10/542= 1.8%). Of these, 57 genes were significantly associated with survival and the 
list included the well-known favorable prognostic markers IDH1/2, 1p19q codeletion, 
CIC, FUBP1 and NOTCH1. Poor prognostic markers included genetic changes in the EGFR 
locus, PTEN-mutations and alt 7/10 (supplementary table 1). IDH1 or IDH2-mutations 
(collectively referred to in our analysis as IDH-mutations unless specifically stated) 
were associated with the lowest HR (0.10 95% confidence interval (CI): 0.07-0.14, 
P<0.0001). Because our aim was to generate a prognostic classification scheme for 
diffuse gliomas based on molecular aberrations, the gene with lowest HR (i.e. IDH-
mutations) provided our first molecular prognostic separator for diffuse gliomas.
Genes associated with prognosis in iDh-wt gliomas
We then screened for prognostic markers separately within IDH- wildtype (wt) and 
IDH-mutated gliomas. Within the subset of IDH-wt gliomas, we identified 4 genes 
that, when mutated, were significantly associated with prognosis (supplementary 
table 2). However, a relatively large number of tests were performed to identify these 
genes. To correct for multiple testing, we performed similar analysis on a set of 100 
genes that were randomly mutated across the TCGA dataset at a population mutation 
frequency of 2.5%, 5% and 10%. In such analysis, we identified between 1-12 genes 
that were significantly associated with outcome. Identification of 4/128 genes associ-
ated with survival in IDH wt gliomas is therefore within the range of the false positive 
frequency (1-12%). By analogy, after Bonferroni correction only one gene (SLC6A3) 
remained significant.
As independent validation is warranted, we screened two additional datasets to 
confirm the prognostic value of these four genes in IDH-wt tumors.6,17 Clinical and 
mutation data are listed in supplementary tables 3 and 4. In a dataset of anaplastic as-
trocytomas, mutations in two of these four genes (PKHD1 and MUC16) were identified 
and in a set of GBMs, mutations in three genes (MUC16, F5 and PKHD1) were identi-
fied. Unfortunately, the mutation frequency of individual genes was too low to allow 
for a statistical comparison, and a combined analysis of mutated genes does not show 
a difference between wt and mutated samples within one dataset. However, when 
combining survival of both datasets, mutations in any of these genes is associated 
with poor prognosis (median survival of 0.88 v. 1.33 years for mutated and wt samples 
respectively, P=0.018 HR 3.81, 95% CI 1.26-11.5). However, because numbers are small, 
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caution should be taken when interpreting these data as it remains possible that the 
four prognostic genes identified in IDH-wt tumors were false positive candidates and 
do not represent true prognostic genes.
IDH-wt diffuse gliomas are often further subdivided into those with trisomy on 
chromosome 7 combined with LOH of chromosome 10 (alt 7/10) and those without 
(7/10 wt). It should be noted that, in the TCGA dataset, alt 7/10 does not confer 
any prognostic information in IDH-wt diffuse gliomas (supplementary table 2). On 
the gene expression levels alt 7/10 GBMs correlate with “classical” GBMs (or those 
assigned to IGS-18); 7/10 wt tumors associate with other molecular subtypes (mes-
enchymal/neural/proneural or IGS-22/IGS-23) (27, 28). We have therefore screened 
for prognostic molecular features within the IDH-wt, alt 7/10 (‘molecular classical’, 
n=214) and within the IDH-wt, 7/10 wt (‘molecular mesenchymal’, n=86) diffuse glio-
mas. Within molecular classical gliomas, 10 genes were significantly correlated with 
survival (supplementary table 5) and 11 genes within the molecular mesenchymal 
gliomas (supplementary table 6). It is interesting to note that TP53 mutations are as-
sociated with a more favorable prognosis in the molecular classical gliomas and PIK3CA 
(or combined PIK3CA and PIK3R1) mutations with poor prognosis in the molecular 
mesenchymal gliomas. Unfortunately, we were unable to validate these results due to 
an absence of copy number data in the two validation datasets.
It should be noted that pilocytic astrocytomas (PAs, brain tumors with favorable 
prognosis) may be present among the IDH-wt tumors. However, detailed analysis 
shows that only one of the samples included in this study harbored a genetic profile 
consistent with PA (TCGA-HT-7691; a diploid genome apart from a tandem duplication 
on chromosome 7q34 involving the BRAF locus), and the survival data for this patient 
is 0.1 months (patient still alive). Omitting this patient from the analysis will therefore 
not impact the survival data as presented.
Pi3 kinase pathway mutations are associated with poor survival in molecular 
astrocytomas
Within IDH-mutated diffuse gliomas, we identified 12/128 genes associated with poor 
survival (Supplementary table 7). Mutations in three and two genes of these were also 
identified in validation datasets of anaplastic astrocytomas and GBMs respectively.6,17 
In both datasets, there were too few samples to allow comparison. The absence of 
a true validation set indicates that caution should be taken as it is possible that the 
twelve prognostic genes identified in IDH-mutant tumors were false positive candi-
dates and do not represent true prognostic genes.
IDH-mutated diffuse gliomas are often further subdivided into molecular astrocyto-
mas (i.e. those with mutations in ATRX and/or TP53) and molecular oligodendrogliomas 
(i.e. those with 1p19q codeletion).16,23 It should be noted that these genetic changes 
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by themselves did not reach statistical significance in IDH-mutated tumors of the 
TCGA. This is likely due to the large number of patients alive at time of analysis (205 
patients alive out of the 243 IDH-mutant glioma patients). We therefore separated 
IDH-mutated samples into those with TP53 or ATRX mutations (n= 151) and those 
with 1p19q codeletion (n=74). Seventeen samples had neither genetic change and five 
samples had both.
Within molecular oligodendrogliomas we identified 1 out of 128 genes associated 
with survival (Supplementary table 8). Unfortunately, there are no external datasets 
to validate this finding.
Within molecular astrocytomas, we identified 8 genes associated with survival 
(Supplementary table 9). PIK3CA was one of the genes identified. Interestingly, a 
similar trend was observed in a highly related gene, PIK3R1, HR 2.45 P=0.075 95% CI 
0.91 – 6.56. As PIK3CA and PIK3R1 are highly related (and mutually exclusive) genes 
within the same PI3-kinase pathway, we combined mutation data into an additional 
single PI3-kinase mutations variable. The median survival in molecular astrocytomas 
with PI3-kinase mutations was 3.7 years v. 6.3 years for PI3-kinase wt molecular 
astrocytomas (P=0.02, HR 2.93, 95% CI 1.16 – 7.38, figure 1a). Individual PI3-kinase 
mutations are listed in supplementary table 10. PIK3CA mutations are missense muta-
tions or in-frame deletions and often affect the known hotspots of the protein (E542, 
E545 or the C-terminal domain, see 29). PIK3R1 mutations are more heterogeneous 
(in-frame deletions, nonsense, frame-shifts, splice site or missense) not confined to 
specific hotspots.
To validate the prognostic value of identified genes, we screened an anaplastic as-
trocytomas dataset and determined survival within defined molecular subtypes of dif-
fuse glioma.17 Within the IDH-mutated and TP53 or ATRX mutated tumors, mutations 
in four genes out of the 15 identified in the TCGA dataset (PIK3R1, PKHD1, NEB1, and 
NOTCH2) were identified. Of these, tumors with PIK3R1 mutations (n=4) had poorer 
prognosis than PIK3R1 wt tumors (n=20), median survival 2.4 and 5.4 years respec-
tively (supplementary figure 1a). We next downloaded mutation data of a cohort of 
GBMs.6 Also in this dataset, we observed a similar poor prognostic trend for PIK3R1 
mutations in IDH-mutated and TP53 or ATRX mutated GBMs: Tumors with PIK3R1 
mutations (n=2) had poorer prognosis than PIK3R1 wt tumors (n=2), median survival 
1.4 and 5.5 years respectively (supplementary figure 1b). Although significance was 
not reached in either of these datasets (perhaps due to the small sample size), a pure 
molecular classification allows combining both datasets. When this is performed, a 
median survival of 1.9 v. 5.4 years was observed for PIK3R1 mut and PIK3R1 wt tumors 
respectively, HR 17.0, 95% CI (2.40-121), P=0.0046 (figure 1). The fact that PI3-kinase 
mutations showed similar trends in prognosis in three independent datasets, strongly 
suggests they are prognostic markers for molecular astrocytomas.
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tumor grade remains prognostic in molecular diffuse glioma subtypes and is 
associated with mutational load of the tumor
Apart from the pure molecular analysis described above, several clinical and histologi-
cal parameters are also associated with survival. For example, tumor grade is inversely 
correlated with patient survival within the defined histological subtypes of diffuse 
glioma3; a correlation that was also present in the TCGA dataset. For example, there 
were 42 grade II and 31 grade III oligoastrocytomas, of which the grade II tumors had 
a significantly better prognosis than the grade III tumors (median survival was 5.3 vs 
6.3 years, P=0.024, HR 0.26, 95% CI (0.08 – 0.84)). A similar trend was observed for 
astrocytomas (table 1, Supplementary figure 2).
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figure 1. PI3-kinase mutations are prognostic in 
molecular astrocytomas (those with ATRX and/
or TP53 mutations). A: Data from TCGA samples 
(test cohort). Histology and grade of samples 
presented are listed in supplementary table 9; 
B: Data from two validation cohorts (combined) 
from astrocytomas (17) and glioblastomas (6). In 
both figures, only samples with an IDH mutation 
and TP53 or ATRX were selected. In these molecu-
lar astrocytomas, PI3 kinase mutations are prog-
nostic for overall survival. P values indicated are 
calculated using the Log-rank test.
table 1. Tumor grade is inversely correlated with patient survival within histological subtypes of dif-
fuse glioma
 
Grade II 
survival (y)
Grade III 
survival (y) HR 95% CI P
Astrocytoma 5.2 3.7 0.27 0.06 - 1.16 0.078
Oligodendroglioma 7.9 5.2 0.49 0.2 - 1.2 0.12
Oligoastrocytoma 5.3 6.3 0.26 0.08 - 0.84 0.024
Survival: median overall survival in years. HR calculated using Cox univariate analysis. HR was calcu-
lated grade II vs grade III.
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As detailed above, an alternative method for histological classification is to classify 
gliomas based on their genetic aberrations. Within defined molecular subtypes (i.e. 
all tumors that harbor mutations in one of the lineage specific genes IDH, CIC, FUBP1, 
ATRX, TP53, PTEN, EGFR, 1p19q codeletion or alt 7/10, frequency listed in table 2) tu-
mor grade often remained inversely correlated with survival (Supplementary figure 3, 
table 3). For example, there were 151 IDH + ATRX/TP53-mutated gliomas in the TCGA 
diffuse glioma datasets of which 73 were of grade II, 65 of grade III and 13 of grade IV 
(GBM) and median survival was 7.3, 5.2 and 2.8 years (P=0.0024). Similar trends were 
observed for most other single molecular changes (i.e. selecting samples only on one 
genetic change, regardless of other molecular changes present). Importantly, tumor 
grade was a prognostic factor for each of the molecular subtypes identified above: i) 
IDH-wt gliomas; ii) IDH and TP53 and/or ATRX-mutated gliomas and; iii) IDH and 1p19q 
codeleted gliomas (figure 2)
table 2. Frequency of genetic changes listed per histological subtype and grade.
Low 
grade
Molecular 
Oligodendroglioma
Molecular 
Astrocytoma Molecular Glioblastoma
N
IDH1/
IDH2
CIC/
FUBP1
LOH
1p19q ATRX TP53
EGFR
alterations PTEN
alt 
7/10 NF1
OD II 95 48 51 28 28 0 2 3 2 65
OD III 82 49 60 18 27 7 2 7 7 45
A II 83 0 0 67 73 0 0 0 0 30
A III 62 1 1 41 65 26 13 26 15 68
OA II 95 14 21 69 74 0 0 2 5 42
OA III 74 10 13 48 58 16 6 16 3 31
GBM 5 0 0 5 30 55 31 71 10 261
N 228 64 74 131 222 170 93 214 44 542
The numbers in the table are percentages of the number of samples mutated (i.e. population frequen-
cies) except the columns listed as N where numbers represent absolute numbers
Grade II
Grade III
Grade IV
IDH-wt
P=0.0325
IDH-mut + ATRX/TP53 mut
P=0.0034
IDH-mut + 1p/19q codeletion
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figure 2. Survival in prognostic molecular subtypes of diffuse glioma stratified by tumor grade. Dif-
ferent subtypes are indicated above each graph. As can be seen, within defined molecular subtypes, 
tumor grade remains a prognostic factor. Number of samples (grade II, III and IV) for each graph: 10, 42 
and 148 (IDH-wt); 73, 69 and 13 (IDH-mut, ATRX/TP53 mut); 41, 32 and 0 (IDH-mut, 1p19q codeleted)
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Because tumor grade was associated with patient survival, we further analyzed the 
TCGA dataset to identify the molecular correlates of tumor grade. When screening for 
mutations that occur at different frequencies between grade II and III diffuse gliomas, 
the only genes identified were the lineage specific genetic changes (IDH, CIC, 1p19q 
co-deletion, ATRX, EGFR, and alt 7/10). These genes are listed in table 2 and such a 
higher rate (where the frequency of mutations in grade II > grade III) has been observed 
in other studies (although other studies did not find such a difference).14,30,31 Perhaps 
the most striking difference between tumors of different grade however was the total 
number of genetic changes (the mutational load). For example, the average number of 
non-silent (i.e. those that result in a change in the primary protein sequence) genetic 
changes in grade II astrocytomas was 18.8 ± 13.1 (n=30), in grade III astrocytomas 
it was 36.8 ± 47.6 (n=68), P = 0.0050 (table 4). This increase in ‘mutational load’ was 
also observed within molecular subtypes of diffuse glioma and is listed in table 5. For 
example, the mutational load of ATRX mutated gliomas increased from 21.6 ± 10.3 
and 26.0 ± 11.2 to 65.4 ± 40.1 mutations per sample (P<0.0001) for grade II, III and IV 
gliomas respectively.
table 3. Tumor grade is inversely correlated with survival within molecular subtypes of diffuse glioma
Genes
Grade II Grade III Grade IV
P P II vs IIIOS (y) n OS (y) n OS (y) n
IDH+CIC/FUBP1/LOH 1p19q “not reached” 47 5.2 34 1 0.040 0.04
IDH+ATRX/TP53 7.3 73 5.2 70 2.8 13 0.0029 0.069
EGFR/PTEN/ alt 7/10 1.9 3 1.5 32 1.2 211 0.13 0.5
NF1 2.1 3 1.9 14 1 27 0.034 NA
IDH+CIC/FUBP1/LOH 1p19q refers to mutations in IDH plus any of the subsequent genes, similar for 
IDH+ATRX/TP53. Statistical tests were performed using a Chi-square test. OS refers to median overall 
survival in years. Frequency comparisons were done between grade II, III and IV. Exceptions were made 
for genes with too few/no data in one of the grades (e.g. there are no grade IV tumors with 1p19q 
codeletion). Therefore, the P value for NF1 is based on comparison between grade III and IV and the P 
value for IDH+CIC/FUBP1/LOH 1p19q is based on a comparison between grade II and III.
table 4. Tumor grade is correlated with mutational load within histological subtypes of diffuse glioma.
 Grade II Grade III Grade IV P
Oligodendroglioma 21.8 ± 10.3(65) 28.1 ± 13.5(45)  0.011
Astrocytoma 18.8 ± 13.1(30) 36.8 ± 47.6(68)  0.0050
Oligoastrocytoma 20 ± 9(42) 29.3 ± 14.3(31)  0.0025
GBM   57.3 ± 19.9 (261)  
Values are listed as the average number of non-silent mutations +/- SD (number of tumors analyzed. P 
values were calculated using an anova.
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the mutational load is associated with patient age
Because age is a well-known prognostic factor in diffuse glioma patients, we included 
age in the analysis. Similar to previously reported, grade II tumors occur in patients 
that were younger than those with grade III or grade IV tumors, 39.6 ± 12.5 (n=137), 
45.6 ± 13.5 (n=144 ) and 61.3 ± 13.0 (n=261) years respectively (average ± standard 
deviation (SD), P<0.0001 for any comparison, ANOVA).1,32,33 As patient age and tumor 
grade were correlated, and tumor grade was correlated to the mutational load, it is not 
surprising that age was also correlated with the mutational load of the tumor (figure 
3). This correlation was observed not only in the entire dataset but also within histo-
logically and molecularly defined subtypes (table 5 and 6). Indeed, when analyzing 
the type of mutations that occur in the TCGA dataset, a large proportion (2962/9281, 
32%) of all mutations were C>T transitions in the sequence xCG (where x represents 
any nucleotide). Only 4/96 possible combinations would lead to this specific mutation, 
and this type of signature has been identified as an age related mutation signature 34.
Univariate analysis confirmed that histology (oligoastrocytoma vs. oligodendrogli-
oma: P=0.41 HR 1.33 95% CI 0.68-2.61; astrocytoma vs. oligodendroglioma: P=0.0029 
HR 2.52 95% CI 1.37-4.63; GBM vs oligodendroglioma: P=<0.0001 HR 10.6 95% CI 
6.47-17.3), tumor grade (grade III vs. II: P= 0.0001, HR 3.14 95%CI 1.76-5.60; grade 
IV vs. II: P<0.0001, HR 14.4 95%CI 8.48-24.5), the number of mutations (P<0.00001, 
HR 4.52, 95%CI 3.42 – 5.97) and patient age (P<0.00001, HR 5.51, 95%CI 4.03 – 7.54) 
were associated with patient overall survival. In a multivariate analysis, the number 
of mutations remained a significant prognostic factor when including histology and 
tumor grade in the analysis. However, when the multivariate analysis also included 
table 5. Tumor grade is correlated with mutational load within molecular subtypes of diffuse glioma.
 Grade II Grade III Grade IV P P II v. III
Overall 20.6 ± 10.6 (137) 32.4 ± 34.3 (144) 57.3 ± 19.9 (261) < 0.0001  
IDH1/IDH2 21.1 ± 10.1 (127) 26.7 ± 12.1 (102) 52 ± 22.1 (13) < 0.0001 0.00023
CIC/FUBP1 21.9 ± 10.3 (37) 28 ± 10.7 (26)  0.030  
LOH 1p19q 21.7 ± 10.1 (42) 28.2 ± 10.2 (32)  0.0081  
ATRX 21.6 ± 10.3 (67) 26 ± 11.2 (51) 65.4 ± 40.1 (14) < 0.0001 0.034
TP53 21.4 ± 10.2 (71) 33 ± 46.1 (74) 60.5 ± 23 (78) < 0.0001 0.038
EGFR  41.9 ± 12.7 (15) 60.3 ± 16.6 (69) < 0.0001  
PTEN  42.8 ± 10.8 (12) 62.7 ± 21.3 (80) < 0.0001  
alt 7/10 24 ± 10.6 (3) 43.5 ± 10.1 (26) 59.6 ± 16.7 (185) < 0.0001  
NF1 12 ± 7.2 (3) 57.6 ± 101.6 (14) 56.6 ± 15.5 (27) 0.97  
Values are listed as the average number of non-silent mutations +/- SD (number of tumors analyzed). 
Alt 7/10: Trisomy chromosome 7 and LOH of chromosome 10. P values were calculated using an anova. 
P II v. III indicates significance of grade II v. grade III tumors based on a T-test. Total number of cases 
analysed = 542.
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patient age, the number of mutations was no longer a significant prognostic marker 
(table 7). Similar results were obtained when performing multivariate analysis within 
defined molecular subtypes (mutations in IDH, CIC or FUBP1, TP53, EGFR, PTEN, NF1 or 
trisomy of Chr7 combined with LOH of Chr 10 or 1p19q codeletion), data not shown. 
Therefore, patient age appears to be stronger associated with patient survival than 
mutational load.
DiScuSSion
In this study, we have aimed to identify genetic changes associated with patient 
prognosis within defined histological and molecular subtypes of diffuse glioma by 
analyzing the TCGA glioma datasets. Our analysis shows that diffuse gliomas are first 
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figure 3. Correlation between 
patient age and mutational load 
in diffuse gliomas. The number 
of non-silent genetic changes 
increases with patient age. This 
increase is irrespective of histo-
logical subtype (not shown) or 
tumor grade
table 6. Tumor grade is correlated with patient age within molecular subtypes of diffuse glioma.
 Grade II Grade III Grade IV P P II v. III
Overall 39.6 ± 12.5 (137) 45.6 ± 13.5 (144) 61.3 ± 13 (261) < 0.0001  
IDH1/IDH2 39.6 ± 12.3 (127) 42 ± 12.1 (102) 39.6 ± 15.7 (13) 0.32 0.14
CIC/FUBP1 42.3 ± 13.4 (37) 48 ± 10.8 (26)  0.065 0.065
LOH 1p19q 42 ± 12.4 (42) 49.4 ± 11.8 (32)  0.012 0.012
ATRX 37.4 ± 11.9 (67) 38.1 ± 11.3 (51) 41.6 ± 17.2 (14) 0.30 0.74
TP53 37.2 ± 11.8 (71) 39.9 ± 11.7 (74) 59.2 ± 15.5 (78) < 0.0001 0.18
EGFR  61.7 ± 7.5 (15) 61.2 ± 11.7 (69) 0.84  
PTEN  56.8 ± 10.5 (12) 62.8 ± 11.9 (80) 0.092  
alt 7/10 49.7 ± 8.3 (3) 59.4 ± 6.8 (26) 62.8 ± 10.8 (185) 0.015  
NF1 51 ± 18.4 (3) 43.7 ± 12.7 (14) 64.4 ± 13.2 (27) 0.00050  
Values are listed as the mean patient age +/- standard deviation (number of tumors analysed). P values 
were calculated using an anova. P II v. III indicates significance of grade II v. grade III tumors based on a 
T-test. Total number of cases analysed = 542.
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classified based on their IDH-mutation status. Further stratification into molecular 
oligodendrogliomas and molecular astrocytomas involves determining the ATRX and/
or TP53 mutation status or determining 1p19q codeletion (these changes are mutually 
exclusive). Within molecular astrocytomas, mutations in PI3 kinase genes PIK3CA and 
PIK3R1 are likely to be associated with poor prognosis. Additional prognostic factors 
include tumor grade and patient age, both of which are correlated to the mutational 
load of the tumor. A scheme for the prognostic classification is proposed in figure 4.
A novel prognostic marker identified by current analysis are PI3 kinase mutations. 
Such mutations are frequently observed in various cancer types including diffuse 
gliomas.29,35 They act as lipid kinase downstream of various receptor tyrosine kinases, 
ultimately resulting in activation of signaling cascades involved in cell growth and 
proliferation, survival and migration.36 It has been speculated that, as PI3 kinase 
mutations are frequently observed in diffuse gliomas, specific inhibitors may provide 
clinical benefit for PI3 kinase mutated diffuse glioma patients.37 Here we show that PI3 
kinase mutations also act as prognostic markers for molecular astrocytoma patients, 
providing the first evidence to demonstrate they are associated with poor outcome 
within a defined glioma subtype.
Our analysis also shows that grade is associated with mutational load of the tumor. 
This is an interesting observation as the mutational load may provide a biological 
explanation for tumor grade. Even if only a subset of the affected genes contributes 
to gliomagenesis and/or progression, an increase in mutational load would increase 
tumor aggressiveness. Indeed, several studies on genes mutated at a low population 
frequency (‘low frequency genes’) have demonstrated that they can contribute to tu-
mor formation or progression.38-43 In a larger study, we have shown that many (but not 
table 7. Multivariate Cox analysis of prognostic markers for overall survival in diffuse glioma patients.
HR P value 95% CI
Histology 1.00   
Oligoastrocytoma vs. oligodendroglioma 1.53 0.22 0.78 - 3.02
Astrocytoma vs. oligodendroglioma 2.19 0.015 1.17 - 4.11
Grade 1.00   
III vs. II 2.46 0.0040 1.33 - 4.54
IV vs. II 6.41 < 0.0001 2.11-4.57
Age 1.00   
> 50 vs. ≤50 3.10 < 0.0001 2.11 - 4.57
Mutational load 1.00   
> 40 vs. ≤ 40 0.69 0.066 0.47 - 1.03
A total of 542 samples were analyzed for this table. HR: Hazard Rate; CI: Confidence interval. Grade 
levels were 2, 3 and 4. Three histology levels were used (oligodendroglioma, oligoastrocytoma and 
astrocytoma), GBMs were categorized as astrocytomas.
31
Prognostic markers in TCGA dataset
2
all) mutations in low frequency genes affect their functional property.44 In addition, 
mouse experiments have demonstrated that the age of the cells in which a glioma is 
generated largely determines their survival and not the age of the mouse into which 
the tumor is transplanted. These data argue for an intrinsic (age-related) property 
of the tumor initiating cell, perhaps mutational load.45 Interestingly however, in a 
multivariate analysis, the mutational load is no longer a significant prognostic marker 
when patient age is included. The mutational load therefore cannot fully explain the 
increased aggressiveness of tumors of higher grade.
Our analysis also indicates that each malignancy grade is associated with a different 
prognosis within molecularly similar tumors. These results appear to be in contrast 
with a recent publication that failed to identify differences in survival between grade II 
and III IDH-mutant astrocytic tumors.24 Similarly, a second paper found only a modest 
impact of tumor grade in IDH-mutated grade II and III gliomas.25 However, our analysis 
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figure 4. Proposed scheme for the prognostic classification of diffuse gliomas. Diffuse gliomas are 
first stratified based on their IDH-mutation status. Further classification is based on the ATRX and/or 
TP53 mutation status or determining 1p19q codeletion (these changes are mutually exclusive). Within 
the ATRX and/or TP53 mutated samples, mutations in PI3 kinase genes PIK3CA and PIK3R1 are associ-
ated with poor prognosis. It should be noted that there are genetic changes that associate with each 
molecular subtype (like EGFR amplification with IDH-wt tumors). They are however, not important for 
prognostic classification and may occur in several molecular subtypes. For example, PI3K mutations 
occur in all molecular subtypes but are only prognostic in IDH-mutated, TP53/ATRX mutated diffuse 
gliomas) it merely says the additional markers are irrelevant in this study for prognostic classification. 
Additional prognostic factors include tumor grade and patient age, both of which are correlated to the 
mutational load of the tumor and are listed below the classification scheme. These additional markers 
are often correlated to the mutational profile of the tumors: Patients with IDH-wt tumors are often 
older and most are diagnosed as grade IV. ATRX/TP53 indicates mutation of either/both genes; 1p19q 
indicates codeletion of these chromosomal arms.
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included all tumor grades (II-IV) whereas those studies focused only on grade II and III. 
In addition, our analysis did not preselect for a specific histological subtype.
It is often reported that IDH1 mutated GBMs have a better prognosis than IDH1-
wt gliomas.6,12 The analysis presented here (using TCGA data) also shows that IDH1 
mutated grade IV tumors have a poorer prognosis than IDH1-mutated lower grade 
gliomas, which has also been observed in other studies. For example, IDH1 mutated 
GBMs have a survival in the range of 24-30 months whereas IDH1 mutated grade III 
astrocytic tumours, median survival is significantly longer surpassing 50-60 months7,12 
and similarly, IDH1-wt GBMs have median survival of 11-15 months whereas IDH1-
wt grade III astrocytic tumours have a median survival in the range of 21 months.12 
Here we show that the correlation between grade and prognosis is also true for other 
molecularly similar tumors. These data therefore argue for inclusion of tumor grade 
as prognostic factor when molecularly classifying diffuse gliomas and indicate that 
molecularly similar tumors of different grade should not be treated identical.
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SuPPlEMEntary MatErial
Supplementary table 1. Genetic changes associated with survival in the entire TCGA (GBM and LGG) 
datasets
Gene
Hazard
Ratio
lower upper p.value
IDH1.or.IDH2 0,103 0,071 0,15 0
IDH2 0,113 0,016 0,807 0,009
IDH1 0,123 0,085 0,179 0
ARID1A 0,17 0,042 0,686 0,005
1p19q codeletion 0,181 0,099 0,334 0
CIC 0,195 0,092 0,415 0
PCDHAC2 0,204 0,051 0,821 0,013
SMARCA4 0,206 0,051 0,831 0,014
ATRX 0,252 0,167 0,381 0
ZBTB20 0,261 0,065 1,051 0,042
LOC283788 0,354 0,113 1,107 0,062
FUBP1 0,364 0,15 0,884 0,02
NOTCH1 0,365 0,172 0,776 0,006
MUC2 0,379 0,094 1,524 0,155
AFF2 0,409 0,13 1,281 0,113
RP1 0,444 0,11 1,785 0,24
ESPNP 0,453 0,185 1,105 0,074
TP53 0,481 0,363 0,637 0
ATRX.or.TP53 0,494 0,374 0,653 0
UBC 0,499 0,124 2,009 0,318
PCDHGC5 0,506 0,209 1,229 0,125
MYH8 0,513 0,164 1,603 0,242
C3 0,537 0,2 1,445 0,211
RYR1 0,619 0,23 1,666 0,338
TPTE 0,631 0,235 1,698 0,358
IL32 0,653 0,209 2,044 0,461
HLA.J 0,656 0,243 1,769 0,401
MLL2 0,683 0,219 2,136 0,51
STK19 0,692 0,172 2,79 0,603
LOC100233156 0,695 0,327 1,477 0,341
FAM47C 0,699 0,26 1,879 0,475
NEB 0,701 0,311 1,579 0,389
KIF2B 0,704 0,262 1,894 0,485
MYH4 0,746 0,306 1,815 0,517
ABCA13 0,764 0,189 3,089 0,705
PCDH19 0,771 0,191 3,11 0,714
NBPF1 0,779 0,345 1,755 0,545
RPL13AP20 0,78 0,29 2,098 0,622
Gene
Hazard
Ratio
lower upper p.value
TUBBP5 0,785 0,292 2,111 0,63
HSD17B7P2 0,821 0,459 1,47 0,507
CSMD3 0,832 0,343 2,019 0,683
CHD9 0,834 0,343 2,024 0,687
HSPG2 0,843 0,347 2,046 0,705
HRNR 0,873 0,43 1,773 0,708
FRG1B 0,875 0,509 1,504 0,629
CHEK2 0,875 0,432 1,773 0,711
MUC5B 0,898 0,461 1,752 0,753
ZNF845 0,902 0,372 2,191 0,82
SCN10A 0,907 0,337 2,44 0,847
DNAH3 0,912 0,291 2,857 0,875
MUC4 0,937 0,511 1,717 0,832
CACNA1S 0,948 0,39 2,303 0,907
TCF12 0,949 0,353 2,552 0,917
FRAS1 0,953 0,486 1,87 0,888
NOTCH2 0,981 0,435 2,209 0,963
FAT2 1,006 0,495 2,045 0,987
LAMA3 1,026 0,381 2,76 0,959
GOLGA8DP 1,037 0,494 2,173 0,924
BCOR 1,039 0,532 2,027 0,912
ABCB1 1,052 0,467 2,371 0,902
GRIN2A 1,057 0,469 2,38 0,893
MYH2 1,066 0,502 2,264 0,868
MYO3A 1,073 0,399 2,887 0,889
DSG3 1,083 0,446 2,632 0,86
LAMA5 1,089 0,404 2,931 0,867
UGT2B10 1,103 0,49 2,483 0,812
LRP2 1,105 0,567 2,155 0,769
KDR 1,109 0,522 2,357 0,788
LRP1 1,119 0,497 2,521 0,786
ZNF292 1,132 0,532 2,407 0,748
CACNA1E 1,133 0,534 2,407 0,744
C15orf2 1,146 0,565 2,326 0,705
DSP 1,149 0,473 2,794 0,759
PIK3R1 1,193 0,782 1,822 0,413
DOCK5 1,194 0,589 2,421 0,622
THSD7B 1,202 0,616 2,343 0,589
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Gene
Hazard
Ratio
lower upper p.value
ZNF814 1,209 0,536 2,729 0,647
MST1P9 1,235 0,546 2,792 0,612
NBPF10 1,25 0,892 1,753 0,194
DNAH9 1,256 0,592 2,668 0,552
WASH3P 1,272 0,674 2,401 0,456
HEATR7B2 1,286 0,701 2,359 0,415
FBN2 1,294 0,481 3,483 0,609
PRDM9 1,296 0,61 2,753 0,499
DNAH5 1,309 0,731 2,344 0,363
SYNE1 1,313 0,696 2,478 0,399
DNAH11 1,315 0,649 2,665 0,445
FLG2 1,337 0,593 3,016 0,483
HMCN1 1,351 0,771 2,365 0,291
CDH18 1,377 0,511 3,707 0,525
LZTR1 1,425 0,529 3,84 0,481
OBSCN 1,426 0,814 2,497 0,213
COL1A2 1,43 0,705 2,901 0,319
TRPV6 1,44 0,591 3,506 0,419
RIMS2 1,441 0,71 2,927 0,309
MYH13 1,459 0,648 3,287 0,359
SDK1 1,476 0,728 2,992 0,278
PI3K 1,486 1,085 2,033 0,013
KRTAP4.11 1,489 0,734 3,019 0,267
USH2A 1,494 0,791 2,821 0,213
EPPK1 1,51 0,669 3,406 0,318
FLG 1,512 0,982 2,33 0,059
RYR2 1,519 0,986 2,338 0,056
KRTAP4.9 1,532 0,915 2,563 0,096
RELN 1,537 0,757 3,12 0,23
CNTNAP2 1,546 0,82 2,916 0,175
POTEC 1,553 0,796 3,031 0,193
NLRP5 1,557 0,768 3,158 0,216
ZNF844 1,557 0,577 4,2 0,378
PIK3CA 1,577 1,051 2,365 0,026
MACF1 1,583 0,745 3,364 0,228
TTN 1,61 1,178 2,201 0,003
RB1 1,615 0,954 2,733 0,072
CXorf22 1,635 0,606 4,416 0,327
MXRA5 1,637 0,808 3,317 0,167
DNAH8 1,659 0,85 3,235 0,133
TCHH 1,674 0,912 3,072 0,093
FCGBP 1,688 0,833 3,421 0,142
Gene
Hazard
Ratio
lower upper p.value
MUC17 1,693 1,079 2,655 0,02
NF1 1,718 1,154 2,555 0,007
KRTAP4.7 1,727 1,025 2,909 0,032
AHNAK2 1,763 1,005 3,092 0,045
CHD8 1,773 0,729 4,314 0,2
PCLO 1,799 1,11 2,917 0,016
GPR98 1,844 1,004 3,388 0,045
MLL3 1,849 0,947 3,611 0,068
COL6A3 1,856 1,008 3,417 0,044
LRP1B 1,863 0,875 3,966 0,101
DCAF12L2 1,871 0,829 4,224 0,125
GABRA6 1,873 0,961 3,652 0,061
ACACB 1,886 0,887 4,011 0,094
SDHAP2 1,951 0,962 3,955 0,059
F5 1,96 1,005 3,825 0,044
ANO2 1,97 0,874 4,437 0,095
SPAG17 1,991 0,981 4,04 0,052
KEL 1,997 1,088 3,668 0,023
ABCC9 1,999 0,884 4,521 0,09
DDX11L2 2,004 0,889 4,519 0,087
APOB 2,069 1,203 3,559 0,007
MUC16 2,086 1,459 2,982 0
DMD 2,086 1,026 4,238 0,038
PKHD1 2,108 1,245 3,571 0,005
ANK2 2,131 1,05 4,326 0,032
DNAH2 2,193 1,219 3,943 0,007
RYR3 2,212 1,284 3,812 0,003
PDGFRA 2,241 1,184 4,243 0,011
SLC6A3 2,262 0,839 6,1 0,097
FBN3 2,321 1,141 4,723 0,017
DRD5 2,326 1,142 4,738 0,017
ADAMTS16 2,34 1,035 5,291 0,035
SPTA1 2,422 1,523 3,85 0
HCN1 2,426 1,282 4,593 0,005
PTEN 2,517 1,852 3,419 0
WBSCR17 2,522 1,186 5,364 0,013
STAG2 2,547 1,305 4,97 0,004
tri7loh10 2,61 1,928 3,534 0
PLEKHG4B 2,71 1,389 5,287 0,002
AHNAK 2,755 1,295 5,858 0,006
SEMA3C 2,883 1,351 6,152 0,004
TAF1L 3,127 1,464 6,678 0,002
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Supplementary table 2. Genetic changes associated with survival in IDH-wt gliomas
Gene
Hazard
Ratio
lower upper p.value
SLIT3 3,238 1,595 6,577 0,001
EGFR 3,299 2,517 4,324 0
LAMA1 3,346 1,644 6,807 0
Gene
Hazard
Ratio
lower upper p.value
PCDH11X 3,55 1,745 7,223 0
SCN9A 3,769 1,927 7,37 0
Gene
Hazard
Ratio
lower upper p.value
RP1 0,214 0,053 0,867 0,018
NOTCH1 0,297 0,041 2,176 0,206
PCDHAC2 0,302 0,042 2,155 0,205
MUC2 0,312 0,077 1,257 0,083
ZBTB20 0,361 0,05 2,579 0,289
TPTE 0,43 0,159 1,164 0,087
NOTCH2 0,447 0,143 1,399 0,155
HLA.J 0,453 0,063 3,237 0,418
ARID1A 0,459 0,064 3,283 0,427
DNAH3 0,464 0,148 1,454 0,177
KIF2B 0,474 0,151 1,486 0,19
CACNA1E 0,475 0,21 1,077 0,068
DSG3 0,486 0,18 1,309 0,145
SCN10A 0,494 0,158 1,548 0,217
CHD9 0,522 0,214 1,272 0,145
ABCA13 0,531 0,131 2,143 0,366
GRIN2A 0,538 0,238 1,218 0,131
RPL13AP20 0,564 0,209 1,521 0,251
MYH8 0,565 0,181 1,77 0,321
DOCK5 0,595 0,292 1,212 0,148
TCF12 0,625 0,087 4,466 0,636
DNAH9 0,632 0,278 1,436 0,269
CDH18 0,656 0,243 1,768 0,401
ATRX 0,659 0,242 1,793 0,411
HSD17B7P2 0,662 0,347 1,264 0,208
ZNF292 0,664 0,243 1,813 0,421
CACNA1S 0,671 0,249 1,809 0,427
TUBBP5 0,677 0,251 1,826 0,438
RIMS2 0,687 0,338 1,398 0,298
LAMA5 0,696 0,258 1,874 0,47
DSP 0,709 0,292 1,727 0,447
ZNF814 0,715 0,317 1,614 0,418
KDR 0,725 0,321 1,639 0,438
MYH4 0,735 0,235 2,302 0,595
RB1 0,75 0,443 1,271 0,284
Gene
Hazard
Ratio
lower upper p.value
ESPNP 0,761 0,272 2,128 0,602
NLRP5 0,762 0,375 1,549 0,451
HSPG2 0,764 0,314 1,861 0,552
AFF2 0,766 0,245 2,4 0,647
C3 0,777 0,248 2,438 0,665
FRAS1 0,778 0,379 1,597 0,493
HRNR 0,782 0,346 1,766 0,553
ABCB1 0,804 0,356 1,813 0,598
MST1P9 0,806 0,35 1,854 0,611
MUC5B 0,813 0,4 1,653 0,566
GOLGA8DP 0,833 0,415 1,672 0,605
CSMD3 0,843 0,312 2,274 0,735
MLL2 0,85 0,271 2,663 0,78
LZTR1 0,861 0,319 2,323 0,768
TCHH 0,861 0,441 1,684 0,662
OBSCN 0,872 0,492 1,546 0,64
TP53 0,877 0,627 1,227 0,442
UGT2B10 0,884 0,363 2,15 0,785
FBN2 0,888 0,283 2,78 0,838
HMCN1 0,892 0,506 1,574 0,693
THSD7B 0,898 0,44 1,832 0,767
RYR2 0,9 0,566 1,433 0,657
TRPV6 0,91 0,374 2,216 0,836
SYNE1 0,912 0,466 1,784 0,788
PCDH19 0,914 0,226 3,708 0,9
ATRX.or.TP53 0,919 0,662 1,276 0,614
NEB 0,926 0,23 3,735 0,914
LOC100233156 0,927 0,296 2,904 0,896
PRDM9 0,928 0,435 1,979 0,847
LRP2 0,93 0,476 1,817 0,832
RYR1 0,934 0,346 2,524 0,894
FLG 0,945 0,594 1,503 0,811
MUC4 0,946 0,484 1,847 0,87
CNTNAP2 0,952 0,469 1,935 0,893
CXorf22 0,953 0,353 2,572 0,924
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Gene
Hazard
Ratio
lower upper p.value
FLG2 0,958 0,424 2,164 0,917
COL6A3 0,966 0,524 1,78 0,912
CHEK2 0,98 0,46 2,091 0,959
NBPF1 0,985 0,365 2,656 0,976
CIC 1 1 1 1
FUBP1 1 1 1 1
IDH1 1 1 1 1
IDH1.or.IDH2 1 1 1 1
IDH2 1 1 1 1
FAT2 1,005 0,472 2,142 0,989
HEATR7B2 1,01 0,516 1,975 0,977
ZNF844 1,016 0,377 2,739 0,975
MYH2 1,027 0,482 2,187 0,945
RELN 1,027 0,481 2,194 0,945
NF1 1,029 0,675 1,568 0,894
FRG1B 1,037 0,547 1,966 0,91
SPAG17 1,038 0,511 2,11 0,918
PCDHGC5 1,041 0,386 2,807 0,936
PTEN 1,046 0,769 1,422 0,776
MACF1 1,049 0,431 2,552 0,917
tri7loh10 1,071 0,791 1,451 0,657
AHNAK2 1,082 0,588 1,992 0,799
WASH3P 1,086 0,556 2,121 0,81
SDK1 1,091 0,538 2,216 0,809
TTN 1,105 0,792 1,541 0,556
ABCC9 1,106 0,489 2,501 0,808
EGFR 1,151 0,865 1,532 0,335
DNAH2 1,152 0,625 2,122 0,651
GABRA6 1,153 0,567 2,345 0,694
RYR3 1,16 0,673 2 0,594
GPR98 1,172 0,618 2,22 0,627
ANK2 1,198 0,562 2,552 0,639
KRTAP4.9 1,199 0,729 1,971 0,472
PCLO 1,2 0,738 1,952 0,461
SPTA1 1,213 0,763 1,928 0,414
DMD 1,223 0,597 2,507 0,581
FAM47C 1,229 0,456 3,312 0,684
KEL 1,236 0,652 2,342 0,516
DCAF12L2 1,24 0,549 2,798 0,604
MUC17 1,24 0,77 1,997 0,375
STK19 1,251 0,31 5,054 0,752
USH2A 1,251 0,638 2,451 0,513
Gene
Hazard
Ratio
lower upper p.value
COL1A2 1,257 0,618 2,555 0,527
FBN3 1,26 0,62 2,561 0,523
LAMA3 1,279 0,408 4,009 0,672
NBPF10 1,29 0,941 1,769 0,11
PDGFRA 1,302 0,688 2,465 0,416
MYO3A 1,316 0,487 3,551 0,587
PIK3R1 1,317 0,799 2,172 0,278
FCGBP 1,322 0,65 2,688 0,439
UBC 1,324 0,328 5,344 0,692
KRTAP4.7 1,372 0,835 2,257 0,205
PLEKHG4B 1,376 0,644 2,94 0,408
PI3K 1,385 0,974 1,969 0,068
HCN1 1,391 0,734 2,636 0,309
PIK3CA 1,397 0,907 2,151 0,127
DRD5 1,403 0,688 2,86 0,349
DNAH5 1,425 0,773 2,626 0,253
MYH13 1,426 0,631 3,226 0,391
LRP1B 1,433 0,671 3,062 0,35
DNAH11 1,491 0,732 3,037 0,268
LRP1 1,514 0,619 3,702 0,36
ACACB 1,545 0,684 3,491 0,291
ADAMTS16 1,557 0,638 3,8 0,327
MUC16 1,559 1,08 2,25 0,017
EPPK1 1,568 0,693 3,548 0,276
PKHD1 1,58 0,895 2,788 0,111
MXRA5 1,585 0,743 3,383 0,23
SDHAP2 1,654 0,801 3,412 0,169
MLL3 1,658 0,815 3,374 0,158
APOB 1,692 0,963 2,976 0,065
C15orf2 1,739 0,714 4,236 0,217
POTEC 1,745 0,816 3,731 0,146
DNAH8 1,748 0,77 3,971 0,176
CHD8 1,794 0,733 4,391 0,194
PCDH11X 1,815 0,892 3,692 0,095
KRTAP4.11 1,842 0,864 3,927 0,108
SLIT3 1,885 0,927 3,836 0,075
LAMA1 1,886 0,927 3,835 0,075
SMARCA4 1,906 0,266 13,664 0,514
SCN9A 1,92 0,981 3,754 0,052
STAG2 2,051 1,046 4,022 0,033
TAF1L 2,123 0,936 4,815 0,065
ZNF845 2,181 0,806 5,902 0,115
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Supplementary table 3. Genetic changes associated with survival in IDH-mutant gliomas
Gene
Hazard
Ratio
lower upper p.value
F5 2,355 1,151 4,82 0,016
BCOR 2,395 1,12 5,12 0,02
IL32 2,535 0,624 10,302 0,178
WBSCR17 2,662 1,175 6,031 0,015
SEMA3C 2,683 1,252 5,748 0,008
AHNAK 2,804 1,236 6,362 0,01
Gene
Hazard
Ratio
lower upper p.value
DDX11L2 3,835 1,69 8,703 0,001
SLC6A3 4,313 1,356 13,714 0,007
ANO2 5,38 2,346 12,337 0
1p19q codeletion NA NA NA NA
LOC283788 NA NA NA NA
Gene
Hazard
Ratio
lower upper p.value
tri7loh10 1 1 1 1
IDH1 2,178 0,296 16,038 0,433
TP53 1,615 0,776 3,362 0,196
ATRX 1,226 0,626 2,402 0,552
TTN 1,554 0,601 4,022 0,359
PTEN 1 1 1 1
MUC16 0,534 0,073 3,921 0,531
PIK3CA 2,871 0,838 9,838 0,079
CIC 0,698 0,304 1,599 0,392
NBPF10 1,266 0,488 3,281 0,627
NF1 2,73 0,818 9,108 0,089
FRG1B 2,744 0,933 8,067 0,056
FLG 2,174 0,657 7,191 0,192
PIK3R1 2,038 0,885 4,693 0,088
RYR2 2,382 0,713 7,955 0,146
MUC17 1,567 0,37 6,639 0,539
PCLO NA NA NA NA
HSD17B7P2 0,818 0,194 3,449 0,784
MUC4 1,224 0,291 5,152 0,782
NOTCH1 1,315 0,545 3,177 0,541
RB1 1 1 1 1
SPTA1 NA NA NA NA
FUBP1 1,594 0,612 4,148 0,335
HMCN1 NA NA NA NA
AHNAK2 9,585 2,147 42,782 0
LRP2 NA NA NA NA
OBSCN NA NA NA NA
DNAH5 0,501 0,068 3,69 0,489
APOB 0,848 0,114 6,308 0,872
PKHD1 6,123 1,377 27,223 0,007
WASH3P 0,625 0,085 4,628 0,643
PCDHGC5 0,496 0,068 3,639 0,482
Gene
Hazard
Ratio
lower upper p.value
RYR3 NA NA NA NA
TCHH 5,623 1,305 24,227 0,009
USH2A 2,308 0,3 17,742 0,408
COL6A3 NA NA NA NA
FAT2 0,547 0,073 4,091 0,551
GPR98 2,833 0,378 21,212 0,289
KEL 2,113 0,282 15,802 0,456
CHEK2 0,908 0,122 6,768 0,925
FRAS1 0,556 0,074 4,163 0,562
PCDHAC2 0,445 0,061 3,273 0,414
SYNE1 0,883 0,118 6,582 0,903
DNAH8 5,496 1,596 18,933 0,002
KRTAP4.11 2,76 0,359 21,23 0,309
MUC5B 0,589 0,079 4,358 0,6
RELN 2,76 0,369 20,653 0,302
COL1A2 NA NA NA NA
DNAH11 NA NA NA NA
DOCK5 NA NA NA NA
HEATR7B2 1,666 0,395 7,024 0,482
MYH2 NA NA NA NA
PDGFRA NA NA NA NA
ZNF814 NA NA NA NA
ARID1A 0,332 0,045 2,442 0,255
BCOR 0,98 0,232 4,148 0,978
CNTNAP2 2,758 0,646 11,766 0,153
EPPK1 NA NA NA NA
ESPNP 0,339 0,046 2,494 0,265
FLG2 NA NA NA NA
HRNR 0,785 0,186 3,309 0,74
LOC100233156 1,516 0,528 4,353 0,436
MST1P9 NA NA NA NA
POTEC 1,462 0,346 6,183 0,604
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Prognostic markers in TCGA dataset
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Gene
Hazard
Ratio
lower upper p.value
DMD NA NA NA NA
DNAH2 NA NA NA NA
FBN3 NA NA NA NA
LOC283788 2,178 0,646 7,342 0,198
LRP1 1,774 0,237 13,284 0,572
MLL3 0,91 0,122 6,795 0,927
MXRA5 2,051 0,275 15,272 0,474
NBPF1 1,002 0,237 4,244 0,998
NEB 2,695 0,934 7,776 0,056
SDHAP2 NA NA NA NA
STK19 NA NA NA NA
TPTE NA NA NA NA
UBC NA NA NA NA
ZBTB20 0,646 0,087 4,784 0,666
CACNA1E 24,548 2,527 238,439 0
DNAH9 7,372 0,94 57,836 0,026
DSP NA NA NA NA
FCGBP NA NA NA NA
GABRA6 2,113 0,282 15,802 0,456
HCN1 NA NA NA NA
HSPG2 NA NA NA NA
KRTAP4.7 NA NA NA NA
KRTAP4.9 NA NA NA NA
MYH8 NA NA NA NA
PRDM9 NA NA NA NA
SMARCA4 0,304 0,041 2,238 0,216
SPAG17 NA NA NA NA
STAG2 NA NA NA NA
THSD7B 1,118 0,151 8,266 0,913
ABCB1 NA NA NA NA
C15orf2 1,699 0,514 5,621 0,379
CACNA1S 2,713 0,359 20,49 0,314
CHD9 NA NA NA NA
CSMD3 1,185 0,16 8,767 0,868
F5 2,309 0,31 17,219 0,401
KDR 2,809 0,365 21,633 0,3
MACF1 5,804 1,344 25,055 0,008
MYH13 NA NA NA NA
MYH4 1,084 0,254 4,628 0,914
NLRP5 NA NA NA NA
PCDH19 NA NA NA NA
RIMS2 1 1 1 1
Gene
Hazard
Ratio
lower upper p.value
RPL13AP20 NA NA NA NA
SDK1 NA NA NA NA
TUBBP5 NA NA NA NA
ABCC9 NA NA NA NA
ACACB 4,427 0,57 34,409 0,12
AFF2 NA NA NA NA
C3 0,573 0,078 4,219 0,58
CDH18 1 1 1 1
CHD8 NA NA NA NA
DCAF12L2 NA NA NA NA
DNAH3 1 1 1 1
DRD5 NA NA NA NA
FAM47C NA NA NA NA
FBN2 6,702 0,868 51,725 0,035
GRIN2A NA NA NA NA
IDH2 0,459 0,062 3,382 0,433
KIF2B 1,28 0,173 9,478 0,808
LAMA1 NA NA NA NA
LAMA3 2,625 0,349 19,751 0,33
LRP1B NA NA NA NA
LZTR1 NA NA NA NA
MLL2 NA NA NA NA
MUC2 NA NA NA NA
NOTCH2 5,799 1,719 19,567 0,001
PCDH11X 1 1 1 1
RP1 NA NA NA NA
SEMA3C NA NA NA NA
TCF12 5,085 1,507 17,159 0,004
UGT2B10 1,467 0,198 10,878 0,706
WBSCR17 5,72 0,735 44,514 0,059
ABCA13 NA NA NA NA
ADAMTS16 16,369 1,967 136,219 0
AHNAK 5,606 0,734 42,816 0,061
ANK2 8,049 1,037 62,448 0,017
ANO2 NA NA NA NA
CXorf22 NA NA NA NA
DDX11L2 NA NA NA NA
DSG3 9,026 1,154 70,577 0,011
GOLGA8DP NA NA NA NA
HLA.J 1,547 0,465 5,14 0,473
IL32 1,408 0,186 10,632 0,739
LAMA5 NA NA NA NA
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Supplementary table 4. Genetic changes associated with survival in IDH- mutated and 1p19q code-
leted gliomas
Gene
Hazard
Ratio
lower upper p.value
MYO3A NA NA NA NA
PLEKHG4B 28,862 5,812 143,325 0
RYR1 NA NA NA NA
SCN10A 3,379 0,449 25,412 0,209
SCN9A 1 1 1 1
SLC6A3 6,361 0,816 49,596 0,043
SLIT3 NA NA NA NA
TAF1L 36,377 3,783 349,822 0
TRPV6 NA NA NA NA
Gene
Hazard
Ratio
lower upper p.value
ZNF292 4,513 1,338 15,228 0,008
ZNF844 NA NA NA NA
ZNF845 1,369 0,183 10,225 0,759
PI3K 2,746 1,308 5,767 0,005
IDH1.or.IDH2 1 1 1 1
ATRX.or.TP53 1,601 0,769 3,334 0,204
1p19q codeletion 0,689 0,338 1,406 0,303
EGFR NA NA NA NA
Gene
Hazard
Ratio
lower upper p.value
tri7loh10 1 1 1 1
IDH1 1,509 0,186 12,27 0,699
TP53 2,545 0,307 21,094 0,37
ATRX NA NA NA NA
TTN 2,641 0,317 22,013 0,351
PTEN 1 1 1 1
MUC16 NA NA NA NA
PIK3CA 2,158 0,399 11,659 0,36
CIC 0,934 0,269 3,237 0,914
NBPF10 4,012 0,797 20,197 0,069
NF1 3,689 0,734 18,542 0,09
FRG1B 2,008 0,229 17,604 0,521
FLG 5,03 0,578 43,766 0,104
PIK3R1 0,99 0,208 4,703 0,99
RYR2 NA NA NA NA
MUC17 NA NA NA NA
PCLO NA NA NA NA
HSD17B7P2 0,953 0,117 7,783 0,964
MUC4 1,294 0,156 10,724 0,811
NOTCH1 1,869 0,56 6,235 0,302
RB1 1 1 1 1
SPTA1 NA NA NA NA
FUBP1 2,579 0,738 9,019 0,124
HMCN1 NA NA NA NA
AHNAK2 NA NA NA NA
LRP2 NA NA NA NA
OBSCN NA NA NA NA
DNAH5 NA NA NA NA
Gene
Hazard
Ratio
lower upper p.value
APOB 23,766 2,11 267,696 0
PKHD1 1 1 1 1
WASH3P NA NA NA NA
PCDHGC5 NA NA NA NA
RYR3 NA NA NA NA
TCHH 9,637 1,812 51,261 0,001
USH2A NA NA NA NA
COL6A3 1 1 1 1
FAT2 NA NA NA NA
GPR98 3,907 0,459 33,27 0,179
KEL NA NA NA NA
CHEK2 NA NA NA NA
FRAS1 0,849 0,098 7,365 0,882
PCDHAC2 NA NA NA NA
SYNE1 1,216 0,143 10,314 0,858
DNAH8 18,856 1,858 191,407 0,001
KRTAP4.11 NA NA NA NA
MUC5B NA NA NA NA
RELN 4,657 0,528 41,107 0,128
COL1A2 1 1 1 1
DNAH11 NA NA NA NA
DOCK5 NA NA NA NA
HEATR7B2 NA NA NA NA
MYH2 NA NA NA NA
PDGFRA NA NA NA NA
ZNF814 1 1 1 1
ARID1A NA NA NA NA
BCOR 1,203 0,147 9,841 0,863
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Gene
Hazard
Ratio
lower upper p.value
CNTNAP2 6,795 0,742 62,256 0,05
EPPK1 NA NA NA NA
ESPNP 1,648 0,196 13,827 0,642
FLG2 NA NA NA NA
HRNR 1,269 0,154 10,473 0,825
LOC100233156 2,071 0,521 8,231 0,291
MST1P9 NA NA NA NA
POTEC 1,286 0,15 11,066 0,818
DMD 1 1 1 1
DNAH2 NA NA NA NA
FBN3 1 1 1 1
LOC283788 3,852 0,448 33,122 0,186
LRP1 NA NA NA NA
MLL3 1,367 0,156 11,981 0,777
MXRA5 4,387 0,504 38,216 0,144
NBPF1 NA NA NA NA
NEB 1,669 0,202 13,802 0,631
SDHAP2 NA NA NA NA
STK19 NA NA NA NA
TPTE NA NA NA NA
UBC NA NA NA NA
ZBTB20 NA NA NA NA
CACNA1E NA NA NA NA
DNAH9 NA NA NA NA
DSP 1 1 1 1
FCGBP 1 1 1 1
GABRA6 1 1 1 1
HCN1 1 1 1 1
HSPG2 NA NA NA NA
KRTAP4.7 NA NA NA NA
KRTAP4.9 NA NA NA NA
MYH8 NA NA NA NA
PRDM9 1 1 1 1
SMARCA4 1,456 0,178 11,909 0,725
SPAG17 1 1 1 1
STAG2 1 1 1 1
THSD7B NA NA NA NA
ABCB1 NA NA NA NA
C15orf2 1,344 0,161 11,223 0,784
CACNA1S NA NA NA NA
CHD9 1 1 1 1
CSMD3 NA NA NA NA
Gene
Hazard
Ratio
lower upper p.value
F5 NA NA NA NA
KDR NA NA NA NA
MACF1 1 1 1 1
MYH13 1 1 1 1
MYH4 NA NA NA NA
NLRP5 NA NA NA NA
PCDH19 NA NA NA NA
RIMS2 1 1 1 1
RPL13AP20 NA NA NA NA
SDK1 1 1 1 1
TUBBP5 NA NA NA NA
ABCC9 NA NA NA NA
ACACB NA NA NA NA
AFF2 NA NA NA NA
C3 NA NA NA NA
CDH18 1 1 1 1
CHD8 NA NA NA NA
DCAF12L2 NA NA NA NA
DNAH3 1 1 1 1
DRD5 1 1 1 1
FAM47C NA NA NA NA
FBN2 1 1 1 1
GRIN2A NA NA NA NA
IDH2 0,663 0,082 5,39 0,699
KIF2B 1 1 1 1
LAMA1 NA NA NA NA
LAMA3 4,464 0,518 38,48 0,136
LRP1B NA NA NA NA
LZTR1 NA NA NA NA
MLL2 NA NA NA NA
MUC2 NA NA NA NA
NOTCH2 NA NA NA NA
PCDH11X 1 1 1 1
RP1 NA NA NA NA
SEMA3C 1 1 1 1
TCF12 5,759 0,642 51,658 0,076
UGT2B10 NA NA NA NA
WBSCR17 1 1 1 1
ABCA13 1 1 1 1
ADAMTS16 1 1 1 1
AHNAK NA NA NA NA
ANK2 1 1 1 1
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Supplementary table 5. Genetic changes associated with survival in IDH-and TP53/ATRX mutated 
gliomas
Gene
Hazard
Ratio
lower upper p.value
ANO2 1 1 1 1
CXorf22 NA NA NA NA
DDX11L2 NA NA NA NA
DSG3 1 1 1 1
GOLGA8DP 1 1 1 1
HLA.J 6,748 0,698 65,226 0,056
IL32 2,663 0,291 24,417 0,368
LAMA5 1 1 1 1
MYO3A NA NA NA NA
PLEKHG4B 41,661 5,691 304,965 0
RYR1 NA NA NA NA
SCN10A 1 1 1 1
SCN9A 1 1 1 1
Gene
Hazard
Ratio
lower upper p.value
SLC6A3 23,766 2,11 267,696 0
SLIT3 1 1 1 1
TAF1L NA NA NA NA
TRPV6 NA NA NA NA
ZNF292 6,156 1,19 31,854 0,013
ZNF844 NA NA NA NA
ZNF845 NA NA NA NA
PI3K 1,676 0,485 5,794 0,409
IDH1.or.IDH2 1 1 1 1
ATRX.or.TP53 2,123 0,259 17,435 0,473
1p19q codeletion 1 1 1 1
EGFR NA NA NA NA
Gene
Hazard
Ratio
lower upper p.value
tri7loh10 1 1 1 1
IDH1 NA NA NA NA
TP53 NA NA NA NA
ATRX 0,471 0,149 1,484 0,188
TTN 1,16 0,395 3,412 0,787
PTEN 1 1 1 1
MUC16 0,473 0,064 3,515 0,454
PIK3CA 64,622 4,026 1037,338 0
CIC NA NA NA NA
NBPF10 0,842 0,284 2,492 0,756
NF1 3,958 0,507 30,883 0,156
FRG1B 2,641 0,763 9,144 0,111
FLG 1,475 0,342 6,368 0,6
PIK3R1 4,938 1,813 13,453 0,001
RYR2 1,192 0,274 5,193 0,814
MUC17 1,253 0,289 5,437 0,763
PCLO NA NA NA NA
HSD17B7P2 0,705 0,094 5,279 0,732
MUC4 1,864 0,239 14,518 0,546
NOTCH1 2,649 0,602 11,65 0,18
RB1 1 1 1 1
SPTA1 1 1 1 1
FUBP1 1,957 0,256 14,993 0,51
Gene
Hazard
Ratio
lower upper p.value
HMCN1 NA NA NA NA
AHNAK2 4,748 0,596 37,843 0,104
LRP2 NA NA NA NA
OBSCN NA NA NA NA
DNAH5 0,568 0,075 4,317 0,58
APOB NA NA NA NA
PKHD1 6,106 1,291 28,887 0,009
WASH3P 0,763 0,1 5,801 0,793
PCDHGC5 0,551 0,074 4,122 0,556
RYR3 NA NA NA NA
TCHH NA NA NA NA
USH2A 2,32 0,289 18,627 0,415
COL6A3 1 0 Inf 1
FAT2 0,461 0,06 3,561 0,448
GPR98 1 1 1 1
KEL 1,698 0,222 12,986 0,606
CHEK2 1,223 0,159 9,384 0,846
FRAS1 NA NA NA NA
PCDHAC2 0,376 0,05 2,847 0,326
SYNE1 NA NA NA NA
DNAH8 3,818 0,84 17,354 0,062
KRTAP4.11 4,049 0,503 32,623 0,155
MUC5B 1,993 0,262 15,185 0,497
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Gene
Hazard
Ratio
lower upper p.value
RELN NA NA NA NA
COL1A2 NA NA NA NA
DNAH11 NA NA NA NA
DOCK5 NA NA NA NA
HEATR7B2 1,585 0,367 6,84 0,534
MYH2 NA NA NA NA
PDGFRA 1 0 Inf 1
ZNF814 1 0 Inf 1
ARID1A 0,94 0,123 7,182 0,952
BCOR 0,97 0,127 7,411 0,977
CNTNAP2 1,483 0,194 11,318 0,702
EPPK1 NA NA NA NA
ESPNP NA NA NA NA
FLG2 NA NA NA NA
HRNR 0,493 0,063 3,838 0,491
LOC100233156 1,733 0,393 7,638 0,462
MST1P9 NA NA NA NA
POTEC 2,996 0,388 23,107 0,269
DMD NA NA NA NA
DNAH2 1 1 1 1
FBN3 NA NA NA NA
LOC283788 1,626 0,369 7,172 0,517
LRP1 1,654 0,215 12,72 0,625
MLL3 1 0 Inf 1
MXRA5 NA NA NA NA
NBPF1 0,784 0,181 3,395 0,744
NEB 3,493 0,976 12,498 0,041
SDHAP2 NA NA NA NA
STK19 NA NA NA NA
TPTE NA NA NA NA
UBC NA NA NA NA
ZBTB20 0,618 0,081 4,742 0,641
CACNA1E 5,05E+31 0 Inf 0
DNAH9 9,3 1,118 77,365 0,012
DSP NA NA NA NA
FCGBP NA NA NA NA
GABRA6 1,698 0,222 12,986 0,606
HCN1 NA NA NA NA
HSPG2 NA NA NA NA
KRTAP4.7 1 1 1 1
KRTAP4.9 1 1 1 1
MYH8 NA NA NA NA
Gene
Hazard
Ratio
lower upper p.value
PRDM9 NA NA NA NA
SMARCA4 NA NA NA NA
SPAG17 NA NA NA NA
STAG2 NA NA NA NA
THSD7B 0,974 0,129 7,328 0,979
ABCB1 NA NA NA NA
C15orf2 2,837 0,648 12,428 0,148
CACNA1S 2,539 0,327 19,686 0,355
CHD9 NA NA NA NA
CSMD3 3,091 0,391 24,441 0,26
F5 2,253 0,295 17,211 0,421
KDR 4,885 0,596 40,023 0,102
MACF1 5,548 1,239 24,838 0,012
MYH13 NA NA NA NA
MYH4 0,828 0,189 3,627 0,801
NLRP5 1 1 1 1
PCDH19 NA NA NA NA
RIMS2 1 1 1 1
RPL13AP20 NA NA NA NA
SDK1 NA NA NA NA
TUBBP5 NA NA NA NA
ABCC9 NA NA NA NA
ACACB 4,488 0,549 36,709 0,125
AFF2 NA NA NA NA
C3 0,812 0,108 6,116 0,839
CDH18 1 1 1 1
CHD8 NA NA NA NA
DCAF12L2 NA NA NA NA
DNAH3 1 1 1 1
DRD5 NA NA NA NA
FAM47C NA NA NA NA
FBN2 7,112 0,873 57,97 0,032
GRIN2A 1 1 1 1
IDH2 NA NA NA NA
KIF2B 0,974 0,129 7,328 0,979
LAMA1 1 0 Inf 1
LAMA3 NA NA NA NA
LRP1B NA NA NA NA
LZTR1 1 1 1 1
MLL2 NA NA NA NA
MUC2 NA NA NA NA
NOTCH2 5,477 1,554 19,302 0,003
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Supplementary figure 1. PI3-kinase mutations are prognostic for survival in independent datasets. 
Validation showing that PI3-kinase mutations are prognostic for survival in a dataset of astrocytomas 
(A) and glioblastomas (B, n=4) after selecting for tumors for IDH1 and TP53/ATRX mutations (1, 2). PI3-
kinase mutations were found in 4/24 and 2/4 samples in the astrocytoma and glioblastoma datasets.
Gene
Hazard
Ratio
lower upper p.value
PCDH11X 1 1 1 1
RP1 1 0 Inf 1
SEMA3C NA NA NA NA
TCF12 4,102 0,925 18,189 0,044
UGT2B10 12,56 1,395 113,113 0,004
WBSCR17 5,843 0,712 47,917 0,062
ABCA13 NA NA NA NA
ADAMTS16 19,903 2,066 191,789 0
AHNAK 5,385 0,678 42,741 0,074
ANK2 7,791 0,957 63,422 0,023
ANO2 NA NA NA NA
CXorf22 NA NA NA NA
DDX11L2 NA NA NA NA
DSG3 7,791 0,957 63,422 0,023
GOLGA8DP NA NA NA NA
HLA.J 0,753 0,172 3,299 0,705
IL32 NA NA NA NA
LAMA5 NA NA NA NA
Gene
Hazard
Ratio
lower upper p.value
MYO3A NA NA NA NA
PLEKHG4B NA NA NA NA
RYR1 NA NA NA NA
SCN10A 2,996 0,388 23,107 0,269
SCN9A 1 1 1 1
SLC6A3 NA NA NA NA
SLIT3 NA NA NA NA
TAF1L NA NA NA NA
TRPV6 NA NA NA NA
ZNF292 4,578 0,582 36,005 0,112
ZNF844 NA NA NA NA
ZNF845 1,594 0,209 12,157 0,65
PI3K 6,246 2,358 16,549 0
IDH1.or.IDH2 1 1 1 1
ATRX.or.TP53 1 1 1 1
1p19q codeletion 1,957 0,256 14,993 0,51
EGFR NA NA NA NA
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Supplementary figure 2. Survival in histological subtypes of glioma stratified by tumor grade of sam-
ples included in the TCGA dataset. Median overall survival (OS) for astrocytomas was 5.2 and 3.7 years 
for grade II (n=30) and grade III (n=68). Median OS for oligodendrogliomas was 7.9 and 5.2 years for 
grade II (n=65) and grade III (n=45). Median OS for oligoastrocytomas was 5.3 and 6.3 years for grade 
II (n=42) and grade III (n=31), all P values stated in the figures are calculated using a Log-rank test. A 
Gehan-Breslow-Wilcoxon test, which gives more weight to early events, was also performed using 
Graphpad Prism software and yields P values of 0.19, 0.28 and 0.0013 for astrocytomas, oligodendro-
gliomas and oligoastrocytomas respectively.
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Supplementary figure 3. Overall survival in distinct molecular subtypes of glioma stratified by tumor 
grade of samples included in the TCGA dataset. As can be seen, within most defined molecular sub-
types, tumor grade remains a prognostic factor. P values were calculated using a log rank test. Number 
of samples (grade II, III and IV) for each graph: 119, 96 and 13 (IDH1); 37, 26 and 1 (CIC and/or FUBP1); 
42, 32 and 0 (1p/19q codeletion); 67, 50 and 14 (ATRX); 71, 73 and 78 (TP53); 0, 26 and 144 (EGFR); 1, 
12 and 80 (PTEN); 3, 26 and 185 (trisomy 7/LOH10); 3, 14 and 27 (NF1). Most cases with CIC/FUBP1, 
1p/19q codeletion, ATRX or TP53, also have an IDH mutation
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abStract
background
At current prognostication of low grade glioma remains suboptimal and might be 
improved with additional markers. These may guide treatment decisions, in particular 
on early adjuvant therapy versus wait and see after surgery.
Methods
We used a targeted Next-Generation Sequencing panel to assess mutational and copy 
number status of selected genes and chromosomes in a consecutive series of adult 
grade II supratentorial glioma, and assessed the impact of molecular markers of inter-
est on overall survival.
results
207 IDH mutated grade II glioma samples were analyzed with a median follow-up 
of 6.9 years. Loss of region 9p21.3 did not show a correlation with outcome in IDH 
mutated 1p/19q-codeleted oligodendroglioma or IDH mutated astrocytoma. We 
found a significant shorter overall survival with univariable analysis in IDH mutated 
astrocytoma patients with polysomy of chromosome 7 (Log rank P = 0.044) and in IDH 
mutated 1p/19q-codeleted oligodendroglioma patients with a PTEN mutation (Log 
rank P = 0.033). We could not validate these findings in multivariate analysis or in the 
TCGA dataset.
conclusions
Loss of 9p21.3 is not associated with outcome in a molecularly defined cohort of grade 
II glioma and therefore it remains unclear if loss of 9p21.3 can be used as additional 
marker of anaplasia or to guide treatment decisions. Trisomy of chromosome 7 in IDH 
mutated astrocytoma and PTEN mutations in IDH mutated oligodendroglioma are 
potential markers of poor prognosis, but require confirmation in larger series.
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introDuction
In 2016 the World Health Organization Classification of Tumors of the Central Nervous 
System (WHO) was updated, resulting in a major change in the classification of diffuse 
gliomas.1 The 2016 WHO classification provides an integrated diagnosis of glioma by 
combining histopathological with genotypic features. Moreover, in the case of dis-
crepancy between genotypic and histopathological features, the genotypic features 
are leading in classifying a glioma subtype. As a result the 2016 CNS WHO markedly 
improved the objectivity of classification and prognosis estimation as compared to the 
previous version.1-3
Three clinically relevant subgroups of diffuse low-grade (grade II) gliomas are identi-
fied and recognized by the WHO 2016 classification based on two molecular markers: 
1) Oligodendroglioma, IDH mutant and 1p/19q-codeleted (IDH1/2 mutation in combi-
nation with presence of a co-deletion of the entire 1p and 19q chromosomal arms), 2) 
diffuse astrocytoma, IDH mutant; (IDH1/2 mutation without 1p19q co-deletion), and 
3) diffuse astrocytoma, IDH1/2 wildtype. Other frequently reported genetic changes in 
glioma are CIC, FUBP1, TP53, ATRX, TERT promoter mutations and copy number chang-
es of chromosome 7, 9, and 10. 1, 2, 4, 5 Although the 2016 CNS WHO update is robust 
and provides a more accurate prognosis estimation, there is still variation in outcome 
within the different entities and the grading of glioma is still depending on histo-
logical features. Prognostication might be further improved if additional molecular 
markers can be identified that correlate with prognosis. These markers may facilitate 
treatment decisions, in particular for early radiotherapy and adjuvant chemotherapy 
versus a wait and watch policy after surgery. This is in particular relevant, as the cur-
rently used criteria (age of 40, less than gross total resection) are quite arbitrary, and 
in some patients that are 40 years or older with a less than gross total resection, a wait 
and watch period of years is possible.6-8 Thus, molecular factors showing a clinically 
significant relation with outcome would be highly welcome.
Several studies have tried to further stratify molecularly defined glioma, most of 
them in anaplastic glioma. For example, some studies showed that loss of chromo-
some 9p or specifically the 9p21.3 region is associated with a worse prognosis in 
various subtypes of grade III and IV glioma.9-11 This could however not be validated in 
a recently published large cohort of grade II and III glioma.12 In the present study we 
aimed to identify molecular prognostic markers for grade II IDH mutated astrocytoma 
(in particular loss of 10q, trisomy of chromosome 7, PTEN mutations) and in grade II 
IDH mutated 1p19q-codeleted oligodendroglioma (in particular loss of 9p21.3, CIC, 
FUBP1, and PTEN mutations). To our knowledge there are no published studies that 
investigated prognostic impact of these markers specifically in molecularly defined 
grade II glioma. Therefore, in a well-defined cohort of histologically proven supraten-
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torial adult grade II glioma we used a targeted Next-Generation Sequencing panel for 
molecular classification and evaluated the prognostic value of glioma specific molecu-
lar markers.
MEthoDS
Patient selection
For this study we used a cohort of patients from a project on extent of resection in 
grade II glioma.13 Adult patients (age ≥ 18 years) with histopathologically confirmed 
supratentorial grade II glioma were included. Tissue samples were collected in two 
Dutch hospitals (Erasmus MC Cancer Institute, Rotterdam; and Elisabeth-TweeSteden 
Hospital, Tilburg). Histopathological diagnosis and low grade was confirmed by a dedi-
cated neuropathologist (J.M.K.). Time-window of patient inclusion was 2003-2016. For 
clinical factors, age, KPS, type of surgery, and treatment after surgery were collected. 
This study was approved by the medical ethics committee of Erasmus MC.
Dna extraction
DNA was isolated from formalin-fixed-paraffin-embedded (FFPE) tissue blocks. Tissue 
areas with high percentage of neoplastic cells (preferably >70%, but at least 50%) 
were manually macrodissected from 10µm sections. Macrodissected tissue was di-
gested using Proteinase K incubation at 56°C overnight in presence of 5% Chelex 100 
resin (Bio-Rad). After overnight incubation, proteinase K was inactivated at 90°C for 
10 minutes. Next, dissolved DNA was separated from Chelex resin and cell debris by 
centrifugation at 20g for 5 minutes. DNA concentration was measured using the Qubit 
3.0 Fluorometer according to manufacturer’s protocol (Life Technologies).
next-Generation-Sequencing
We used Next-Generation Sequencing to assess mutational and copy number status 
of selected genes and chromosomes. The primer panel consisted of primers for glioma 
specific genes of interest (hot spot regions, or whole gene) and primers for highly 
polymorphic single nucleotide polymorphisms to detect large genomic alterations 
in chromosomes of interest. Chromosomal imbalances and loss of heterozygosity 
(LOH) were estimated as described previously.3 An overview of the targeted hotspots/
whole genes and chromosomes is shown in Supplementary Table 1. Sequencing was 
performed with the Ion Torrent Personal Genome Machine or Ion S5 (Life Technolo-
gies). TERT promoter mutational status (C228T & C250T mutation) was assessed in a 
separate assay as described before (SNaPshot, Life Technologies).3
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Survival
All patients were followed until death or censored at date of last follow-up. Overall 
survival (OS) was measured from the date of diagnostic scan until date of death or 
censorship. Date of death was provided by patient records or the Municipal Personal 
Records Database. The database was developed and maintained at Erasmus MC, and 
locked on March 21st 2018.
Statistical analysis
All analyses were performed using R (3.3.2) and RStudio (1.0.44). Overall survival was 
measured as time between date of diagnostic scan and date of death or censorship. 
Overall survival is shown in Kaplan-Meier plots (ggplot2 package in R). Univariable 
analyses were performed using the Log-rank test and multivariable analyses with 
Cox proportional-hazards models. Categorical data were analyzed with Pearson’s 
chi-square test or Fisher’s exact test when assumptions of the chi-square test were 
violated (as indicated in the respective tables). Kruskal-Wallis test was used for con-
tinuous data. All calculations were two-sided tests, with a p-value <0.05 considered as 
statistically significant.
rESultS
We identified 246 patients with a pathologically confirmed grade II glioma with avail-
able FFPE material. Of these, 2 patients were excluded due to insufficient DNA yield 
and no remaining tissue for DNA isolation, and 14 were excluded from analysis due 
to sequencing failure (very low coverage and/or uniformity for most amplicons after 
two attempts). At the time of analysis, 53 patients were reported dead, 15 of the 95 
IDH mutated 1p/19q-codeleted oligodendroglioma patients and 38 of the 112 IDH 
mutated astrocytoma patients.
Molecular classification
As we were interested in additional markers for IDH mutated grade II glioma, 23 
patient samples that were classified as IDH wildtype were excluded from further 
analyses. 207 patients were included in final analyses with a median follow-up of 6.9 
years (range 0.4-21.7 years). Clinical characteristics are shown in Table 1. An oncoprint 
plot with all mutations and copy number alterations for the 207 patients is shown in 
figure 1. Mutation frequencies per molecular subgroup are shown in table 2. Median 
overall survival per CNS WHO 2016 molecular subgroup was consistent with literature 
(Supplementary Figure 1).
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iDh mutated astrocytoma
107 of the 112 IDH mutated astrocytomas could be reliably evaluated for imbalance of 
chromosome 7: 13 samples showed imbalance compatible with trisomy of the entire 
chromosome 7. In univariable analysis trisomy of chromosome 7 was significantly 
associated with shorter overall survival (Log rank P = 0.044). However, this survival dif-
ference lost significance when correcting for age and KPS (HR 2.22; 95% CI 0.95-5.20; 
P =0.066). Only 2 samples showed loss of entire chromosomal arm 10q, both with a 
relatively poor overall survival of less than 8 years (figure 2). Loss of 9p21.3 (n = 18) was 
not associated with outcome. Out of the 18 patients with loss of 9p21.3, 13 showed 
loss of the entire 9p chromosomal arm, which was also not associated with outcome. 
A PTEN mutation was detected in 3 patients (all three no loss of 10q) and did not show 
an impact on outcome (figure 2).
table 1. Patient characteristics
Characteristics
Oligodendroglioma Astrocytoma IDHmt
PN % N %
Patients (n) 95  112   
Sex     0.149
Male 49 51,6 71 63.4  
Female 46 48,4 41 36.6  
Age     <0.0001
Median (IQR) 45 (37-52) 37 (29 - 45)  
Type of 1st surgery     0.002†
Awake craniotomy 51 53,7 54 48.2  
Normal resection 23 24,2 49 43.8  
Open biopsy 7 7,4 2 1.8  
Stereotactic biopsy 14 14,7 7 6.2  
Preoperative KPS     0.064
Median (IQR) 100 (100-100) 100 (90 - 100)  
Histopathological diagnosis      
Grade II Astrocytoma 8 8,4 87 77.7  
Grade II Oligodendroglioma 77 81,1 9 8.0  
Grade II Oligo-astrocytoma 10 10,5 16 14.3  
Treatment after 1st surgery     <0.0001
Wait & Scan 52 54,7 52 46.4  
Chemotherapy 24 25,3 5 4.5  
Radiotherapy 16 16,8 42 37.5  
Chemoradiation 3 3,2 13 11.6  
Follow-up (years)      
Median (range) 7.3 (0.8-20.4) 5.7 (0.3 - 15)  
† Fisher’s exact test
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figure 1. Oncoprint plot with overview of somatic alterations per patient. At the top of the figure 
the WHO 2007 and WHO 2016 classification are shown. In the middle part all somatic variants and 
copy number alterations are shown. Patients are separated based on the WHO 2016 classification. 
IDH mutated 1p/19q-codeleted patients are depicted in the left part of the figure and IDH mutated 
astrocytoma patients on the right part of the figure. The bottom part of the figure shows the clinical 
characteristic age per patient.
table 2. Frequencies of gene mutations per WHO subgroup
Gene
IDH mutated astrocytoma IDH mutated 1p/19q-codeleted 
oligodendroglioma
N % N %
IDH1 111 99,1 87 91,6
IDH2 1 0,9 8 8,4
TP53 105 93,8 0 0
ATRX 75 67 0 0
CIC 2 1,8 52 54,7
FUBP1 0 0 36 37,9
TERT 3 2,7 91 95,8
PIK3CA 1 0,9 2 2,1
EGFR 0 0 0 0
NOTCH1 3 2,7 3 3,2
PTEN 3 2,7 5 5,3
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iDh mutated 1p/19q-codeleted oligodendroglioma
In IDH mutated 1p/19q-codeleted oligodendroglioma, both CIC and FUBP1 mutations 
were frequent events, but neither was associated with prognosis (figure 3). In 27 out 
of the 77 patients that could be reliably evaluated for copy number changes on chro-
mosome 9p, loss of 9p21.3 was found. Of these, 23 showed loss of entire chromosomal 
arm 9p. No homozygous deletions or mutations of CDKN2A were detected. Loss of 
9p21.3 did not have significant impact on overall survival (Log rank P=0.12) (figure 
3). Additional analysis for impact of loss of entire 9p did not show different results. 
Trisomy of chromosome 7 and loss of chromosomal arm 10q were present in a few 
samples, both without impact on overall survival (figure 3). Five patients were PTEN 
mutated and showed a significantly shorter OS in univariable analysis (Log rank P = 
0.033). This survival difference was not significant anymore when correcting for age 
and KPS (HR 3.73; 95% CI 0.78-17.76; P =0.097).
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figure 2. Kaplan-Meier plots with overall survival of IDH mutated astrocytoma patients stratified for 
presence of (A) Imbalance pattern consistent with trisomy of chromosome 7, (B) loss of 9p21.3 region, 
(C) loss of chromosomal arm 10q, (D) and presence of a PTEN mutation.
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figure 3. Kaplan-Meier plots with overall survival of IDH mutated 1p/19q-codeleted oligodendroglio-
ma patients stratified for presence of (A) Imbalance pattern consistent with trisomy of chromosome 7, 
(B) loss of 9p21.3 region, (C) loss of chromosomal arm 10q, (D) presence of CIC mutation, (E) presence 
of FUBP1 mutation, (F) and presence of a PTEN mutation.
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Exploratory analyses
On further exploratory analyses, we found no other molecular markers that sig-
nificantly impact on overall survival in molecularly defined LGG with the targeted 
sequencing panel we used.
Validation of findings in the TCGA
We aimed to validate our findings in the publically available dataset The Cancer Ge-
nome Atlas (TCGA). In the TCGA dataset, 9 out of 72 grade II IDH mutated astrocytoma 
showed trisomy of chromosome 7, but this was not significantly associated with a 
difference in overall survival in univariate analysis (Log rank P = 0.3). We also analyzed 
the TCGA dataset for presence of loss of 10q in grade II IDH mutated astrocytoma. Only 
one sample showed loss of 10q, with a poor survival (1.75 years). Among the 47 grade 
II IDH mutated 1p/19q-codeleted oligodendroglioma samples in the TCGA dataset, 
there were no samples with a PTEN mutation, confirming the rarity of this event.
DiScuSSion
In this study we aimed to investigate the prognostic impact of additional molecular 
markers in grade II IDH mutated astrocytoma and grade II IDH mutated 1p/19q-code-
leted oligodendroglioma. We used a targeted NGS panel to investigate genes that are 
frequently mutated in glioma and to investigate regions that are frequently reported 
to have copy number changes.
Loss of chromosome 9p or in particular the 9p21.3 region is a frequently reported 
copy number variation in all glioma subtypes.2, 9-11 Several studies investigated the im-
pact of loss of 9p/9p21.3 on prognosis. A meta-analysis published in 2015 pooled the 
data of 13 different studies that were published between 2002 and 2013.10 Although 
most individual studies in this meta-analysis did not show a survival difference, the 
pooled data showed that loss of 9p was significantly associated with a poorer prog-
nosis. However, most studies in this analysis did not take into account confounding 
factors such as IDH1/2 mutational status, and a subgroup analysis of types of gliomas 
showed that impact of loss of 9p on overall survival was particularly present in the glio-
blastoma subtype. A recent study specifically focused on the impact of 9p loss in grade 
II and III glioma and found that loss of 9p is an independent prognostic factor in IDH 
mutated glioma, however, the effect was most clear in IDH mutated astrocytomas.11 In 
opposite, Alentorn et al. found loss of 9p to be a poor prognostic marker in anaplastic 
oligodendroglioma.9 A later study by Aoki et al. did not confirm this finding however.12 
Our study is the first that specifically focusses on the impact of loss of 9p21.3 and 
entire 9p in histologically defined grade II glioma. We could not confirm impact of 
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loss of 9p21.3 region or entire 9p on prognosis neither in IDH mutated astrocytoma 
nor in IDH mutated 1p/19q-codeleted oligodendroglioma. However, a trend towards 
shorter overall survival in IDH mutated 1p/19q-codeleted oligodendroglioma with loss 
of 9p21.3 is visible, and longer follow-up and larger sample size is necessary for final 
conclusions. Exact comparison of our data with previous literature is difficult, because 
of different selection criteria in the different cohorts. Therefore, it is yet unclear if in 
grade II IDH mutated glioma loss of 9p21.3 region can be used as marker of anaplasia 
or to guide more aggressive treatment strategies.
Trisomy of chromosome 7 is also frequently reported in glioma.2, 14, 15 In combination 
with loss of 10q it is considered an early event in glioblastoma IDH wildtype and is 
correlated with dismal prognosis in grade II and III IDH wildtype glioma.2, 15-17 Trisomy 
of chromosome 7 is also described in lower grade glioma, though less frequently. The 
impact of trisomy of 7 on overall survival in IDH mutated low grade glioma is not clear. 
To our knowledge no large series are published. Wessels et al. reported that polysomy 
of 7 was associated with a poorer prognosis in grade II astrocytoma, but this report 
antedates the discovery of the role IDH mutations in glioma.14 In our cohort we found 
that trisomy of chromosome 7 might be a marker of poor prognosis in IDH mutated 
astrocytoma. However, this could not be validated in multivariate analysis or in the 
TCGA data, and this observation requires validation in a larger independent cohort to 
define the clinical value.
CIC and FUBP1 mutations are frequently mutated in IDH mutated 1p/19q-codeleted 
oligodendroglioma and the prognostic impact has been investigated in several series. 
One study by Gleize et al reported that inactivating CIC mutations in IDH mutated glio-
ma correlate with poorer outcome. In other cohorts this effect was not observed.3, 18-20 
In our cohort we also did not find a correlation between CIC nor FUBP1 mutation and 
prognosis.
Our study has several limitations. The retrospective nature comes with the risk of 
a selection bias. We tried to avoid selection bias by analyzing a consecutive cohort of 
all grade II gliomas undergoing surgery within a specified period. Also due to the ret-
rospective nature, treatment was heterogeneous. Furthermore, we may have missed 
smaller region copy number alterations and other mutations in regions not covered 
by our NGS panel. We used a diagnostically validated21 and targeted NGS panel that 
consists of highly polymorphic SNPs that cover whole chromosomes of interest with 
roughly 1 SNP per 3MB. Large scale copy number variations of whole chromosomes 
or large parts of chromosomes can therefore be reliably detected, but small region 
or subclonal copy number variations are potentially missed. However, the aim of this 
study was to validate the impact of large region copy number variations which were 
described before and that are considered to be early events, and these can be reliably 
detected with the panel used.21 Also, it is known that lengthy follow-up in studies on 
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low-grade glioma is necessary for definitive conclusions, so longer of follow up of this 
dataset is necessary.
In conclusion, in univariable analysis we found a significant shorter overall survival 
in IDH mutated astrocytoma patients with trisomy of chromosome 7, and in IDH mu-
tated 1p/19q-codeleted oligodendroglioma patients with a PTEN mutation. However, 
we could not confirm these findings in multivariate analysis or in the TCGA validation 
set and therefore these findings require validation in other larger series. We could not 
confirm the impact on OS of LOH of 9p21.3 (the CDKN2A region) which is frequently 
reported as a progression marker particularly in higher grade glioma. However, we 
need lengthy follow-up for definitive conclusions. Also, other strategies should be 
pursued to identify prognostic relevant molecular markers within these IDH mutant 
glioma subgroups, like methylation patterns and total number of chromosomal aber-
rations.
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Supplementary table 1. Overview of targeted genes and chromosomes
Whole Gene Hotspots SNPs SNaPshot
TP53 EGFR (exon 3+15) chr1 TERT promoter
FUBP1 H3F3A (exon 2) chr10 (including PTEN)
PTEN IDH2 (exon 4) chr12 (including MDM2)
CIC IDH1 (exon 4) chr19
CDKN2A PIK3CA (exon 10+21) chr7 (including EGFR and MET)
NOTCH1 BRAF (exon 11+15) chr9 (including CDKN2A)
ATRX chrY
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Supplementary figure 1. Kaplan-Meier plot with overall survival stratified by WHO 2016 molecular 
subgroup. IDH mutated 1p/19q-codeleted patients have significantly longer overall survival (median 
OS not reached) compared to IDH mutated astrocytoma patients (median OS 10.2 years) ( Log rank 
test: P = 0.0001).
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With the 2016 revision of the World Health Organization classification of tumors 
of the central nervous system (WHO 2016) testing for the presence of mutations in 
isocitrate dehydrogenase 1 and 2 (IDH) and chromosome 1p/19q status is the cor-
nerstone of glioma classification.5 Approximately 80% of diffuse lower-grade (grade 
II & III) gliomas (DLGG) are IDH mutated and have a relatively favorable prognosis 
compared to their IDH wildtype (IDHwt) counterparts.2 The prognosis of IDHwt DLGG 
is almost similar to primary glioblastoma and genetic aberrations that are seen in 
primary glioblastoma are also reported in IDHwt DLGG: the combination of trisomy 
of whole chromosome 7 and loss of chromosomal arm 10q (+7/-10q), and telomerase 
reverse transcriptase gene promoter (TERTp) mutations.2, 6, 7 However, +7/-10q or TERTp 
mutations are not part of the WHO 2016 criteria and not all IDHwt DLGG have these 
specific molecular aberrations.2, 5 Although clinical trials have not been performed, in 
view of their poor prognosis aggressive treatment regimens for IDHwt DLGG has been 
suggested. However, as this is not a well-defined separate entity, the question remains 
whether IDHwt DLGG classified according to current WHO classification qualifies as a 
single entity, with sufficient information to estimate prognosis adequately and there-
fore guide treatment, or if the assessment of additional markers is necessary and if so 
which. A recent study by Aibaidula et al. showed that IDHwt DLGG are prognostically 
heterogeneous and that markers like TERTp, EGFR amplification and H3F3A mutation 
could be of additional value.1 The prognostic role of +7/-10q and its relationship with 
TERTp mutations were not reported however. In this study we report on the impact of 
additional molecular markers, including +7/-10q and TERTp, on overall survival in adult 
IDHwt DLGG.
In our institute targeted Next-Generation Sequencing is part of routine diagnostics 
for DLGG. We assess copy number changes of chromosome 1, 7 (including EGFR ampli-
fication), 9p, 10, 12, 19, and mutational status of genes IDH1/2, TP53, ATRX, CIC, FUBP1, 
EGFR, PIK3CA, CDKN2A, PTEN, H3F3A, BRAF, NOTCH1, TERTp. In our routine diagnostics 
we use gain of whole chromosome 7 and loss of whole chromosomal arm 10q as 
criterion for +7/-10q status. Our sequencing protocol has been described previously.3, 4 
Between January 2003 and January 2017 we sequenced a total of 639 tumors as part 
of daily diagnostic routine (samples since 2013) and as part of a project on extent 
of resection in DLGG (samples since 2003).8 Of these, 510 tumors were histologically 
classified as DLGG and on sequencing 74 were IDHwt. We collected Karnofsky Perfor-
mance Status (KPS) at diagnosis, age, gender and overall survival which was defined as 
time between date of diagnostic imaging and date of death. Patients that were alive 
at the time of analysis were censored.
Further stratification of these IDHwt DLGG showed a molecularly heterogeneous 
group of tumors. Only 52,7% of patients (n=39) showed a +7/-10q phenotype that is 
presumed to be a molecular characteristic of glioblastoma. Of these, all but one also 
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had a TERTp mutation. In contrast, 18.9% of patients (n=14) were TERTp mutated, but 
showed no +7/-10q pattern. 4.1% (n=3) were classified as BRAF mutated glioma, and 
4.1% (n=3) as H3F3A mutated glioma. Age at diagnosis of BRAF and H3F3A mutant 
patients was generally younger compared to the other groups (table 1). A substantial 
part of samples (20.3%; n=15) could not be further stratified (either no known classify-
ing variants or no variants found at all). The clinical importance of this heterogeneity 
becomes clear by overall survival analysis(Figure 1). The few BRAF mutant patients 
(median overall survival not reached) and the unclassified patients had better outcome 
compared to +7/-10q, TERTp mutated only and H3F3A mutated patients. The latter 
three all have a very poor prognosis. The longer overall survival of unclassified patients 
is remarkable. An explanation might be that these unclassified IDHwt DLGG belong 
to a specific, not yet identified, molecular subset with better prognosis. Additional 
immunohistochemistry with IDH1 R132H antibody was negative in 12 unclassified 
patients. For the 3 other unclassified patients there was no available tissue anymore 
for immunohistochemistry. However, in each of these 3 samples we found somatic 
variants or copy number alterations suggestive of tumor, although not classifying. In 
these samples there was sufficient coverage of both IDH1 and IDH2. Therefore, it is 
less likely that these tumors are actually true low-grade gliomas of oligodendroglial 
or astrocytic lineage wherein the corresponding molecular aberrations escaped detec-
tion due to technical limitations or unexpected low tumor cell percentage. Another 
table 1. Patient characteristics
 All patients IDH 7+/10- Only TERTp BRAF H3F3A Unclassified
N (%) N (%) N (%) N (%) N (%) N (%)
Characteristic       
Number of patients 74 39 14 3 3 15
Gender
 Male 49 (66.2%) 24 (61.5%) 11 (78.6%) 3 (100.0%) 2 (66.7%) 9 (60.0%)
 Female 25 (33.8%) 15 (38.5%) 3 (21.4%) 0 (0.0%) 1 (33.3%) 6 (40.0%)
KPS at diagnosis
 100 29 (39.2%) 14 (35.9%) 1 (7.1%) 3 (100.0%) 2 (66.7%) 9 (60.0%)
 90 21 (28.4%) 12 (30.8%) 4 (28.6%) 0 (0.0%) 1 (33.3%) 4 (26.7%)
 80 19 (25.7%) 10 (25.6%) 7 (50.0%) 0 (0.0%) 0 (0.0%) 2 (13.3%)
 70 3 (4.1%) 2 (5.1%) 1 (7.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
 60 2 (3.7%) 1 (2.6%) 1 (7.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Age at diagnosis
 median (IQR) 56 (47-63) 57 (52-64) 60 (51-68) 47 (32-49) 25 (24-32) 52 (42-62)
 age <40 11 (14.9%) 2 (5.1%) 1 (7.1%) 1 (33.3%) 3 (100.0%) 4 (26.7%)
 age 40 - 60 34 (45.9%) 21 (53.8%) 6 (42.9%) 2 (66.7%) 0 (0.0%) 5 (33.3%)
 age >60 29 (39.2%) 16 (41.0%) 7 (50.0%) 0 (0.0%) 0 (0.0%) 6 (40.0%)
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interesting observation is the survival difference between the IDHwt +7/-10q (also 
TERTp mutated, except for one patient) patients and the patients with only a TERTp 
mutation; the patients with only a TERTp mutation have a significant shorter over-
all survival ( Log-Rank test: p = 0.024). To confirm our findings we analyzed the 56 
IDHwt DLGG in the publically available Cancer Genome Atlas (TCGA) and found that 
20 samples showed a +7/-10q phenotype (all but two also TERTp mutated) and 18 
samples were only TERTp mutated. Unfortunately the small sample size and limited 
follow-up do not allow to adequately give conclusions about prognostic differences 
between these groups. Therefore our findings require confirmation in an independent 
dataset to determine whether the TERTp mutated subgroup without +7/-10q is a 
biological distinct group.
In conclusion, we showed that adult IDHwt DLGG is a molecularly heterogeneous 
group of tumors with a widespread variation in prognosis. Consequently, assessment 
of only IDH and 1p19q status is not accurate enough to label IDHwt DLGG as prognosti-
cally poor and therefore to guide treatment decisions of these tumors. According to our 
results at least assessment of TERTp mutational status or +7/-10q status is necessary 
in IDHwt glioma to confirm whether a patient with DLGG has poor survival. However, 
when validated in independent series, assessment of both +7/-10q status and TERTp 
status seems preferable since TERTp mutation without +7/-10q shows shorter overall 
survival in our dataset. When TERTp is wildtype or +7/-10q is not present, further test-
ing for other markers ( at least H3F3A and BRAF) is necessary to adequately inform 
patients about prognosis and to decide on treatment.
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abStract
background
Extensive resections in low-grade glioma are associated with improved overall sur-
vival. However, WHO classification of gliomas has been completely revised and is now 
predominantly based on molecular criteria. This requires re-evaluation of the impact 
of surgery in molecularly defined low-grade glioma subtypes.
Methods
We included 228 adults who underwent surgery since 2003 for a supratentorial 
low-grade glioma. Pre-and postoperative tumor volumes were assessed with semi-
automatic software on T2-weighted images. Targeted Next-Generation Sequencing 
was used to classify samples according to current WHO classification. Impact of 
postoperative volume on overall survival, corrected for molecular profile, was assessed 
using a Cox proportional-hazards model.
results
Median follow-up was 5.79 years. In 39 (17.1%) of histopathologically classified glioma 
the subtype was revised after molecular analysis. Complete resection was achieved 
in 35 patients (15.4%), and in 54 patients (23.7%) only small residue (0.1-5.0 cm3) 
remained. In multivariable analysis, postoperative volume was associated with overall 
survival with a HR of 1.01 (95% CI 1.002-1.02; p=0.016) per cm3 increase in volume. The 
impact of postoperative volume was particularly strong in IDH mutated astrocytoma 
patients, where even very small postoperative volumes (0.1-5.0 cm) already negatively 
affected overall survival.
conclusions
Our data provides the necessary re-evaluation of the impact of surgery in molecularly 
defined low-grade glioma and supports maximal resection as first-line treatment for 
molecularly defined low-grade glioma.
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introDuction
Low-grade (WHO grade II) gliomas (LGG) are primary brain tumors that grow relatively 
slow but with a diffuse infiltrative pattern, which makes them impossible to fully 
eradicate. Recurrences always occur, and despite all advances in the field of oncology, 
the treatment modalities for LGG remain to be surgery, radiotherapy, and chemo-
therapy.1,2 The optimum use of these regimens has been controversial for many years, 
though the use of chemo-and radiotherapy for LGG has been studied in several ran-
domized controlled clinical trials.3-7 The role of surgery has never been investigated in 
a randomized manner, and it is unlikely this ever will be due to ethical reasons in view 
of the assumptions about equipoise and the duration of such a trial. However, more 
extensive surgery was associated with an increased overall survival (OS) in several 
retrospective series.8-13 Unfortunately, interpretation of these studies is not straight-
forward, due to probable selection bias. For example, the resectability of a brain tumor 
and the decision to operate depends on its location, size, and delineation: small and 
superficially located tumors in non-eloquent areas are more likely to be extensively 
resected. However, location, eloquency and size are major prognostic factors by them-
selves.14 In addition, previous studies were based on the histopathological diagnosis of 
gliomas which is subject to a large degree of interobserver variability, particularly for 
LGG.15 Nowadays, gliomas can also be classified based on a limited set of molecular 
markers (isocitrate dehydrogenase 1/2 (IDH1/2) gene mutation, chromosome 1p and 
19q co-deletion), and this classification outperforms the prognostic value of the previ-
ous histopathological classification of gliomas. 16,17 This molecular approach to glioma 
diagnosis is now incorporated in the 2016 WHO Classification of tumors of the Central 
Nervous System (WHO 2016).15,18,19 Since some mutations preferentially manifest in 
distinct brain regions, the impact of extent of resection in the different molecular 
subtypes remains to be determined, as well as to what extent previous studies are 
confounded by this major prognostic factor. 20,21 To address this issue, we examined 
the impact of surgery on OS in molecularly defined LGG in a large retrospective cohort.
MEthoDS
Patient selection and clinical data acquisition
We studied a cohort of adult patients with a supratentorial LGG (age ≥ 18 years) who 
underwent a resection or biopsy in one of two neurosurgical centers (Erasmus MC 
Cancer Institute, Rotterdam, The Netherlands (Erasmus MC); Elisabeth-TweeSteden 
Hospital, Tilburg, The Netherlands (ETZ)), with tumor material (formalin-fixed-paraffin-
embedded (FFPE) tissue) available for tissue analysis and pre- and post-operative MR 
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scans (T2-weighted and/or T2-weighted Fluid Attenuated Inversion Recovery (FLAIR); 
either 2D or 3D) available for radiological review. We included only histopathologi-
cally confirmed LGG (grade II) diagnosed by a dedicated neuropathologist (J.M.K.). As 
the extent of resection can be improved with the advent of awake craniotomy for 
tumors in eloquent areas, the time-window of patient inclusion was based on the 
year of introduction of awake craniotomies in the respective institutes (2003-2016 for 
Erasmus MC and 2008-2016 for ETZ).22 Patients that underwent their first resection 
or biopsy in this period were included, even when radiological diagnosis was made 
before this time window. Patients only undergoing a biopsy were also included, since 
those samples potentially reflect a distinct subset of patients with tumors that are 
more difficult to resect and/or with a distinct molecular profile. We excluded patients 
with WHO grade II histology who had a radiological appearance (extensive tumor 
enhancement) suggestive of a high-grade lesion. Clinical data were collected from 
patient records. All included patients were followed until death or censored at the 
date of last follow-up. Date of death was provided by patient records or the Municipal 
Personal Records Database. OS was defined as time between date of diagnostic scan 
and death or censorship. Progression free survival (PFS) was defined as time between 
date of first surgical intervention and date of first clinical or radiological progression 
as indicated by the treating clinician. The database was developed and maintained at 
Erasmus MC, and locked on January 30th 2017. This study was approved by the medical 
ethics committee of Erasmus MC.
Volumetric analysis and acquisition of Mri characteristics
Pre-and postoperative tumor volumes were assessed in a semi-automatic fashion 
using the SmartBrush tool in Brainlab Elements (version 2.1.0.15; see supplemental 
figure 1A-C). A 3D-volume-of-interest can be created by first manually segmenting the 
tumor on one MRI slice of a chosen plane. Then, a second manual segmentation is car-
ried out on one perpendicular slice. Next, the software calculates the full 3D-volume-
of-interest, which can be easily manually adjusted where necessary. If available, the 
T2-weighted FLAIR sequence (3D where possible) was used for pre-and postoperative 
volumetric assessment, otherwise the T2-weighted (T2w) sequence was used. All 
T2w and T2w-FLAIR signal abnormalities were included in the segmentations. Within 
single patients the same MRI sequence was used for pre-and postoperative analysis. 
Preferentially, we used the postoperative scan ≥ 3 months to minimize overestimation 
of postoperative volume due to postoperative edema or ischemia. Proportion of resec-
tion was calculated as (preoperative volume – postoperative volume) / preoperative 
volume. Localization of tumor in/near eloquent area was assessed using the criteria 
of Chang et al.14
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Mutation analysis, copy number analysis and molecular classification
We used a targeted Next-Generation Sequencing panel to assess mutational and 
copy number status as described in detail elsewhere, using an Ion Torrent Personal 
Genome Machine or Ion S5XL (Life Technologies).16,23 DNA was isolated from selected 
tissue areas composed of a high percentage of neoplastic cells on 10µm FFPE sec-
tions using Proteinase K digestion in presence of 5% Chelex 100 resin (Bio-Rad). TERT 
promoter mutations (C228T & C250T) were assessed in separate assays (SnaPshot) as 
described.16
The following criteria for molecular classification were used (consistent with the 
current WHO 2016 classification for brain tumors):
• Oligodendroglioma: IDH1 or IDH2 mutated and loss of heterozygosity consistent 
with co-deletion of the entire 1p and 19q chromosomal arms.
• Astrocytoma IDH mutated (IDHmt): IDH1 or IDH2 mutated.
• Glioblastoma-like (GBM-like): IDH1 or IDH2 wildtype and; TERT promoter mutation 
without 1p19q co-deletion, or loss of heterozygosity of chromosome 10q and 
imbalance of chromosome 7, or EGFR amplified (in the WHO 2016 classification 
described as astrocytoma IDHwt)18
Statistical analysis
All primary analyses were carried out according to a predetermined analysis protocol; 
all other analyses are indicated as post-hoc. Categorical data were analyzed with Pear-
son’s chi-square test or Fisher’s exact test when assumptions of the chi-square test 
were violated (as indicated in the respective tables). Kruskal-Wallis test was used for 
continuous data. We used postoperative tumor volume as primary measure of extent 
of resection. The same calculations were made using resection percentage as alter-
native measure, which can be found in the supplementary material. Multiple linear 
regression models were used to explore correlations of molecular subtype with post-
operative tumor volume and resection percentage. To meet the assumption of normal 
distribution of residual errors in multiple linear regression, postoperative volume was 
log10 transformed, and resection percentage was arcsin square root transformed. To 
investigate impact of surgery, univariable and multivariable analyses of overall sur-
vival were performed using a Cox proportional-hazards model. In this model pre- and 
postoperative tumor volumes were treated as continuous variable, and postoperative 
tumor volume was log transformed to prevent inappropriate weighting of results by 
very large preoperative tumor volumes. The assumption of proportional hazards was 
tested based on the scaled Schoenfeld residuals. All calculations were two-sided tests, 
with a p-value <0.05 considered as statistically significant. All analyses were performed 
using R (3.3.2) and RStudio (1.0.44) using ggplot2 and CRAN survival packages.24,25
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rESultS
Our initial cohort included 246 patients with confirmed LGG, and with MR scans and 
FFPE material available. Of these, 18 patients were excluded from analyses; two due 
to insufficient amount of DNA for sequencing, 14 due to sequencing failure, and 
two due to a preoperative radiological appearance suggestive of glioblastoma (both 
stereotactic biopsy samples, molecularly classified as GBM-like). 228 patients were 
included in final analyses. Median follow-up was 5.79 years (range 0.3 – 20.4). Clinical 
characteristics are shown in table 1. When comparing histopathological classification 
with molecular subtype, there was a change of diagnosis in 39 patients (17.1%, mixed 
oligo-astrocytomas not included); all mixed oligo-astrocytomas were reclassified ac-
cording to the WHO 2016 update. There were no significant differences in clinical char-
acteristics between oligodendroglioma and astrocytoma IDHmt, except for age and 
type of first surgery: oligodendroglioma patients were significantly older (median age 
45 vs. 37 years; p<0.0001) and type of first surgery was more often a biopsy (p=0.006). 
We observed however several statistically significant different characteristics in the 
GBM-like group. Patients in this group were significantly older (median age 61 years), 
had a different presentation (only 11 (47.8%) patients presenting with epileptic sei-
zures, vs. 77 (82.8%) and 82 (73.2%) in oligodendroglioma and astrocytoma IDHmt 
respectively), and a different tumor localization (more often situated in eloquent 
areas, N=16; 69.6%). Interestingly, the majority of GBM-like patients (N=19; 82.6%) 
underwent a biopsy, compared to only a small fraction in the oligodendroglioma and 
astrocytoma IDHmt group (N=20 (21.5%) and N=9 (8%) respectively; p<0.0001). This 
is also reflected in postoperative tumor volume: although preoperative tumor volume 
did not differ between the molecular groups, the postoperative tumor volume was 
significantly higher in the GBM-like tumors compared to oligodendroglioma and 
astrocytoma IDHmt (median volume 30.0 cm3; 8.0 cm3; 8.9 cm3 respectively, p=0.005). 
Postoperative tumor volume did not differ between oligodendroglioma and astrocy-
toma IDHmt (p=0.553). An overview of salvage treatments is shown in supplementary 
table 3 and an overview of surgical outcome is shown in supplementary table 4.
Factors influencing postoperative tumor volume
We used multiple linear regression to explore which factors influence the amount of 
postoperative tumor volume. Results are shown in table 2. Factors such as increasing 
age, higher preoperative tumor volume (see also supplementary figure 2) and insular 
localization were significantly correlated with a higher postoperative tumor volume 
(p=0.002; p<0.0001; p<0.0001 respectively). Tumors located in eloquent areas were 
also significantly correlated with a higher postoperative volume (p<0.0001). Interest-
ingly, corrected for the factors mentioned above, the molecular subtype of the tumor 
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5
did not correlate with postoperative tumor volume. A similar model but using resec-
tion percentage instead of postoperative tumor volume is shown in supplementary 
table 1.
Patient outcome per molecular subtype and extent of resection
Projected median OS was 13.1 years at a median follow-up of 5.79 years. At time of 
analysis 69 patients had died and the remaining 159 patients had a median follow-up 
of 6.3 years (IQR 3.6 - 9.6 years). There were no surgery related mortalities. GBM-like 
tumors had a significantly shorter median OS (2.1 years) compared to astrocytoma 
IDHmt (10.2 years) and oligodendroglioma (not reached) (three group comparison; 
p = 0.0001, GBM-like vs astrocytoma IDHmt; p = 0.0001, astrocytoma IDHmt vs 
oligodendroglioma; p =0.0001) (supplementary figure 3). The factors age, Karnof-
sky Performance Status (KPS), log preoperative volume, resection percentage and 
eloquency were also significantly correlated with OS in univariable analysis (Table 3, 
supplementary table 2).
table 2. Multiple linear regression of factors influencing postoperative tumor volume
 Estimate SE t p-value
Intercept 0.307 0.134 2.291 0.023
WHO 2016 classification     
Oligodendroglioma * * * *
Astrocytoma IDHmt 0.007 0.062 0.107 0.915
GBM-like 0.183 0.127 1.438 0.152
Age 0.008 0.003 3.064 0.002
Preoperative tumor volume 0.008 0.001 14.831 0.000
Eloquency     
Eloquent location * * * *
Non-eloquent location -0.320 0.061 -5.230 0.000
Tumor location     
Frontal * * * *
Parietal -0.005 0.106 -0.047 0.963
Temporal 0.074 0.082 0.894 0.372
Occipital 0.078 0.151 0.515 0.607
Insula 0.482 0.086 5.577 0.000
Basal ganglia 0.316 0.240 1.319 0.189
Gliomatosis cerebri 0.161 0.157 1.027 0.305
Multiple linear regression model with log10 postoperative tumor volume as dependent variable.
* = Reference variable
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In univariable analysis the amount of postoperative tumor volume (as a continuous 
variable) was significantly associated with OS with a Hazard Ratio (HR) of 1.01 per 1 
cm3 increase in volume (95% CI 1.01 – 1.01; p < 0.0001). A particularly strong effect on 
OS was seen in patients with no detectable tumor after resection (Figure 1A). Interest-
ingly, any residual volume negatively affects OS, but this effect was most notable in 
astrocytoma IDHmt (Figure 1B & 1C). In this group, even if residual volume was only 
0.1-5.0 cm3, OS was impaired compared to 0.0 cm3 residue. No difference in OS was seen 
between 5.1-15.0 cm3 and >15.0 cm3 residue. In oligodendroglioma patients, a trend 
towards better OS with more extensive resection was observed, though the difference 
in OS benefit of no detectable tumor versus small residues was less impressive than in 
astrocytoma IDHmt patients. This analysis was not feasible in GBM-like tumors, due to 
small sample size. A similar pattern was observed when looking at resection percent-
ages rather than postoperative tumor volume (supplementary figure 4). Progression 
free survival stratified by postoperative volume is shown in supplementary figure 5, 
table 3. Univariable and multivariable Cox regression with postoperative volume as
measure of extent of resection
Variable
Univariable Multivariable
HR 95% CI P-value HR 95% CI P-value
Age 1.04 1.02 - 1.06 0.0002 1.01 0.98 - 1.04 0.527
Gender       
Male *      
Female 0.68 0.41 - 1.12 0.129    
KPS 0.94 0.91 - 0.96 <0.0001 1.01 0.97 - 1.06 0.666
Eloquency       
Yes *   *   
No 0.49 0.3 - 0.79 0.004 1.59 0.90 - 2.82 0.110
Log preoperative volume 1.66 1.22 - 2.26 0.001 1.70 1.06-2.75 0.029
Postoperative volume 1.01 1 - 1.01 <0.0001 1.01 1.002 - 1.02 0.016
Molecular diagnosis       
Oligodendroglioma *   *   
Astrocytoma IDHmt 3.77 1.9 - 7.46 0.0001 5.31 2.40 - 11.75 <0.0001
GBM-like 112.9 45.93 - 277.55 <0.0001 218.81 68.75 - 696.38 <0.0001
RTx after surgery       
No *   *   
Yes 2.45 1.52 - 3.94 0.0002 1.13 0.59 - 2.13 0.716
Chemo after surgery       
No *   *   
Yes 1.19 0.68 - 2.09 0.545 0.64 0.27 - 1.52 0.315
* = Reference category
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figure 1. OS stratified by sub-
groups of postoperative volume 
for all patients (A), oligodendrogli-
oma patients (B), and astrocytoma 
IDHmt patients (C).
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which shows similar patterns. Postoperative tumor volume remained an independent 
prognostic factor in a multivariable analysis (HR 1.01; 95% CI 1.002-1.02; p=0.016; per 
1 cm3 increase in volume). Univariable and multivariable Cox-regression with resec-
tion percentage as measure of extent of resection is shown in supplementary table 2.
In a post-hoc analysis we dichotomized postoperative volume with different cut-
offs to explore at what maximal postoperative volume a resection is still associated 
with improved OS. In astrocytoma IDHmt, a postoperative volume of up to 25 cm3 
still showed a significant longer OS compared to > 25cm3. More importantly though, 
any residual tumor (i.e. greater than 0.0 cm3) already impacts OS negatively (Figure 
2 & supplementary Figure 6). In oligodendroglioma patients such cut-off points for 
postoperative tumor volume and patient benefit could not be defined (supplementary 
Figure 7).
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figure 2. OS in astrocytoma IDHmt stratified by different cut-offs of postoperative tumor volume to 
explore at what maximal postoperative volume a resection is still beneficial. A postoperative volume 
of up to 25 cm3 still shows a significant better OS compared to >25cm3. However any residual tumor 
negatively impacts survival. The same figure with more cut-offs is shown in supplementary figure 6.
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DiScuSSion
With the incorporation of a molecular classification for glioma, WHO classification 
of tumors of the central nervous system has been completely revised and molecular 
markers now overrule the histopathological diagnosis.18,19 Differences in sensitivity 
and overall outcome to chemo- and/or radiotherapy according to molecular subgroup 
have emerged in past years, but the assessment of the role of surgery in the molecu-
larly defined subgroups of low grade glioma was lacking so far. Since the molecular 
markers in the WHO 2016 update are prognostically very powerful, a re-evaluation of 
the impact of surgery is important to validate and evaluate current clinical practice.
Several studies have suggested that early and extensive surgery has a positive 
impact on survival for LGG patients. Unfortunately, most of these studies used quali-
tative measures for extent of resection or used tumor diameter to calculate tumor 
volume.9-13,26,27 These approaches do not allow accurate assessment of extent of 
resection. A recent report by Duffau et al. incorporated volumetric measurements in 
a large molecularly defined LGG cohort. The authors showed that resectability was 
independent of molecular markers, however, survival data were not reported.28 One 
report that used a volumetric approach and included survival analysis was the study 
by Smith et al.8 These authors showed that a larger extent of resection predicts sig-
nificant longer OS and that even small postoperative tumor volumes negatively influ-
ence OS. Their 2008 study, however, was based on histopathologically diagnosed LGG 
(WHO 2007) without molecular classification. A recent paper by Wahl et al. reported 
on the impact of postoperative tumor volumes on OS corrected for molecular subtype. 
Every 10cm3 increase in postoperative tumor volume was associated with shorter OS. 
However, definite conclusions cannot be drawn since this was an exploratory, post-hoc 
analysis in a selected cohort of 71 patients with only significant residual disease after 
first surgical treatment.29
In this study we show that postoperative volume remains a prognostic factor for OS 
in molecularly defined LGG. This is an important finding, since it supports the policy 
of maximal safe resection in all molecular subtypes of LGG. Our data also shows that 
even very small tumor residues already negatively impact OS in astrocytoma IDHmt 
tumors. This is exemplified by the clear survival difference between tumor residues 
as little as 0.1-5.0 cm3 and 0.0 cm3, and the absence of a survival difference between 
5.1-15.0 cm3 and >15.0 cm3 residue. Also, in a post-hoc analysis with dichotomization 
of postoperative volume we show that up to 25 cm3 residue is still associated with a 
significant better OS compared to > 25cm3. Since this is a post-hoc analysis, we should 
interpret this specific cut-off value with caution. More importantly though, this analy-
sis shows that any residual tumor (i.e. greater than 0.0 cm3) already impacts survival 
negatively in astrocytoma IDHmt. In oligodendroglioma it seems that a small residue 
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does not have that strong impact on OS as is observed in astrocytoma IDHmt. The 
absence of a strong relationship between OS and limited amounts of residual tumors 
might be explained by the more indolent natural course of these tumors and their 
increased sensitivity to treatment which may have more impact on survival than sur-
gical intervention.19,30 Although residual tumor probably is located in eloquent areas 
in the majority of cases, one may argue that a second-look look operation if safely 
possible might be something to consider in the few astrocytoma IDHmt patients with 
minor residual tumor located in non-eloquent area. On the other hand, our data also 
encourages further efforts to implement new methods that aid in safely maximizing 
extent of resection. Imaging techniques like intraoperative MRI or ultrasound to assess 
extent of resection during surgery might be valuable in this setting. At current these 
techniques are not available in most clinics however.
Our data suggest that some of the findings in previous studies may have been 
impacted by the presence of GBM-like tumors, which were more likely to undergo 
a biopsy only in this series. This might be explained by the more frequent location 
of GBM-like tumors in eloquent areas (N=16; 69.6%) and thus a higher frequency of 
biopsy or limited resections.
Our study has limitations that need to be addressed. The main limitation is the 
retrospective nature. However, due to ethical and practical reasons a randomized 
trial on the impact of early and of extent of resection is considered not feasible, and 
retrospective data with detailed clinical and molecular annotation is the best avail-
able data to address this issue.31 Clearly, the preoperative volume of LGG has a major 
impact on outcome, and this also influences the postoperative volume. A larger series 
is necessary to further study this. Due to the retrospective nature of this study the 
follow-up, postoperative treatment and the used MRI protocol were heterogeneous. 
We corrected OS for administration of chemo- and/or radiotherapy, but correcting for 
different timing and sequence of these treatments is not informative due to the large 
variety of possible combinations. T2w-FLAIR sequences were not available for both pre- 
and postoperative measure for some patients. When this was the case, T2-weighted 
images were used. We used the late postoperative scan to minimize overestimation 
of postoperative tumor volume due to edema or ischemia and to minimize potential 
differences between sequences.32 Also, non-standardized MRI follow-up limits the 
reliability of evaluation of PFS in terms of the importance of the extent of resection. 
Another important limitation that comes with the retrospective nature of this study is 
the inclusion based on histology. This has to be taken into account when generalizing 
results, since histology is only known after surgery.
Also, several recent studies have shown that final conclusions in studies on LGG 
require lengthy follow-up for definitive conclusions.33 Further follow-up and more 
importantly expanding this dataset is very important. This especially concerns the 
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oligodendroglioma group, since the impact of small tumor residues in this commonly 
slow-growing tumor might become more clear with longer follow-up. Lastly, confir-
mation of our findings in an independent dataset is needed before definitive clinical 
conclusions are drawn.
In conclusion, we validated and added substantial and necessary evidence to current 
practice of early maximal resection for LGG. Importantly, we show that even very small 
tumor residues in astrocytoma IDHmt patients already have negative impact on OS.
Chapter 5
90
table s1. Multiple linear regression of factors influencing resection percentagea
Estimate SE t p-value
Intercept 1.384 0.124 11.177 <0.0001
WHO 2016 classification
Oligodendroglioma * * * *
IDH mutated, 1p19q intact 0.049 0.057 0.850 0.396
IDH wildtype, TERT mutated -0.400 0.117 -3.405 0.001
Age -0.008 0.002 -3.545 0.001
Preoperative tumor volume -0.003 0.000 -5.802 <0.0001
Eloquency
Eloquent location * * * *
Non-eloquent location 0.256 0.057 4.531 <0.0001
Tumor location
Frontal * * * *
Parietal -0.039 0.098 -0.396 0.693
Temporal -0.031 0.076 -0.412 0.681
Occipital -0.120 0.139 -0.862 0.390
Insula -0.269 0.080 -3.364 0.001
Basal ganglia -0.363 0.222 -1.637 0.103
Gliomatosis cerebri -0.260 0.145 -1.794 0.074
aLinear regression model with resection percentage as dependent variable. To meet the assumption 
of normal
distribution of residual errors, resection percentage was arcsin square root transformed.
* = Reference category
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table s2. Univariable and multivariable Cox-regression with resection percentage as
measure of extent of resection
Variable
Univariable Multivariable
HR 95% CI P-value HR 95% CI P-value
Age 1.04 1.02 - 1.06 0.0002 1.00 0.98 - 1.03 0.734
Gender
Male *
Female 0.68 0.41 - 1.12 0.129
KPS 0.94 0.91 - 0.96 <0.0001 0.97 0.93 - 1.01 0.112
Eloquency
Yes * *
No 0.49 0.3 - 0.79 0.004 1.40 0.77 - 2.54 0.273
Resection percentage 0.16 0.08 - 0.3 <0.0001 0.41 0.16 - 1.05 0.062
Molecular diagnosis
Oligodendroglioma * *
Astrocytoma IDHmt 3.77 1.9 - 7.46 <0.0001 4.23 2.03 - 8.81 0.0001
GBM-like 112.9 45.93 - 277.55 <0.0001 63.77 22.35 - 181.99 <0.0001
RTx after surgery
No * *
Yes 2.45 1.52 - 3.94 0.0002 1.26 0.93 - 1.01 0.481
Chemo after surgery
No * *
Yes 1.19 0.68 - 2.09 0.545 1.19 0.56 - 2.51 0.652
* = Reference category
Chapter 5
92
table s3. Overview of salvage treatments
All patients Oligodendroglioma Astrocytoma 
IDHmt
GBM-like
Number of re-resections
0 182 (79.82%) 83 (89.25%) 78 (69.64%) 21 (91.30%)
1 43 (18.86%) 10 (10.75%) 31 (27.68%) 2 (8.70%)
2 3 (1.32%) 0 (0.0%) 3 (2.68%) 0 (0.0%)
Treatment after 1st surgery
Wait & Scan 104 (45.61%) 51 (54.84%) 52 (46.43%) 1 (4.35%)
Chemotherapy 35 (15.35%) 24 (25.81%) 5 (4.46%) 6 (26.09%)
Radiotherapy 71 (31.14%) 15 (16.13%) 42 (37.50%) 14 (60.87%)
Chemoradiation 18 (7.89%) 3 (3.23%) 13 (11.61%) 2 (8.70%)
Ever radiotherapy
Yes 155 (67.98%) 38 (40.86%) 97 (86.61%) 20 (86.96%)
No 73 (32.02%) 55 (59.14%) 15 (13.39%) 3 (13.04%)
Ever chemotherapy
Yes 146 (64.04%) 54 (58.06%) 78 (69.64%) 14 (60.87%)
No 82 (35.96%) 39 (41.94%) 34 (30.36%) 9 (39.13%)
No progression during f/u yet
N (%) 74 (32.46%) 37 (39.78%) 37 (33.04%) 0 (0.0%)
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table s4. Overview of surgical outcome
Frequencies of deficits after surgery/biopsy N (%)
No deficitis 182 (79.8%)
Speech disorder 23 (10.1%)
Palsy 23 (10.1%)
Recovery of deficits N (%)
Speech disorder
Full recovery within 3 months 16 (69.6%)
Partial recovery 7 (30.4%)
Permanent deficit 0 (0.0%)
Palsy
Full recovery within 3 months 11 (47.8%)
Partial recovery 8 (34.8%)
Permanent deficit 4 (17.4%)
Work resumption after surgery N (%)
Yes 153 (67.1%)
No 17 (7.5%)
Unknown 58 (25.4%)
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A
B
C
Supplementary figure 1. (A) Assessment of preoperative tumour volume. A 3D volume of interest can 
be created by first manually segmenting the tumour on one MRI slice of a chosen plane (i.e.the top-
right panel of this figure). Then, a second manual segmentation is carried out on one perpendicular 
slice (i.e. the bottom-right panel). Next, the software automatically calculates the full 3D volume-of-
interest (see top-left panel). (B) Assessment of postoperative tumour volume. (C) The volume of inter-
est can be check slice by slice and where necessary, the volume can be easily manually adjusted.
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Supplementary figure 2. Quartiles of preoperative tumour volume vs postoperative tumour volume.
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Supplementary figure 4. Overall survival stratified by resection percentage. (A) Overall survival of all 
patients stratified by resection percentage. (B) Overall survival of oligodendroglioma patients strati-
fied by resection percentage. (C) Overall survival of IDH mutated astrocytoma stratified by resection 
percentage
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Supplementary figure 5. Progression free survival stratified by postoperative tumor volume. (A) Pro-
gression free survival of all patients stratified by postoperative tumor volume. (B) Progression free 
survival of oligodendroglioma patients stratified by postoperative tumor volume. (C) Progression free 
survival of IDH mutated astrocytoma stratified by postoperative tumor volume.
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Supplementary figure 6. Overall survival with dichotomisation of postoperative tumour volume in 
IDH mutated astrocytoma patients.
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Supplementary figure 7. Overall survival with dichotomisation of postoperative tumour volume in 
oligodendroglioma.
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abStract
background
Early resection is standard of care for presumed low-grade gliomas. This is based 
on studies including only tumors that were post-surgically confirmed as low-grade 
glioma. Unfortunately this does not represent the clinicians’ situation wherein he/she 
has to deal with a lesion on MRI that is suspect for low-grade glioma (i.e. without 
prior knowledge on the histological diagnosis). We therefore aimed to determine the 
optimal initial strategy for patients with a lesion suspect for low-grade glioma, but not 
histologically proven yet.
Methods
We retrospectively identified 150 patients with a resectable presumed low-grade-
glioma and who were otherwise in good clinical condition. In this cohort we compared 
overall survival between three types of initital treatment strategy: a wait-and-scan 
approach (n=38), early resection (n=83), or biopsy for histopathological verification 
(n=29).
results
In multivariate analysis, no difference was observed in overall survival for early resec-
tion compared to wait-and-scan: hazard ratio of 0.92 (95% CI 0.43-2.01; p=0.85). How-
ever, biopsy strategy showed a shorter overall survival compared to wait-and-scan: 
hazard ratio of 2.69 (95% CI 1.19-6.06; p=0.02).
conclusions
In this cohort we failed to confirm superiority of early resection over a wait-and-scan 
approach in terms of overall survival, though longer follow-up is required for final 
conclusion. Biopsy was associated with shorter overall survival.
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introDuction
Diffuse low-grade gliomas (LGGs) are primary brain tumors that, due to their infiltra-
tive nature, cannot be fully eradicated by resection, chemotherapy, radiation, or a 
combination of these regimens. Most LGGs will gradually evolve into higher-grade 
gliomas and almost all patients will ultimately die from the disease.1,2
The typical LGG patient presents with a first epileptic seizure and a lesion on MRI that 
is suspect for a LGG (isointense to hypointense and non-enhancing on T1-weighted 
images; hyperintense on T2-weighted and fluid attenuated inversion recovery (FLAIR) 
images).3 Consequently, in combination with clinical parameters, but yet without 
confirmed histology, physicians have to decide on a treatment strategy. They can opt 
for a wait-and-scan policy, take a biopsy for histopathological verification, or opt for 
immediate resection. Treatment strategy is patient dependent, influenced by the 
clinical condition of the patient, seizure control, size of the tumor and resectability 
of the tumor.4 An initial wait-and scan approach is usually followed by resection or 
biopsy at the time the lesion starts to show growth or enhancement on MRI, or when 
clinical deterioration occurs. Resection and biopsy can either be followed by a wait-
and-scan policy, radiotherapy, chemotherapy, or a combination of the latter two.4 Both 
chemotherapy and radiotherapy have been extensively investigated in randomized 
controlled trials.5-11 Controlled trials exploring the role and timing of surgery are lack-
ing and, therefore, surgery for LGG has been controversial for many years.
In the past an initial wait-and-scan approach was advocated, since LGGs tend to 
grow slowly and patients usually present with controllable seizures as the only clini-
cal symptom.12-14 However, in the last 20 years, general opinion has shifted and early 
maximal resection is now widely accepted for patients with LGG-like lesions that are 
eligible for resection. Indeed, multiple retrospective studies showed that a more ex-
tensive resection is associated with a marked improvement of overall survival.15-23 Also, 
a study in Norway showed that early resection significantly improves overall survival 
compared to a biopsy with a subsequent watch-and-wait period.24,25 This growing bulk 
of evidence, although retrospective, has logically resulted in early maximal resection 
being standard of care and being incorporated in international guidelines nowadays.4
However, we have to bear in mind that these retrospective studies are subject to at 
least some form of selection and indication bias. Firstly, these studies excluded the 
non-enhancing presumed LGGs that are diagnosed as a higher grade after early sur-
gery. Secondly, these studies discarded the presumed LGGs that progressed to a higher 
grade during the wait-and-scan period. Thirdly, these studies included patients with 
confirmed LGG, but with preoperative enhancement on MRI, which is usually not a 
presumed low-grade glioma.26-28 Possibly there is also indication bias present in these 
studies; the physicians choice for initial treatment is potentially influenced by factors 
Chapter 6
108
that also have impact on prognosis itself.29 In conclusion, the cohorts used in these 
previous studies are not entirely representative for the daily clinical situation in which 
physicians are confronted with a LGG-like lesion on MRI without histological confirma-
tion and, consequently, in combination with clinical parameters, have to decide for an 
initial treatment strategy. Therefore, a study with patient selection based solely on 
preoperative clinical and imaging characteristics is more clinically relevant and can 
add significant evidence to support current daily clinical practice. A prospective trial is 
warranted but is unlikely to be conducted due to the duration of such a study (median 
survival of ≥ 15 years in oligodendroglioma subtype13), ethical considerations raised 
by physicians who strongly believe in early resection, as well as obtaining patients’ 
consent to randomize between radically different treatment strategies.
In this retrospective study we approached the issue of treatment strategy from a 
more clinical and preoperative point of view and selected patients with a resectable 
LGG-like lesion based on diagnostic imaging and not on histopathological confirma-
tion. We included those patients that we retrospectively consider equally eligible for 
either a wait-and-scan approach, a biopsy for histological verification, or early resec-
tion as initial treatment strategy; i.e. patients had to have limited neurological deficits 
that allowed a wait-and-scan strategy but also a LGG-like lesion that was eligible for 
extensive resection (estimation of at least 80% volume reduction possible, with use of 
current available techniques like awake surgery). In this manner we eliminated selec-
tion bias by histology and we avoided selection bias on indication as much as possible.
The aim was to determine the optimal initial treatment strategy for a resectable, 
presumed low-grade glioma by comparing overall survival between wait-and-scan, 
early resection and a biopsy approach.
MEthoDS
Patient selection
Three large neurosurgical institutions participated in this cohort study, together 
serving a population of 6.5 million people in the southwest of the Netherlands. The 
institutions involved were the Erasmus MC Cancer Institute in Rotterdam (EMC), 
Elisabeth-TweeSteden Hospital in Tilburg (ETZ), and Medical Centre Haaglanden in The 
Hague (MCH).
We identified patients with a presumed LGG (LGG-like lesion) that were retrospec-
tively eligible for either initial treatment strategy: i.e. initial wait-and-scan approach, 
biopsy for histopathological verification, or immediate resection. Well-established 
prognostically favorable radiological and clinical characteristics were used as inclusion 
criteria 30-32. Radiological criteria were: supratentorial location of lesion, no contrast 
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enhancement, no midline shift, maximal diameter <6 cm, sharply defined borders, and 
no involvement of corpus callosum, basal ganglia or thalamus. Clinical criteria were: 
age ≥18 years, Karnofsky Performance Status (KPS) >70, neurologically stable (with 
only epilepsy or minimal neurological deficits), and no dexamethasone dependency. 
Patients with active synchronous cancer of other origin were excluded.
To identify glioma patients, the digital archives of patient letters were searched for 
all neurological and neurosurgical patients registered 1990-2010 in EMC, 1996-2010 
in ETZ, and 1992-2010 in MCH. In this first selection, high-grade gliomas were included 
so as not to exclude patients who progressed to a higher grade during a wait-and-scan 
period. In this search, of the 1115 glioma patients identified, a diagnostic scan could be 
retrieved for 498 of them, while the other part mainly originated from the pre digital 
era and was not available anymore. All diagnostic scans were reviewed to check if they 
met the criteria for a) the radiological diagnosis of a low-grade glioma and b) for the 
feasibility of an extensive resection (estimation of at least 80% volume reduction pos-
sible with modern surgical techniques like awake surgery) by a single neurosurgeon 
(AJPEV). Tumor near eloquent location was not an exclusion criterion per se, since the 
vast majority is eligible for resection with modern surgical techniques. The reviewing 
neurosurgeon has more than 10 years’ experience in awake surgery and was blinded 
for clinical information such as initial treatment strategy, the histopathological di-
agnosis and outcome. Of these 498 patients, 348 were excluded: 305 did not meet 
the radiological criteria, 21 did not meet the clinical criteria, and for 22 the complete 
medical records were not available. Eventually, 150 patients remained for analysis. An 
overview of the selection procedure is shown in Figure 1.
Study variables
Baseline characteristics of the patients were collected from the medical records and 
diagnostic scan; i.e. initial treatment strategy, gender, age, KPS, presenting symptom, 
tumor location, mean tumor diameter and tumor eloquence; eloquence was graded 
with the criteria of Chang et al.32
Three types of initial treatment strategy were compared: initial wait-and-scan strategy 
after radiological diagnosis, early resection, and initial biopsy procedure for histological 
verification. Treatment decisions were based on local, national and international guide-
lines in each individual center at that time, by an experienced multidisciplinary team. 
Postoperative characteristics were also collected: first histology and grade, total number 
of resections, type of surgery (awake vs. general anesthesia), subsequent strategy after 
early resection, or biopsy and administration of radiotherapy and/or chemotherapy. 
Because postoperative MRI or CT scans were not available for most operated patients, 
the extent of resection could not be reliably investigated. In most tumors, molecular 
markers were not available and therefore not included in the analysis.
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outcome measure
The primary outcome measure was overall survival (OS), which was defined as the 
time between the diagnostic scan and death. All included patients were followed until 
death or censored at the date of last follow-up. Date of death was provided by patient 
records or the Municipal Personal Records Database.
Statistical analysis
All analyses were performed using R (3.1.3) and RStudio (0.99.486). Categorical data 
were analyzed with Pearson’s chi-square test or Fisher’s exact test when assumptions 
of the chi-square test were violated. Continuous data were analyzed with a Kruskal-
Wallis test. Overall survival is shown in Kaplan-Meier plots (ggplot2 package in R). 
Univariate and multivariate analyses were performed using a Cox proportional hazard 
model (survival CRAN package in R). All calculations were two-sided tests, with a p-
value <0.05 considered as statistically significant.
Ethics and approvals
Need for informed consent was waived by the Medical Ethical Committee of Erasmus 
MC, Rotterdam.
1115 glioma cases
617 cases excluded as diagnostic 
scan was not available
498 cases screened for inclusion criteria
348 excluded
305 not meeting radiological criteria
21 not meeting clinical criteria
22 medical record not completely available
150 cases included in study
65 EMC; 55 ETZ; 30 MCH
38 wait-and-scan 83 early resection 29 biopsy
figure 1. Consort flow diagram of patient inclusion. Of the 1115 glioma patients identified with a 
search in the digital patient archives, a diagnostic scan could be retrieved for 498 of them. Of these, 
305 were excluded as they did not meet radiological criteria, 21 did not meet clinical criteria, and for 
22 the complete medical record was not available. A total of 150 cases remained for analysis.
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rESultS
The medical records and diagnostic scans of 498 identified glioma patients were 
screened with our selection criteria to select patients with a resectable lesion and 
relatively favorable prognostic characteristics. A total of 150 patients with a resect-
able presumed LGG were included (Figure 1). The initial treatment strategy was either 
an initial wait-and-scan approach (n=38), a biopsy for histopathological verification 
(n=29), or early resection (n=83). Median follow-up was 7.1 years (25-75% interquar-
tile range: 5.4-9.8 years). Baseline characteristics were equally distributed between 
treatment groups, except for tumor location in eloquent area (15.8% in wait-and-scan 
vs. 10.3% in biopsy and 32.5% in early resection; p=0.02) (Table 1).
Median time between diagnostic scan and intervention was 35.4 months in the 
wait-and-scan group, 0.8 months in the biopsy group, and 2.9 months in the early 
resection group. In 80% (n=66) of patients in the early resection group surgery was 
performed within 6 months after the diagnostic scan. Of the remaining 20% (n=17), 
all received surgery within 1 year, without any sign of tumor growth, enhancement or 
clinical deterioration at time of surgery. In these latter patients the physicians’ initial 
choice of treatment was an early resection. However, the time between diagnosis and 
resection was ≥ 6 months, mainly due to practical reasons; either because referral 
from the diagnosing center to neurosurgical center was delayed, or due to patients’ 
doubts about the treatment strategy. Nevertheless, these 17 patients were not ex-
cluded from the analysis as the actual initial choice of treatment was early resection 
and the intervention took place when there was still no sign of clinical deterioration, 
tumor growth or contrast enhancement on the control MRI. However to rule out bias, 
a sensitivity analysis was performed with the exclusion of these patients (see below).
In the group with wait-and-scan as initial treatment strategy, 79% of the patients 
eventually underwent a resection during follow-up. In these patients, surgery was 
initiated because of signs of growth or enhancement on follow-up imaging. There 
were no patients with uncontrolled seizures in the wait-and-scan group, nor was this a 
reason for surgery during follow-up. In the biopsy group, 51.7% eventually underwent 
resective surgery. Distribution of the postoperatively obtained tumor characteristics 
(histology and grade) differed between the groups: the biopsy group consisted of more 
astrocytomas (75.9% vs. 42.1% in wait-and-scan and 48.2% in early resection; p=0.01) 
and the wait-and-scan group consisted of more gliomas of higher-grade (24.3% vs. 
10.8% in resection and 3.4% in biopsy; p=0.04).
Median OS in the early resection group was not reached and showed no significant 
difference (p=0.42) from the wait-and-scan group in which the median OS was 11.9 
years (95% CI, 9.5-∞) (Figure 2). However, the median OS of 9.1 years (95% CI, 5.8-∞) 
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in the biopsy group was significantly shorter compared to both the wait-and-scan and 
early resection group (log-rank test; p=0.04 and p=0.001, respectively) (Figure 2).
In the univariate analysis, histology, grade, tumor location and tumor eloquence also 
had a significant impact on OS (Table 3) and were, therefore, included in the mul-
tivariate Cox regression. In this multivariate analysis, the difference in OS remained 
with a hazard ratio (HR) of 2.53 (95% CI 1.1-6.1; p=0.04) (Table 3) for the biopsy group 
table 1. Patient characteristics at baseline
Treatment strategy P
Wait-and-scan Early resection Biopsy
(N = 38) (N = 83) (N = 29)
Characteristic N (%)a N (%)a N (%)a
Gender    0.14
Male 25 (65.8) 40 (48.2) 18 (62.1)  
Female 13 (34.2) 43 (51.8) 11 (37.9)  
Age in years
Median (IQRb) 38 (16.3) 39 (14.6) 41 (21.4) 0.14
<40 23 (60.5) 46 (55.4) 13 (44.8) 0.43
KPS at diagnosis 0.28
100 37 (97.4) 77 (92.8) 24 (82.8)  
90 1 (2.6) 5 (6.0) 4 (13.8)  
80 0 (0.0) 1 (1.2) 1 (3.4)  
Presenting symptom 0.56
Epilepsy 35 (92.1) 71 (85.5) 23 (79.3)  
Cognitive disorder 0 (0.0) 1 (1.2) 0 (0.0)  
Hemiparesis 0 (0.0) 1 (1.2) 2 (6.9)  
Speech disorder 0 (0.0) 1 (1.2) 1 (3.4)  
Incidental finding 3 (7.9) 6 (7.2) 3 (10.3)  
Headache 0 (0.0) 3 (3.6) 0 (0.0)  
Tumor location 0.94
Frontal 18 (47.4) 46 (55.4) 13 (44.8)  
Temporal 7 (18.4) 14 (16.9) 6 (20.7)  
Parietal 5 (13.2) 11 (13.3) 4 (13.8)  
Occipital 1 (2.6) 1 (1.2) 0 (0.0)  
Insula 7 (18.4) 11 (13.3) 6 (20.7)  
Eloquent area 0.02
Yes 6 (15.8) 27 (32.5) 3 (10.3)  
No 32 (84.2) 56 (67.5) 26 (89.7)  
Tumor diameter (mm)
Median (IQRb) 39.5 (12.0) 41.0 (16.5) 41.0 (10.0) 0.67
aData are numbers (%) unless indicated otherwise. bInterquartile range (25-75%)
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compared to wait-and-scan, whereas no difference was observed for early resection 
compared to wait-and-scan (HR 0.92; 95% CI 0.43-2.01; p=0.85).
A sensitivity analysis was also performed excluding those patients in the early resec-
tion group that did not undergo a resection within 6 months after diagnosis. No differ-
ence in OS was found for early resection compared to wait-and-scan with a HR of 0.70 
(95% CI 0.33-1.46; p=0.34) in univariate analysis and 0.83 (95% CI 0.37-1.86; p=0.65) in 
multivariate analysis (including also histology, grade, and tumor location/eloquence 
as variables). A significant difference in OS remained for biopsy versus wait-and-scan, 
with a HR of 2.03 (95% CI 1.03-3.99; p=0.04) in univariate analysis and 2.82 (95% CI 
1.24-6.43; p=0.01) in multivariate analysis.
DiScuSSion
Early maximal safe resection is considered standard of care for presumed LGG. Evidence 
to support this approach is mainly derived from retrospective studies; clear evidence 
from prospective trials for this early aggressive surgical approach is not available. 
Arguments in favor of early resection include uncertainty about the radiological diag-
nosis, the assumption that resection will postpone malignant transformation and will 
improve overall survival.20,26 Indeed, several retrospective studies affirm the hypothesis 
that extensive resection for LGG improves overall survival.15-23 Concerns that resection 
in a later stage of the disease could technically be more difficult and induce malignant 
transformation are not unimaginable. In the light of these concerns and the associa-
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figure 2. Kaplan-Meier plot show-
ing the overall survival per treatment 
strategy. The p-value is calculated by 
the log-rank test including all three 
treatment groups. In the lower table, 
data indicate the numbers of patients 
at risk at the given time.
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tion between extent of resection and overall survival, one may argue that the attempt 
for an extensive resection should be made as early as possible. These concerns that 
extent of resection can be influenced by timing of surgery in LGG have not been inves-
tigated by any study so far. Timing of treatment itself without incorporation of extent 
of resection has been studied before however. In a study by Jakola et al., a unique 
table 2. Tumor and treatment characteristics of the three groups.
Treatment strategy P
Wait-and-scan Early resection Biopsy
(N = 38) (N = 83) (N = 29)
Characteristics N (%)a N (%)a N (%)a
Number of resections <0.001
Zero 8 (21.1) 0 (0.0) 14 (48.3)  
One 25 (65.8) 47 (56.6) 10 (34.5)  
Two 5 (13.2) 34 (40.9) 5 (17.2)  
Three 0 (0.0) 2 (2.4 %) 0 (0.0)  
Procedure of first surgery    0.36
Awake 14 (46.7) 38 (45.8) 4 (26.7)  
General anesthesia 16 (53.3) 45 (54.2) 11 (73.3)  
Subsequent treatment after 
initial resection or biopsyb
<0.001
Wait-and-scan Not applicable 53 (66.3) 3 (11.5)  
Radiotherapy Not applicable 26 (32.6) 22 (84.6)  
Other Not applicable 1 (1.3) 1 (3.8)  
Ever radiotherapy 0.01
Yes 28 (73.7) 57 (68.7) 28 (96.6)
No 10 (26.3) 26 (31.3) 1 (3.4)
Ever chemotherapy 0.02
Yes 23 (60.5) 30 (36.1) 16 (55.2)
No 15 (39.5) 53 (63.9) 13 (44.8)
First histology    0.01
Astrocytoma 16 (42.1) 40 (48.2) 22 (75.9)  
Oligodendroglioma 12 (31.6) 30 (36.1) 7 (24.1)  
Oligo-astrocytoma 9 (23.7) 13 (15.7) 0 (0.0)  
Not yet known 1 (2.6) 0 (0.0) 0 (0.0)  
Grade 0.04
II 28 (75.7) 74 (89.2) 28 (96.6)  
III 7 (18.9) 9 (10.8) 1 (3.4)  
IV 2 (5.4) 0 (0.0) 0 (0.0)  
aData are shown as numbers (%). bTreatment after intervention is shown for the groups in which the 
initial strategy was immediate resection or biopsy
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situation in Norway was studied wherein treatment outcome was compared between 
two centers: one center favored biopsy with subsequent watchful waiting strategy 
and the other center early resection. The early resection strategy in one center was 
clearly associated with a longer overall survival.24,25 For several years now, after years 
of controversy, the approach of early maximal resection logically is incorporated in 
treatment guidelines for LGG. However, despite current guidelines, we have to bear in 
mind those studies were biased by histopathological diagnosis as inclusion criterion. 
This selection is actually not representative for the daily clinical setting whereby an 
initial treatment decision is based on imaging and patient characteristics. Although a 
prospective trial is the golden standard to clarify this issue, this is generally considered 
to be infeasible. We therefore tried to confirm the observations and assumptions from 
earlier studies that early resection prolongs overall survival in a cohort that more 
closely mimics daily clinical situation.
table 3. Univariate and multivariate analysis of overall survival using the Cox proportional hazards 
model.
Variable
Univariate Multivariate
HRa (95% CI) P HRa (95% CI) P
Treatment     
Wait-and-scan 1  1  
Early resection 0.72 (0.36-1.46) 0.37 0.92 (0.43-2.01) 0.85
Biopsy 2.04 (1.05-3.99) 0.04 2.69 (1.19-6.06) 0.02
Eloquency     
Yes 1  1  
No 2.36 (1.00-5.54) 0.05 1.41 (0.57-3.49) 0.46
Histology     
Astrocytoma 1  1  
Oligodendroglioma 0.40 (0.19-0.87) 0.02 0.49 (0.22-1.09) 0.08
Oligo-astrocytoma 1.10 (0.52-2.30) 0.81 1.34 (0.58-3.11) 0.49
Grade     
>II 1  1  
II 0.49 (0.24-0.98) 0.04 0.40 (0.17-0.93) 0.03
Tumor location    
Frontal 1  1  
Temporal 3.40 (1.65-6.88) <0.001 3.49 (1.66-7.35) <0.001
Parietal 1.90 (0.88-4.24) 0.10 1.60 (0.72-3.56) 0.25
Occipital 0.00 (0.0-∞) 0.99 0.00 (0.00-∞) 0.99
Insula 2.30 (1.03-4.94 0.04 2.79 (1.21-6.40) 0.02
aHR = hazard ratio, ∞=infinite
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The strength of the present study is that we selected patients in a way that was not 
done before. We included patients with a presumed LGG that were equally eligible 
for all three treatment strategies, by using preoperative characteristics typical for a 
prognostically favorable LGG, and not histopathological diagnosis. Survival was mea-
sured from the date of the first diagnostic scan. We consider this design to result in 
more clinically relevant conclusions than those of earlier studies, since our selection 
resulted in more unbiased inclusion and, therefore, a more equitable comparison of 
strategies compared to previous studies.
We observed no difference in OS between early resection and an initial wait-and-
scan approach. This suggests that a wait-and-scan strategy can be safely proposed 
until evident growth, contrast enhancement or clinical deterioration occurs, and that 
the timing of surgery does not influence the prognosis. How to interpret this result? 
Similar findings have been found in other cancers with typically long survival times; 
early prostatectomy did not increase survival as compared to a watchful waiting policy 
in a large prospective trial in localized prostate cancer with 10 years follow-up.33,34 
This trial shows that timing of the intervention does not have the impact as expected. 
Overall survival is not influenced by early intervention as long as the patient is moni-
tored and intervention takes place when necessary. Although our study was not set-up 
prospectively, the results are comparable. It suggests that in tumors with relatively 
long overall survival, the relative short timing to treatment intervention is not influ-
encing prognosis. The intrinsic biological behavior of the tumor (molecular markers) 
has more impact than the timing of treatment. It also implies that potential morbidity 
of surgery or biopsy can be safely delayed in these patients and lead to higher quality 
of life until treatment.35 On the other hand, surgical techniques like awake craniotomy 
have been shown to be safe and could also decrease seizure frequency and medica-
tion intake in patients with LGG. The data are however not mature yet to give final 
conclusions, but might already argue that a prospective trial is urgently needed to 
investigate if surgery can be safely delayed in a subset of presumed LGG patients.
In contrast to early resection versus wait-and-scan, this study shows that biopsy as 
initial strategy has a negative impact on OS. This observation is in line with that of the 
Norwegian study24 and suggests that this strategy should be avoided. It is difficult to 
explain the significantly shorter OS for the biopsy group compared to the wait-and-scan 
group. In our cohort, we tried to select patients that were equally eligible for all treat-
ment strategies. Nevertheless, we did observe a higher percentage of astrocytomas 
in the biopsy group, which may partly explain the poorer prognosis. Alternatively, this 
difference in histology might be caused by sampling error in the biopsy group. Indeed, 
in a study examining histological diagnosis in paired biopsy and resection samples, an 
oligodendroglial component was missed in 50% of the biopsy samples.36 If this is so, 
our study implies that biopsy is associated with a less favorable outcome. Moreover, 
117
Timing of surgery for presumed LGG
6
in our multivariate analysis that corrected for histology, a worse prognosis remained 
for the biopsy group. Nevertheless, it cannot be ruled out that confounding factors 
that we missed/did not consider might have influenced physicians’ decision to choose 
for a biopsy procedure and, therefore, biased the selection for patients with poorer 
prognosis for the biopsy. To be on the safe side we think a biopsy should be avoided 
when possible. A negative effect of the biopsy itself seems unlikely although an acute 
inflammatory response induced by biopsies is reported to promote metastasis and 
proliferation in other types of cancer and recently it was shown in a murine model that 
reactive astrocytes can potentiate glioma aggressiveness after resection.37-40
This study has a few limitations. First, this study is retrospective in design. Although 
our selection criteria aimed to diminish the possible selection and indication bias, 
which comes with such a design, bias is never ruled out completely. Also, the stringent 
selection criteria that were used resulted in a relatively small cohort size, but they were 
used to identify those patients in whom an extensive resection is possible according to 
current standards. Secondly, a longer follow-up is required before definite conclusions 
can be drawn, as we have not yet reached the median OS in the early resection group. 
Longer follow-up time is necessary.
Thirdly, the extent of resection also has an impact on OS.15-17,20,22,23 Perhaps the most 
important limitation of our study is that the extent of resection was not measured in 
our cohort, since this might have influenced survival. Moreover, the awake craniotomy 
procedure that has emerged in glioma surgery, is reported to increase resection per-
centage and decrease morbidity compared to general anesthesia.41 In our three treat-
ment groups, the type of anesthetic procedure at the time of resection was chosen 
based on the best practice at that time. Of the 128 patients that had any resection dur-
ing follow-up, 56 (43%) were operated with an awake craniotomy procedure and the 
use of this procedure was equally distributed between the treatment groups. Given 
this equal distribution and the fact that we selected patients with a lesion eligible 
for extensive resection, it is unlikely that the extent of resection plays an explanatory 
role in our results. It can never be ruled out however. Also, of the patients in the early 
resection group, 20% underwent the actual intervention within 6-12 months after the 
diagnostic scan. Nevertheless, as the initial choice of treatment by the physician was 
early resection and the intervention took place without any sign of clinical deteriora-
tion, tumor growth or contrast enhancement on MRI scan, we decided not to exclude 
these patients from the analysis. The sensitivity analysis performed after exclusion of 
these patients, failed to show different results.
It should be noted that there were imbalances in the treatment and tumor charac-
teristics that were obtained after initial treatment decision, which should be taken 
into account when interpreting the data. The wait-and-scan group consisted of more 
high-grade gliomas; this is, however, to be expected since the histological diagnosis 
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in the wait-and-scan group was obtained at a median of 35.4 months after the initial 
imaging diagnosis. Also, there was an imbalance in chemotherapy administration, 
showing a lower percentage of patients exposed to chemotherapy in the early resec-
tion group. This is possibly explained by the fact that a significant part of the patients 
in the early resection group had a subsequent wait-and-scan approach after initial 
resection. It is to be expected that also these patients will receive chemotherapy when 
follow-up is longer. On the other hand, although median follow-up in the early resec-
tion group is shorter, this might suggest that patients in the early resection group are 
more clinically stable than the other treatment groups. If this is so, we would expect 
the survival curves to further diverge with longer term follow-up.
Recently the WHO classification of tumors of the central nervous system was 
updated and now incorporates molecular markers. This new classification outflanks 
classic histopathological classification in terms of prognosis estimation and can also 
tailor therapy. Impact of surgery possibly differs between molecular subgroups, but 
this remains to be investigated. The integration of these markers in our study would be 
very interesting in the light of the new WHO classification. Unfortunately, the status 
of these markers was not available for the majority of our population.42,43 However, 
these molecular markers are only determined after resection and should therefore 
not play a role in the selection and decision criteria of this study. New techniques are 
now developed to determine the molecular make up of presumed LGG on preoperative 
MRI’s.44 This will hopefully lead to optimal treatment strategies of these tumors in the 
near future, which will also require further analysis of the value of early and of extent 
of resection in the molecular glioma subtypes.
concluSion
Investigation of three different treatment strategies in a clearly defined set of pre-
sumed LGG patients who were candidates for extensive resection could not confirm 
superiority of early resection over wait-and-scan. In agreement with previous studies, 
biopsy as first treatment strategy seems to be associated with significantly shorter 
overall survival. Still, this observation is difficult to explain. However, to be on the safe 
side, we think avoidance of this strategy should be considered when possible. To our 
knowledge this is the first study to investigate treatment strategies for presumed 
LGG with this design based on preoperative imaging characteristics, which is highly 
representative for daily clinical presentation of this patient group. We need longer 
term follow-up upon final conclusion, but this data highlights prospective data is of 
vital importance.
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abStract
background
Several studies reported a correlation between anatomic location and genetic 
background of low-grade gliomas (LGG’s). As such, tumor location may contribute to 
pre-surgical clinical decision-making. Our purpose was to visualize and compare the 
spatial distribution of different WHO 2016 gliomas, frequently aberrated single genes 
and DNA copy number alterations within subgroups, and groups of postoperative 
tumor volume.
Methods
Adult grade II glioma patients (WHO 2016 classified) diagnosed between 2003 and 
2016 were included. Tumor volume and location were assessed with semi-automatic 
software. All volumes of interest were mapped to a standard reference brain. Location 
heatmaps were created for each WHO 2016 glioma subgroup, frequently aberrated 
single genes and copy numbers (CNV’s), as well as heatmaps according to groups of 
postoperative tumor volume. Differences between subgroups were determined using 
voxelwise permutation testing.
results
110 IDH mutated astrocytoma patients, 92 IDH mutated and 1p19q co-deleted oli-
godendroglioma patients, and 22 IDH wildtype astrocytoma patients were included. 
We identified small regions in which specific molecular subtypes occurred more 
frequently. IDH mutated LGG’s were more frequently located in the frontal lobes and 
IDH wildtype tumors more frequently in the basal ganglia of the right hemisphere. We 
found no localizations of significant difference for single genes/CNV’s in subgroups, 
except for loss of 9p in oligodendrogliomas with a predilection for the left parietal 
lobes. More extensive resections in LGG were associated with frontal locations.
conclusions
WHO low-grade glioma subgroups show differences in spatial distribution. Our data 
may contribute to pre-surgical clinical decision-making in LGG patients.
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introDuction
Classification of diffuse gliomas is based on histological and molecular criteria accord-
ing to the 2016 WHO classification of tumors of the central nervous system.1 Three 
major subtypes of diffuse low-grade (grade II) glioma (LGG) are recognized based on 
testing of two molecular markers: mutations of isocitrate dehydrogenase 1 or 2 gene 
[further abbreviated as IDH] and combined deletion of chromosomal arms 1p and 
19q. Next to the WHO classification, (eloquent) location, size, presence of contrast 
enhancement, and delineation of the tumor margins on magnetic resonance (MR) 
imaging are important prognostic factors.2–5
Previous studies suggest that the anatomic location of a glioma is correlated with 
the molecular background of the tumor.6–9 If so, tumor location may contribute to pre-
surgical clinical decision-making and may provide a non-invasive marker for prediction 
of molecular subtype. However, current evidence to support this is mainly derived 
from relatively small series which are often single molecular marker studies. 6–9 For 
example it was shown that loss of 1p is associated with more frequent location in the 
frontal lobes and that 1p19q co-deletion is absent in insular tumors.7,8 In a series of 47 
patients Metellus et al. showed that IDH wildtype LGG are preferentially located in the 
insular region.9 We recently reported on a cohort of resected LGG samples, wherein 
we found that IDH wildtype tumors were more often located in eloquent areas. In that 
study, just as in many other previous studies on glioma location, we used the cerebral 
lobes as the location description factor, which is not accurate. A recent study by Tejada 
Neyra et al. showed a location predilection for IDH mutated tumors in the frontal lobes 
in the rostral extension of the lateral ventricles.10 Despite these data, no large series 
have been described that actually visualize anatomic location of WHO 2016 low-grade 
(grade II) glioma subtypes in a voxel-based manner. As the WHO 2016 criteria are more 
objective than the previous WHO 2007 criteria and result in a more refined and prog-
nostic classification of tumors, it is possible that the spatial distributions of different 
WHO 2016 glioma subtypes are more distinct than previously shown for the classical 
histopathological classification.11
Previously we investigated the impact of extent of resection in WHO 2016 classified 
LGG and assessed tumor volume location and volume in a semi-automatic manner.12 
We used this cohort in the present study to visualize the spatial distribution of different 
WHO 2016 LGG subtypes, by creating voxel-based probability maps of tumor location 
for every subtype. Using this cohort also enabled us to visualize spatial distributions of 
LGG’s according to the extent of resection. These maps might be helpful in pre-surgical 
decision-making.
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Patient selection
Adult patients (age ≥ 18 years) with histopathologically confirmed supratentorial grade 
II glioma were included. Patients and samples were previously described in a study 
investigating the extent of resection in grade II glioma.12 All patients were treated in a 
single institute between 2003 and 2016, The Brain Tumor Center at Erasmus MC Can-
cer Institute in Rotterdam, the Netherlands. The study was approved by the medical 
ethics committee of Erasmus MC and conducted according to national and European 
regulations.
image acquisition and processing
We used the preoperative MR scans that were available from routine clinical setting. 
MR sequence protocols varied per patient, as patients were diagnosed in several 
centers without the use of a uniform tumor MR imaging protocol. For inclusion in 
this study, at least a T2-weighted (T2w) fluid attenuated inversion recovery (FLAIR) or 
T2w sequence needed to be available. We did not use inclusion or exclusion criteria 
for voxel size and/or slice thickness. We segmented preoperative and postoperative 
glioma lesions on MR imaging in a semi-automated fashion with the SmartBrush tool 
that is incorporated in Brainlab Elements (version 2.1.0.15). With this tool a three-
dimensional (3D) volume-of-interest (VOI) can be created by manually segmenting 
the lesion on two perpendicular slices, from which the software calculates a full 3D 
VOI, which was manually adjusted where necessary. We used the T2w FLAIR sequence 
when available (3D where possible), otherwise the conventional T2w sequence was 
used for segmentation. All tumor related T2w and T2w-FLAIR signal abnormalities 
were included in the segmentation. The T2w and T2w-FLAIR images of all patients were 
affinely registered (preserving parallel lines and planes) to the Montreal Neurological 
Institute (MNI) International Consortium for Brain Mapping (ICBM) 152 non-linear 
T2w atlas13,14, and the 3D VOIs were transformed accordingly for further analysis. We 
registered all MR images using an automated algorithm based on maximization of 
mutual information,15 as implemented in the open-source SimpleElastix software (ver-
sion 9dfa8cb).16 All registrations were manually checked to assure proper alignment 
with the atlas, and adjusted where necessary.
Dna extraction and next-Generation-Sequencing
Areas with high tumor content were manually macrodissected from formalin-fixed-
paraffin-embedded (FFPE) tissue slides as described previously.12 We used a targeted 
Next-Generation Sequencing (NGS) panel to classify samples according to the WHO 
2016 criteria, using an Ion Torrent Personal Genome Machine or Ion S5XL (Life Tech-
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nologies). The panel assesses mutational status of IDH1/2, TP53, FUBP1, PTEN, CIC, 
CDKN2A, NOTCH1, ATRX (whole gene) and hotspots of EGFR (exon 3+15), H3F3A (exon 
2), PIK3CA (exon 10+21), BRAF (exon 11+15), and also copy number variations of chro-
mosome 1, 7, 9, 10, 12, and 19. TERT promoter mutations (C228T & C250T) were as-
sessed in a separate assay (SnaPshot). Detailed methods were described previously.12,17
The following criteria for molecular classification were used:
• Oligodendroglioma: IDH1 or IDH2 mutated and loss of heterozygosity consistent 
with co-deletion of the entire 1p and 19q chromosomal arms.
• IDH mutated astrocytoma: IDH1 or IDH2 mutated.
• IDH wildtype astrocytoma, with molecular features of glioblastoma (according to 
recent cIMPACT-NOW update 318, in further text named as “IDH wildtype astro-
cytoma”): IDH1 or IDH2 wildtype and: TERT promoter mutation without 1p19q 
co-deletion, or loss of heterozygosity of chromosome 10q and imbalance of chro-
mosome 7, or EGFR amplification.
Statistical analysis
We created tumor location heatmaps for the different WHO subtypes by iterating over 
all voxels in the MNI atlas and counting the number of tumor occurrences for each 
group in each voxel. Via this procedure we created location heatmaps for the WHO 
2016 molecular subgroups. Additional heatmaps were generated for glioma specific 
single genes and chromosomes of interest (CIC, FUBP1, chromosome 7 and 9p), as well 
as location heatmaps stratified for extensiveness of resection (four groups of postop-
erative tumor volumes; 0 cm3/0.1-5.0cm3/5.1-15cm3/>15cm3).
To test for differences in spatial distribution between WHO 2016 subgroups, we 
assessed the cluster-wise significance at the voxel-level between distributions, using 
permutation testing with Threshold Free Cluster Enhancement in the software package 
“FSL Randomise”19 (version 5.0.9, using 15000 permutations). This approach corrects 
p-values for the family wise error in testing the many voxels, considering a corrected P-
value of <0.05 as statistically significant. We first compared all IDH wildtype LGG’s with 
all IDH mutated LGG’s. In a subsequent analysis we assessed statistical significance of 
location differences of IDH mutated astrocytoma and oligodendroglioma separately.
rESultS
Our initial cohort consisted of 246 patients with confirmed LGG, for which FFPE mate-
rial and MR scans were available. 22 patients were excluded: 16 due to sequencing 
failure, 2 due to a preoperative contrast enhancement suggestive of glioblastoma, and 
another 4 due to insufficient image quality. Of the remaining 224 patients, 110 were 
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IDH mutated astrocytomas, 92 were oligodendrogliomas, and 22 were IDH wildtype 
astrocytomas. Clinical characteristics of this cohort were consistent with LGG patient 
characteristics known from the literature and are shown in Table 1.
table 1. Patients characteristics
Characteristics Total cohort
(n=224)
Oligodendroglioma
(n=92)
Astrocytoma, IDH 
mutated
(n=110)
Astrocytoma, IDH 
wildtype
(n=22)
n % n % n % n %
Sex         
Male 133 59.4 % 47 51.1 % 70 60.9 % 16 72.7 %
Female 91 40.6 % 45 48.9 % 40 36.4 % 6 27.3 %
Age
Median 42  45  37  59  
IQR 33 - 51  37 - 52  29 - 45  52 - 63  
< 40 99 44.2 % 32 34.8 % 67 60.9 % 0 0 %
40-60 101 45.1 % 49 53.3 % 41 37.3 % 11 50 %
> 60 24 10.7 % 11 12 % 2 1.8 % 11 50 %
Presenting symptom         
Epilepsy 167 74.6 % 76 82.6 % 81 73.6 % 10 45.5 %
Incidental 23 10.3 % 8 8.7 % 14 12.7 % 1 4.5 %
Headache 8 3.6 % 1 1.1 % 6 5.5 % 1 4.5 %
Miscellaneous 
neurologic complaints
26 11.6 % 7 7.6 % 9 8.2 % 10 45.5 %
Type of 1st surgery
Awake craniotomy 103 46 % 49 53.3 % 53 48.2 % 1 4.5 %
Normal resection 74 33 % 23 25 % 48 43.6 % 3 13.6 %
Open biopsy 15 6.7 % 7 7.6 % 2 1.8 % 6 27.3 %
Stereotactic biopsy 32 14.3 % 13 14.1 % 7 6.4 % 12 54.5 %
Preoperative KPS
Median 100  100  100  90  
IQR 90 - 100  100 - 100  90 - 100  82 - 90  
100 145 64.7 % 70 76.1 % 70 63.6 % 5 22.7 %
90 61 27.2 % 17 18.5 % 33 30 % 11 50 %
<=80 18 8 % 5 5.4 % 7 6.4 % 6 27.3 %
Eloquent Area 90 40.2 % 35 38 % 39 35.5 % 16 72.7 %
Side of lesion
Right 95 42.4 % 37 40.2 % 51 46.4 % 7 31.8 %
Left 117 52.2 % 50 54.3 % 57 51.8 % 10 45.5 %
Bilateral 12 5.4 % 5 5.4 % 2 1.8 % 5 22.7 %
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Spatial distribution of Who 2016 glioma subgroups
Spatial distribution heatmaps for each WHO 2016 grade II glioma subgroup are shown 
in Figure 1. Upon visual inspection most oligodendrogliomas were located in the fron-
tal lobes and cortex, while IDH mutated astrocytomas were more frequently located 
in the frontotemporal lobes and the insular region. IDH wildtype astrocytomas were 
more frequently located in the basal ganglia and rostral areas of the hemispheres. In 
this cohort, tumors were slightly more frequently located in the left hemisphere, both 
for IDH mutated astrocytomas and oligodendrogliomas.
Statistical analysis of the spatial distributions indicated that tumors were more fre-
quent in the anterior extensions of the lateral ventricles for IDH mutated LGG’s (oligo-
dendrogliomas and IDH mutated astrocytomas combined) compared to IDH wildtype 
astrocytomas (Figure 2A). With IDH wildtype astrocytomas as reference category, our 
analysis indicated that IDH wildtype astrocytomas are more frequently located in the 
basal ganglia of the right hemisphere (as compared to IDH mutated LGG’s) (Figure 2B).
table 1. Patients characteristics (continued)
Characteristics Total cohort
(n=224)
Oligodendroglioma
(n=92)
Astrocytoma, IDH 
mutated
(n=110)
Astrocytoma, IDH 
wildtype
(n=22)
n % n % n % n %
Pre-operative tumor volume, cm3
<25.0 64 28.6 % 26 28.3 % 31 28.2 % 7 31.8 %
25.1-50.0 54 24.1 % 24 26.1 % 24 21.8 % 6 27.3 %
50.1-100.0 65 29 % 23 25 % 38 34.5 % 4 18.2 %
100.1-250.0 38 17 % 17 18.5 % 16 14.5 % 5 22.7 %
250.1-351.0 3 1.3 % 2 2.2 % 1 0.9 % 0 0 %
Median 47.3  45.9  50.95  38.2  
Range 3.01 - 350.5  4.29 - 350.5  3.01 - 302.8  9.05 - 213.1  
Postoperative tumor volume, cm3
0.0 33 14.7 % 15 16.3 % 17 15.5 % 1 4.5 %
0.1-5.0 54 24.1 % 27 29.3 % 26 23.6 % 1 4.5 %
51-10.0 21 9.4 % 6 6.5 % 13 11.8 % 2 9.1 %
10.1-50.0 66 29.5 % 19 20.7 % 38 34.5 % 9 40.9 %
50.1-265.0 50 22.3 % 25 27.2 % 16 14.5 % 9 40.9 %
Median 11  7.13  9.26  31.5  
Range 0 - 263.6  0 - 263.6  0 - 232.7  0 - 213.1  
Follow-up (years)         
Median 5.8  7.3  5.7  2.2  
Range 0.3 - 20.4  0.8 - 20.4  0.3 - 15  0.3 - 4.7  
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Direct comparison between IDH mutated astrocytomas and oligodendrogliomas 
showed a small area in the left frontal cortex where oligodendrogliomas occurred 
more frequently, and a small region in the right temporal lobe where IDH mutated 
astrocytomas (supplementary Figure 1) occurred more frequently. However, in a 
subsequent 3-group comparison including IDH wildtype astrocytomas, there were no 
locations of signifi cant differences for IDH mutated astrocytomas or oligodendroglio-
mas individually, only for IDH wildtype astrocytomas individually.
Oligodendroglioma, IDH mutated 1p/19q-codeleted (n=92)
Astrocytoma, IDH mutated (n=110)
Astrocytoma, IDH wildtype (n=22)
b
a
c
0
20
10
0
30
15
0
10
5
figure 1. Spatial distribution heatmaps of WHO 2016 glioma subgroups. The color of a voxel corre-
sponds with the number of tumors localized at that location, ranging from red (low number), to white 
(high number). The color bars on the right indicate the frequencies corresponding with the color per 
voxel; (a) location distribution of oligodendroglioma shows most are located in the frontal lobes. (b) 
IDH mutated astrocytoma shows a distribution with most tumors located in or near the insular region. 
(c) IDH wildtype astrocytomas are more often located in midline region and basal ganglia.
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Exploratory analysis of location predilection of single gene and copy number 
variations
As an exploratory analysis, we also generated spatial distribution heatmaps of the 
additional genes and copy number variations we tested with our dedicated NGS 
panel that were frequently mutated or aberrant. For this, we analyzed CIC and FUBP1 
mutations, and loss of chromosomal arm 9p for oligodendroglioma (supplementary 
- 0.05
- 0.10
- 0.20
P-values
IDH-mutated LGG
IDH-wildtype LGG
A
B
figure 2. Differences in location distribution between IDH wildtype and mutated low-grade gliomas. 
Voxel-color indicates corrected p-value with color bar for scale; (a) regions more often occupied by 
IDH mutated low-grade gliomas; (b) regions more often occupied by IDH wildtype low-grade gliomas.
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Figure 2). We found no preferential locations for any of those molecular aberrations, 
except for loss of 9p (compared to oligodendroglioma with intact 9p), which seemed 
to be more frequently located in the left parietal area (supplementary Figure 3). In 
IDH mutated astrocytoma we created heatmaps of loss of chromosomal arm 9p and 
imbalance of chromosome 7, and found no preferential brain locations for either of 
those (supplementary Figure 4).
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0.0 cm3 postoperative tumor volume (N=33)
0.1-5.0 cm3 postoperative tumor volume (N=54)
5.1-15.0 cm3 postoperative tumor volume (N=41)
>15.0 cm3 postoperative tumor volume (N=96)
b
a
c
d
figure 3. Spatial distribution heatmaps of WHO 2016 grade II glioma stratifi ed according to postop-
erative tumor volume. The color bars on the right indicate the frequencies corresponding with the 
color of the voxels; (a) gliomas with a total resection (0.0 cm3 residue); (b) gliomas with a postopera-
tive tumor volume of 0.1 - 5.0 cm3; (c) gliomas with a postoperative tumor volume of 5.1-15.0 cm3; (d) 
gliomas with a postoperative tumor volume of more than 15.0 cm3.
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resection probability of low grade glioma
For a previous study on the extent of resection in the same cohort, postoperative tumor 
volumes were also assessed with the BrainLab Elements SmartBrush Tool. We assigned 
patients into one of four groups based on the postoperative tumor volume: 0.0 cm3, 
0.1-5.0 cm3, 5.1-15.0 cm3, and > 15.0 cm3 postoperative tumor volume. We generated 
location distribution heat maps stratified by these four groups, to investigate if there 
are preferential localizations for gross total resections. Results are shown in Figure 3. 
All tumors with a total resection (0.0 cm3 postoperative residue) were located in the 
frontal lobe. Similarly, the majority of tumors with a low postoperative tumor volume 
(0.1 - 5.0 cm3) were located in the frontal lobes. Tumors with a postoperative volume 
of more than 5.0 cm3 more frequently occurred in the insular region, temporal lobes, 
and in or near the primary sensory and motor cortex.
DiScuSSion
In this study we aimed to visualize and compare the spatial distribution of WHO 2016 
grade II glioma subgroups. By using advanced image processing analyses, we were 
able to generate accurate spatial distribution maps, especially compared to previ-
ous studies that were primarily based on location description/scores.7–9,20 Our data 
indicate there are significant differences in spatial distribution patterns dependent 
on IDH status, with IDH mutated LGG’s more frequently located in the rostral exten-
sions of the lateral ventricles, and IDH wildtype astrocytomas more frequently in the 
basal ganglia of the right hemisphere. Our data are in line with earlier observations 
and confirm there is a correlation between molecular background of a glioma and 
anatomic location.6–10 On the other hand, our data also indicate an overlap in anatomic 
location between WHO 2016 subgroups.
Upon visual inspection, a distinct pattern is clearly recognized between groups: most 
oligodendrogliomas are located in the frontal lobes and cortex, while IDH mutated 
astrocytomas are more frequently located in the frontotemporal and insular region. 
However, the substantial overlap between IDH mutated astrocytomas and oligoden-
drogliomas can be appreciated as well. This is also indicated by our voxel-cluster based 
statistical analysis, wherein we find a significant predilection for IDH mutated LGG’s in 
the rostral extensions of the anterior lateral ventricles (IDH mutated astrocytomas and 
oligodendrogliomas grouped together), while we could not find regions significantly 
associated with either IDH mutated astrocytomas or oligodendrogliomas when we 
analyzed them as individual entities. Although oligodendrogliomas and IDH mutated 
astrocytomas differ in clinical behavior (overall survival, sensitivity to chemotherapy) 
and are recognized as independent entities by the WHO classification, both entities 
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share the IDH mutation. It is suggested that the cell of origin for IDH mutated gliomas 
is localized within the subventricular zone.21 If oligodendrogliomas and IDH mutated 
astrocytomas share the cell-type of origin this might explain the significant predilec-
tion of IDH mutated LGG’s in the rostral extensions of the anterior lateral ventricles, 
and the absence of a location difference between IDH mutated astrocytomas and 
oligodendrogliomas.
Compared to IDH mutated LGG’s, IDH wildtype astrocytomas showed a distinct 
spatial distribution with more lesions located in the midline and basal ganglia. This 
different spatial distribution is an interesting observation, as it shows that, in the 
setting of grade II gliomas, IDH wildtype astrocytomas have a different anatomical 
and thus clinical presentation. The spatial distribution explains the high percentage of 
biopsies in these patients we reported previously, as tumors in these locations are not 
eligible for safe resections.12 We also reported previously12 that these tumors often do 
not present with epilepsy, in contrast to IDH mutated grade II gliomas, and this might 
also be explained by their preferential, non-cortical location. On the other hand, it 
has also been postulated that high frequency of epilepsy in IDH mutated gliomas is 
explained by mimicking the activity of glutamate on the NMDA receptor due to high 
levels of d-2-hydroxyglutarate.22
Upon visual inspection in this series, both oligodendrogliomas as well as IDH mutated 
astrocytomas were slightly more frequently located in the left hemisphere, especially 
in insular location. An explanation might be a selection bias of patient referral due to 
the fact that our center was one of the first in the Netherlands that performed awake 
craniotomies, which are performed for tumors located in presumed eloquent regions 
such as the left insular, frontal, and temporal region.
A current hot topic in glioma research is the development of non-invasive predic-
tion of WHO 2016 classification of tumor diagnosis based on preoperative MR scans. 
This would be very helpful for pre-surgical decision making. In a previous study for 
example we showed that minor postoperative tumor residues have more impact on 
survival in IDH mutated astrocytomas than in oligodendrogliomas.12 Our data shows 
that anatomic location could contribute to this non-invasive prediction, but requires 
the combination with other parameters to accurately predict WHO subtype.
We performed an exploratory analysis to assess the spatial distribution of other 
frequently reported mutations and copy number variations in glioma. Potential differ-
ences in spatial distribution might generate hypotheses or clues about the origin of 
glioma or specific subgroups and aggressiveness of certain glioma subtypes. We found 
no specific spatial distributions for the tested aberrations however, except for loss of 
chromosome 9p in the context of oligodendroglioma. Oligodendrogliomas with loss 
of 9p were significantly more frequently located in the left parietal area. This finding 
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needs to be confirmed in independent series before any assumptions regarding the 
relevance on the biological level can be made.
As a second aim we visualized the possible correlation between anatomic location 
of LGG and the extent of their resection. State-of-the-art neurosurgical techniques 
including awake craniotomies were used in this cohort to achieve resections as ex-
tensive as possible in a safe way. Upon visual inspection we found that LGG’s with 
no or very small postoperative tumor residues (more extensive resections) were more 
frequently located in the frontal lobes, while LGG’s with larger postoperative tumor 
volumes were more frequently located in the insular and temporal regions. This is an 
expected result, as extent of resection is associated with anatomic location and also 
with proximity of eloquent areas of the brain.12 Our heatmaps provide an insightful 
visualization which might be helpful in surgical planning and in informing patients on 
resectability of a LGG.
Our study has several contributions compared to previous studies. We used a rela-
tively large and representative consecutive cohort of LGG’s, which were all classified 
with NGS according to the integrated WHO 2016 criteria. To our knowledge this is 
the first study that visualizes spatial distribution of gliomas classified according to 
the WHO 2016 classification. Also, we scored location in a voxel-based manner with 
the use of semi-automated segmentation software, which gives a far more accurate 
representation of location compared to a manual scoring of location. Some limitations 
have to be addressed as well. Our study was retrospective in nature, and the MRI 
protocols were not standardized. Consequently, voxel size and slice thickness were not 
homogeneous in the cohort. Images with large voxel size and slice thickness pose chal-
lenges for accurate segmentation and registration. More subtle differences in location 
between groups might be missed. However, our aim was not to find subtle differences, 
but clinically relevant differences between groups, and our cohort with heteroge-
neous MR protocols is sufficient for this aim (and also reflects the ‘real life’ situation). 
More importantly, the mapping of patient MR scans with segmentations to the MNI 
standard brain can lead to distortion and a slight change of location on the standard 
brain compared to the original MR scan. This is especially relevant for relatively large 
lesions with mass effect, for example tumors that compress the ventricles. Because of 
this our heatmaps erroneously showed some tumors to be located in the ventricles. 
However, if a registration that perfectly mapped the tumor to its position along the 
ventricle (instead of mapping it inside the ventricle), the tumor would have be com-
pressed. As such the resulting mapping would misrepresent the actual tumor volume. 
Therefore, we have chosen to accept the erroneous mappings into the ventricles in 
favor of these volume effects. To be as accurate as possible, we manually checked all 
registrations and corrected where necessary. Furthermore, although this is a relatively 
large consecutive series of molecular defined grade II glioma, a further expansion of 
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our dataset is needed, as especially the group of IDH wildtype astrocytomas is small. 
We need larger numbers to confirm that the spatial distribution of IDH wildtype LGG 
is indeed different compared to IDH mutated LGG, as it is known that glioblastomas 
are also frequently located in the frontal lobes. However, a recent study showed that 
in the context of glioblastoma, the frontal cortex is also significantly associated with 
the presence of IDH mutations.10
In conclusion, WHO 2016 low-grade glioma molecularly defined subgroups show 
both differences and similarities in spatial distribution, with IDH mutated LGG’s sig-
nificantly more frequently located in the frontal lobes and IDH wildtype tumors more 
frequently in the basal ganglia of the right hemisphere.
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Supplementary fi gure 1. Results of voxelwise permutation testing with 15000 permutations for sta-
tistical differences in location distribution. The color of a voxel inidcates the p-value as indicated in the 
top-right color bar; (a) heatmap of signifi cantly more frequent occuring localizations for oligodendro-
glioma compared with IDH mutated astrocytomas (b) heatmap of signifi cantly more frequent occur-
ing localizations for IDH mutated astroctyomas compared with oligodendrogliomas.
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IDH mutated 1p19q co-deleted oligodendroglioma, CIC mutated (N=51)
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Supplementary fi gure 2. Spatial distribution heatmaps of presence of individual gene or copy number 
alterations in the context of oligodendroglioma.
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Oligodendrogliomas with loss of 9p are more frequently located in the left parietal lobe 
Supplementary fi gure 3. Results of voxelwise permutation testing showing signifi cant more frequent-
ly occuring localizations for loss of 9p in the context of oligodendroglioma, compared with 9p intact 
oligodendroglioma.
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Supplementary fi gure 4. Spatial distribution heatmaps of presence of individual copy number altera-
tions in the context of IDH mutated astrocytoma.
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General discussion
8
GEnEral DiScuSSion
In 2016 the World Health Organization (WHO) classification of tumours of the central 
nervous system was updated.1 This update marks a historic moment in the glioma 
field as testing for molecular markers became central in the diagnosis of glioma sub-
types. The update altered the composition of diagnostic subtypes, which led to more 
accurate prognosis estimation.2 Current treatment strategies are based on several pa-
tient factors, of which the WHO subtype is a very important one which determines the 
treatment intensity. Therefore, due to the changes in diagnostic groups that occurred 
after the WHO 2016 revision, the clinical management of especially lower-grade 
gliomas requires reevaluation. Also, the WHO 2016 update does not mark the end of 
a search for an improved classification, but marks the start of a molecular era in the 
neuro-oncology field wherein one of the goals is to further refine the molecular clas-
sification in order to personalize and further improve clinical management of gliomas. 
In this thesis we aimed to evaluate surgical management of glioma in the light of the 
WHO 2016 classification, and to further refine molecular diagnostics.
SurGical ManaGEMEnt of (PrESuMED) loW-GraDE GlioMaS
Despite the “low-grade” prefix, and the fact that low-grade gliomas never metasta-
size, it is in principle a fatal disease. Complete eradication (surgical and with systemic 
therapy) is barely possible due to the infiltrative growth into, and eventually destruc-
tion of, vital brain areas, as the skull is a closed and non-compliant compartment.3, 4 
The optimal surgical management of (presumed) low-grade glioma remains a matter 
of controversy, as surgery comes with a risk of neurological sequelae, especially in 
low-grade gliomas as these tumors are often located in or near eloquent areas. As no 
randomized trials exist related to effect of timing and extent of surgery on outcome, 
surgical treatment strategy varied per treatment center and was mostly depending on 
local opinions in the past. For a long time, the general consensus on initial treatment 
for low-grade glioma was a wait and scan policy. With this strategy MR scans (and in 
the early days CT scans), were performed at regular intervals. Hereby a lesion suspected 
to be a low-grade glioma was followed over time, with the intention to start active 
treatment once significant growth, clinical deterioration, or new contrast enhance-
ment (taken as a sign of malignant transformation) were present. This strategy was 
supported by limited data from some retrospective cohort studies performed in the 
1990’s that did not find an association between timing of surgery and prognosis.5-7 In 
the last two decades the general opinion in the field shifted and nowadays early maxi-
mal safe resection is considered standard of care in symptomatic lesions suspected 
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to be a low-grade glioma. There is a growing bulk of evidence that more extensive 
resections are associated with a longer overall survival, but the optimal timing of 
surgery is hardly investigated and most evidence supporting early resections remains 
retrospective and circumstantial.8-13 With randomized trails considered not feasible, 
an influential retrospective study in Norway that was published in 2012 showed that 
early surgery was associated with a longer overall survival compared to a diagnostic 
needle biopsy followed by a wait-and-scan approach.14 In this study the outcome of 
a unique situation was studied, also labeled as ‘postal code randomization’. In this 
study treatment outcome was compared between two neurosurgical centers in two 
different regions in Norway with different treatment strategies. One center favored a 
biopsy followed by a wait-and-scan policy as initial treatment, the other favored early 
maximal surgical resection; patients were treated in one of these centers depending 
on their region of residence. The authors concluded that patients treated in the center 
favoring early resections had a significant longer overall survival.14 The drawback of 
this study, and indeed of all studies investigating extent of resection in low grade 
glioma, is the patient selection that is based on histology obtained during surgery. 
This is not reflecting the actual clinical situation in which surgery is decided upon 
preoperative patient characteristics, while the histology is unknown yet. Therefore 
these retrospective studies are subjected so selection bias due to exclusion of patients 
with a suspected low-grade gliomas that turn out to be high grade gliomas, and with 
inclusion of patients with histologically proven low-grade glioma with preoperative 
enhancement on imaging that was suggestive of a high grade glioma. In our study 
described in chapter 6 we tried to address this issue by approaching this clinical is-
sue from a preoperative and more clinically relevant perspective. We retrospectively 
included patients with a presumed low grade glioma that was eligible for an extensive 
resection by selection based on imaging and preoperative clinical characteristics and 
not on histological diagnosis. In this manner we eliminated selection bias by histology 
and avoided selection bias on indication as much as possible. We investigated three 
different treatment strategies (wait-and scan, early resection, (needle or open) biopsy) 
and compared overall survival between groups. We could not confirm superiority of 
early resection over wait-and-scan (HR 0.92; 95% CI 0.43-2.01; P = 0.85). These data 
suggest that a wait-and-scan strategy can be safely proposed until some evidence of 
progression occurs, and that the timing of surgery does not influence the prognosis as 
long as the patient is monitored and treatment is initiated when necessary. An expla-
nation for this unexpected result could be that the intrinsic biological behavior of the 
tumor has more impact than the timing of surgery, especially in tumors with a relatively 
long overall survival. The median time till intervention in the wait-and-scan group was 
35.4 months, which is still relatively early in the course of the disease (median overall 
survival of 11.9 years in the wait-and-scan group). As is showed in chapter 5 (of which 
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the results will be discussed later in this chapter), extent of resection is associated 
with overall survival. We did not have information on extent of resection in the study 
in chapter 6, and that is an important limitation. As low-grade gliomas grow slowly 
(~4mm per year), it is to be expected that total resections are more achievable when 
surgery is performed early in the natural course of the disease, especially in larger le-
sions that are not superficially located. As there is no evidence available that timing of 
surgery is indeed correlated with extent of resection however, it remains speculative 
how this might have influenced the survival curves of the cohort of chapter 5. There is 
however a plausible explanation for another observation we made: a worse outcome 
in the biopsy group, as in chapter 5 we showed that the percentage of biopsies was 
significantly higher in patients with IDH wildtype low-grade gliomas compared to IDH 
mutated reflecting a difference in location of IDHwt versus IDHmt tumors (which we 
also show in chapter 7). We think it is therefore likely that the shorter overall survival 
observed in the biopsy group in chapter 6 is explained by a similar higher proportion of 
patients with IDH wildtype tumors. This does not explain the poor results of the biopsy 
patients in the Jakola cohort. In 2017 Jakola et al. published an survival update on 
their 2012 cohort and now added molecular classification as well: after adjustment for 
molecular markers the positive effect on overall survival with early surgery persisted.15
In chapter 5 we investigated the association between extent of resection and overall 
survival in low-grade glioma in the light of the WHO 2016 classification. We were the 
first to report on a relatively large series of molecularly classified low-grade glioma 
patients that were investigated for extent of resection with a quantitative measure. 
We could validate current standard of care, as we showed that postoperative tumor 
volume was inversely correlated with outcome irrespective of molecular subtype. 
The effect of even small postoperative tumor volumes was particularly strong in IDH 
mutated astrocytomas, as any residual tumor >0 cm3 already negatively impacted 
overall survival. This finding argues for second-look surgeries when this is safely pos-
sible, when a small residue remains in this subtype. Similar findings were reported for 
anaplastic glioma, although not in a volumetric manner as in our study. Kawaguchi et 
al. showed that gross total resection (GTR) was associated with longer overall survival 
when lumping together all 3 molecular subtypes of anaplastic glioma. However, when 
looking at molecular subtypes individually, GTR had a positive significant impact on 
overall survival only in IDH mutated astrocytoma, and not in IDH wildtype astrocy-
toma and oligodendroglioma.16 Another study in 2016 by Wahl et al. reported on 
clinical outcomes by molecular subtype of a phase II study of adjuvant chemotherapy 
for low-grade glioma. Although it was not the primary objective of the study, in an 
exploratory analysis it was found that postoperative tumor volumes were associated 
with outcome irrespective of molecular subtype.17
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How to interpret the data form these studies and translate this into treatment 
guidelines for glioma patients? At first glance the results in chapter 5 and 6 seem 
conflicting. However, we have to realize both cohorts are differently selected and try 
to answer different questions: first, when to resect and second, if one decided to resect 
how much should be resected. Uniform treatment recommendations that apply to all 
patients are impossible to give, but one thing is clear: a biopsy should not be part of 
standard care if a resection is possible. It should only be used in patients wherein a 
resection is not possible, but with a need for active treatment, to establish an accurate 
diagnosis. With chapter 5 we provided the evidence that also for molecularly defined 
low-grade glioma, lower postoperative tumor volumes are associated with longer 
overall survival. Therefore a resection should be as extensive as safely possible in all 
newly diagnosed lower grade glioma patients. That introduces another important 
element; the question when a lesion is considered eligible for a meaningful extensive 
resection that is also safely possible (thus with low risk of complications). Resectability 
is dependent on tumor size, delineation, location, eloquency, and patient condition. 
Although a total resection is the ultimate aim, this is not possible in most patients, 
leaving the question what cut-offs for a minimal extent of resection is meaningful 
in terms of survival benefit. Although the results obtained in chapter 6 do not show 
a survival benefit from early surgery, all other presently available data suggests that 
when a safe and extensive resection is possible, it should be performed early in the 
course of the disease, once the radiological diagnosis of a presumably low grade 
glioma is established. We also think this is in patients’ best interest as a resection in 
a later stage will be technically more challenging and may be associated with a less 
extensive resection. However, when a meaningful resection is considered not possible 
and a patient has no symptoms other than well controlled seizures, a wait-and-scan 
period (‘active surveillance’) can be considered until treatment is necessary. Ideally, in 
the future we would have prospective data generated from a randomized trial that 
provides us unbiased evidence on optimal timing of surgery, as well as on the impact 
of extent of resection, and if so, the minimum extent of resection to aim for. However, 
it is unlikely that a trial like this will ever be performed and early surgery is now in 
general accepted as standard of care, despite the lack of prospective data.
MolEcular tEStinG for GlioMaS
Even though prognosis prediction for patients with glioma improved significantly with 
the WHO 2016 update, there is still variation in outcome within specific subtypes, and 
therefore further refinement of this classification would be valuable. Historically, the 
grade of glioma used to be a strong prognostic marker and grading is still part of the 
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WHO criteria. Grading is however purely based on microscopic features examined on 
hematoxylin and eosin stained slides, and currently no molecular markers are avail-
able to discriminate outcome within grade II (low-grade) and grade III (anaplastic) 
gliomas. In chapter 2 we analyzed the publically available TCGA dataset (The Cancer 
Genome Atlas) and found that also for molecular glioma subtypes the histological 
tumor grade was inversely correlated with patient overall survival. We could not find 
in this dataset specific single molecular markers that were associated with tumor 
grade, but we did found that tumor grade was correlated with the mutational load 
(total number of genetic changes within one sample). This is an interesting observa-
tion, as it may partially explain the increased aggressiveness of gliomas with higher 
tumor grades. However, in the WHO 2016 classification the impact of tumor grade on 
prognosis seems to be more subtle and not as distinct as in the WHO 2007 classifica-
tion. Reuss et al performed a study wherein they combined multiple datasets of IDH 
mutated astrocytoma (including the TCGA dataset) and found that both low-grade and 
anaplastic IDH mutated astrocytoma present at a similar age and that the difference 
in overall survival between grade II and III IDHmt astrocytoma is minimal. Partially 
this may be explained because IDH wildtype astrocytomas are now a separate entity 
and the differences between grades in the WHO 2007 classification were probably 
predominantly dependent on this subgroup.18 In chapter 2 we also showed that within 
IDH mutated astrocytomas, mutations in PI3 kinase genes PIK3CA and PIK3R1, are as-
sociated with poorer prognosis, and we could confirm this finding in two independent 
datasets. The prevalence of these mutations in low-grade glioma patients is low how-
ever, and does not explain all variation in prognosis within subgroups. Several large 
efforts have aimed to identify molecular markers that correlate with tumor grade 
and could replace the current histological grading system. Most studies in the past 
focused on anaplastic glioma, with different studies showing conflicting results. For 
example loss of entire chromosomal arm 9p or loss of 9p21.3 region was reported 
as a marker of poor prognosis, mainly in grade III and grade IV glioma, but results 
are conflicting.19-22 It is also unclear which region should be tested for: the entire 9p 
arm, the 9p21.3 region or the CDKN2A gene only. In chapter 3 we used a targeted 
next generation sequencing panel to evaluate the prognostic relevance of frequently 
reported prognostic glioma markers in a consecutive treated series of grade II glioma. 
We analyzed 207 IDH mutated glioma samples and investigated the impact of loss of 
9p21.3 and entire 9p on outcome in both oligodendroglioma and IDH mutated astro-
cytoma. In both groups of our cohort loss of 9p21.3 of entire 9p was not associated 
with overall survival, although a trend towards shorter overall survival was visible in 
grade II oligodendrogliomas. Therefore, longer follow-up and expansion of our dataset 
is necessary for more definitive final conclusions. We did not find homozygous dele-
tions of CDKN2A/B in our dataset, which is in line with a recently published cohort 
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of grade II,III, and IV IDH mutated 1p19q intact tumors. The authors describing that 
cohort found that CDKN2A/B homozygous deletions and total number of copy num-
ber variations were strong predictors of worse outcome in a cohort of grade II,III, and 
IV IDH mutated 1p19q intact tumors. In line with our grade II cohort, they did not find 
CDKN2A/B homozygous deletions in WHO 2016 grade II gliomas.23
In chapter 4 we showed that IDH wildtype low-grade gliomas, in contrast to the cur-
rent WHO 2016 classification, are not a single entity, but in fact a clinical and molecular 
heterogeneous group of tumors. We found that IDH wildtype gliomas with trisomy of 
chromosome 7, loss of chromosome 10 (+7/-10q) and TERTp mutations have a dismal 
prognosis almost similar to glioblastoma. We also identified a group of IDH wildtype 
tumors with only a TERTp mutation without presence of +7/-10q. These patients even 
had a worse prognosis than the patients with +7/-10q. More importantly, we found 
IDH wildtype glioma patients without these molecular aberrations, and observed they 
had a significant better outcome. Our results were confirmed in independent stud-
ies.24-26 This implies that more extensive molecular testing should be performed in 
IDH wildtype gliomas, in order to accurately estimate prognosis and guide treatment 
decisions. At least assessment of TERT promoter status or +7/-10q status is necessary 
on case of IDH1/2 wildtype low-grade or anaplastic glioma. When these markers are 
absent, then further testing for at least BRAF and H3F3A mutations is necessary. Ide-
ally, however, all makers are included in a single panel for routine diagnostics, to avoid 
diagnostic delay.
In chapter 7 we aimed to correlate WHO 2016 molecular subtypes with anatomic 
location of grade II glioma. Several studies reported a correlation between anatomic 
location of gliomas and the genetic background of the tumor. 27-29As such, tumor loca-
tion might contribute to pre-surgical decision-making and non-invasive prediction of 
molecular diagnosis, which would be particularly helpful for lesions wherein there 
is doubt if it is actually a glioma or in patients wherein surgery has too high risk of 
morbidities but where systemic treatment is eligible. We reported on a large series of 
WHO 2016 classified tumors of which we created anatomic location heatmaps. De-
spite relevant overlap between molecular subgroups, we still found unique locations 
for IDH mutated grade II gliomas in the anterior extensions of the lateral ventricles. 
Interestingly, IDH wildtype astrocytomas were predominantly located in the midline 
and basal ganglia. This explains the relatively high percentage of biopsies in this group 
(chapter 5). Our data shows that location is a potentially important parameter for ra-
diogenomics, but also emphasizes that other parameters are necessary to accurately 
predict molecular subtype, as there is significant overlap between groups.
In conclusion, we provide several insights that further refine the WHO classifica-
tion. We suggest testing for mutations in PI3K genes to be added to clinical routine 
diagnostics, and to further stratify IDH mutated astrocytoma. Furthermore, stratifica-
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tion of IDH wildtype gliomas is essential, as this group of tumors turns out to be very 
heterogeneous molecularly, and even more important, clinically (strong differences 
in overall survival), which has direct implications for clinical management. In figure 
1 we summarize our fi ndings and propose an updated diagnostic scheme. Still, not 
all variation in clinical outcome is explained by this scheme. To unravel this we need 
even larger glioma datasets than in TCGA, including matched primary and recurrent 
tumor samples to fi nd markers of progression and of poor outcome. Just as important 
as sample size, or maybe even more important, these datasets need a more detailed 
and accurate clinical annotation than is provided in TCGA. Including MR imaging with 
standardized protocols is also important, as this might provide us with imaging cor-
relates of molecular markers and/or prognostic subgroups. This can only be achieved 
with large international collaborations, as glioma is a rare disease.
Glioma
IDH-mutIDH-wt
TP53/ATRX
1p19qPI3K-mut PI3K-wt
TERTp-mut
NOS +7/-10q
7/10q 
intact
TERTp-wt
BRAF-mut H3F3A-mut
Age ~ 40-60yrs ~ 20-50yrs ~ 20-30yrs ~ 50-70yrs ~ 50-70yrs ~ 25-45yrs ~ 40-60yrs
Anatomic location
figure 1. This fi gure forms a summary of our fi ndings and proposes an updated classifi cation scheme.
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Summary
SuMMary
Gliomas are the most common type of primary malignant brain tumors. Several sub-
types of glioma are recognized by the World Health Organization (WHO), based on his-
tological and molecular criteria. The WHO classification of brain tumors was updated 
in 2016 and in this thesis the results of several studies on classification and clinical 
management of lower-grade glioma in the context of these updated WHO criteria are 
described. In chapter 1, the general introduction, we provide an overview of the WHO 
2016 criteria and current clinical management of low-grade glioma.
In chapter 2 we analyzed the publically available whole exome sequencing data of 
the Cancer Genome Atlas (TCGA) of both low and high grade glioma, to find additional 
markers of prognosis within WHO 2016 recognized glioma subgroups. We investigated 
all genes that were mutated at a population frequency of more than 1.7% and frequent 
chromosomal imbalances. In the entire dataset 57 genes were significantly correlated 
with overall survival. IDH1/2 mutations showed the lowest hazard ratio, confirming 
IDH1/2 is the most important prognostic marker in diffuse gliomas. With subsequent 
subgroup analysis, we found that within IDH mutated astrocytomas, mutations in PI3 
kinase genes PIK3CA and PIK3R1, are associated with poorer prognosis (median OS 3.7 
vs. 6.3 years; P=0.02; HR 2.93; 95% CI 1.16-7.38). We also demonstrated that tumor 
grade remains an independent prognostic factor within molecular subgroups and 
found that tumor grade is correlated with mutational load.
In chapter 3 we report on a study wherein we assessed the prognostic relevance 
of additional mutations and copy number alterations in a consecutive series of IDH 
mutated grade II glioma. In univariate analysis we found a significant shorter overall 
survival in IDH mutated astrocytoma patients with a trisomy of chromosome 7, and in 
oligodendroglioma patients with a PTEN mutation, but could not confirm these find-
ings in multivariate analysis. We could also not confirm the impact of loss of 9p21.3 
on overall survival, which is frequently reported as progression marker in high grade 
glioma. However, we need lengthy follow-up for definitive conclusions.
In chapter 4 we report on a relatively large group of IDH-wildtype low-grade and 
anaplastic gliomas, which are recognized as a single entity and do not require further 
stratification according to the current WHO classification. We showed that this is actu-
ally a molecular and clinical heterogeneous group of tumors, which requires additional 
molecular testing beyond IDH1/2, in order to accurately estimate prognosis and guide 
treatment. Only 52.7% of patients showed a phenotype with trisomy of chromosome 
7 and loss of 10q, which is a molecular characteristic of glioblastoma. Except one 
patient, all of these also had a TERT promoter mutation. 18.9% of patients had only 
a TERT promoter mutation, and had even a poorer prognosis than patients with the 
classical molecular characteristics of glioblastoma. More importantly, approximately 
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20% of patients did not have any of the investigated molecular aberrations, and had a 
significant better outcome.
In chapter 5 we describe a study wherein we assessed the impact of extent of sur-
gery on outcome in molecularly defined low grade glioma. As the WHO classification 
of gliomas has been completely revised and is now predominantly based on molecular 
criteria, the impact of extent of resection needed to be re-evaluated in molecularly 
defined low grade glioma. We included 228 adult patients who underwent surgery 
for a supratentorial low-grade glioma and semi-automatically assessed pre- and post-
operative tumor volumes. In multivariable analysis, postoperative tumor volume was 
inversely correlated with overall survival (HR 1.01 per cm3 increase in volume; 95% 
CI 1.002-1.02; P = 0.016). Therefore, our data supports maximal resection as first-line 
treatment for low-grade glioma. The impact of even small tumor residues was particu-
larly strong in IDH mutated astrocytomas, where even small postoperative volumes 
already negatively affect overall survival.
In chapter 6, we focused on the timing of surgery and the impact on outcome in 
presumed low-grade glioma, but with a set-up wherein we tried to indication and 
selection bias that was present in previous studies. We retrospectively identified a 
cohort of patients in good clinical condition with a presumed low-grade glioma that 
was eligible for an extensive resection. We compared outcome between three types 
of treatment strategies: a wait-and-scan strategy, a biopsy, or early resection. We 
observed no difference in overall survival for early resection compared to wait-and-
scan (HR 0.92; 95% CI 0.43-2.01; p = 0.85). Biopsy as initial treatment strategy was 
associated with a significant shorter overall survival compared to wait-and-scan (HR 
2.69; 95% CI 1.19-6.06; P = 0.02).
In chapter 7, we provide insight in the location distribution of specific WHO molecular 
subgroups of glioma in the human brain. We created heatmaps of anatomic location 
per WHO molecular subgroup of the patients described in chapter 5. We showed there 
are both differences and similarities in spatial distribution between WHO subgroups. 
We found a significant predilection for IDH mutated low-grade gliomas in the rostral 
extensions of the anterior lateral ventricles and for IDH wildtype astrocytomas in het 
basal ganglia of the right hemisphere.
Finally, chapter 8 discusses the main findings of chapters 2 to 7 and put these results 
in perspective with recent literature.
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SaMEnVattinG
Gliomen zijn de meest voorkomende vorm van primaire kwaadaardige hersentumo-
ren. Primair wil zeggen dat deze tumoren ontstaan in het hersenweefsel zelf, een 
wezenlijk verschil met tumoren die elders in het lichaam ontstaan en soms uitzaaien 
naar de hersenen. Gliomen ontstaan uit het steunweefsel dat alom aanwezig is in de 
hersenen, de zogenaamde gliale cellen. Glioom is een overkoepelende term voor de 
verscheidenheid aan verschillende subtypen die worden onderscheiden door de World 
Health Organization (WHO) in de WHO classificatie van hersentumoren. De WHO clas-
sificatie wordt wereldwijd toegepast voor de indeling van gliomen in verschillende 
subtypen en deze vormt een leidraad bij het instellen van de juiste behandeling en het 
informeren van de patiënt over de prognose. De basis van deze classificering was oor-
spronkelijk de beoordeling van enkele gedefinieerde kenmerken van het tumorweefsel 
(histologie) onder de microscoop door de patholoog. De afgelopen jaren is er echter 
steeds meer bekend geworden over de onderliggende DNA mutaties en chromoso-
male afwijkingen in de tumor, en het is gebleken dat gliomen nauwkeuriger zijn in 
te delen in subtypen op basis van deze moleculaire kenmerken. De WHO classificatie 
van hersentumoren werd daarom gereviseerd in 2016, en de subtypering van gliomen 
vind nu naast alleen histologische criteria, ook plaats op basis van moleculaire criteria. 
Bij discrepanties tussen de histologische en de moleculaire kenmerken binnen een 
tumor zijn de moleculaire kenmerken leidend voor het bepalen van het type glioom. 
De nieuwe criteria hebben in de praktijk geleid tot een verschuiving van diagnostische 
groepen en dit heeft consequenties voor de dagelijkse praktijk, gezien behandeling 
en prognose gekoppeld zijn aan deze classificatie. Het is derhalve noodzakelijk om 
enkele aspecten van bijvoorbeeld de behandeling te her-evalueren in het kader van de 
nieuwe classificatie. In dit proefschrift worden de resultaten van verschillende studies 
beschreven naar de prognosestelling en chirurgische behandeling van laaggradige 
gliomen in de context van deze gereviseerde classificatie. In hoofdstuk 1, de algemene 
inleiding, wordt een overzicht gegeven van de WHO criteria en de huidige behandeling 
van laaggradige gliomen.
hoofdstuk 2 beschrijft een analyse van The Cancer Genome Atlas: een openbare da-
tabase met genetische en klinische gegevens van een groot cohort van laag- en hoog-
gradige gliomen. De doelstelling van deze studie was het identificeren van additionele 
prognostische moleculaire markers binnen de door de WHO 2016 erkende glioom 
subtypen. We onderzochten frequent voorkomende chromosomale afwijkingen en 
alle genen met een mutatiefrequentie in de populatie van meer dan 1.7%. In totaal 
waren 57 genen significant gecorreleerd met overleving. Mutaties in het IDH1/2 gen 
waren geassocieerd met de laagste hazard ratio (HR) (relatieve kans op overlijden bij 
een mutatie in het betreffende gen, ten opzichte van geen mutatie), wat bevestigt dat 
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een mutatie in het IDH1/2 gen de belangrijkste prognostische marker is bij diffuse 
gliomen. Middels een subgroep analyse toonden we aan dat mutaties in PI3 kinase 
genen PIK3CA en PIK3R1 bij IDH gemuteerde astrocytomen geassocieerd zijn met 
een slechtere prognose (mediane overleving 3.7 vs. 6.3 jaar; P = 0,02; HR 2,93; 95% CI 
1.16-7.38). We toonden ook aan dat tumorgraad ( een score van 1-4 die de mate van 
agressiviteit aangeeft) nog steeds een onafhankelijke prognostische factor is binnen 
de gedefinieerde moleculaire subgroepen, en dat tumorgraad gecorreleerd is met het 
aantal DNA mutaties in de tumor.
In hoofdstuk 3 onderzochten we de prognostische waarde van frequent voorkomen-
de DNA mutaties en chromosomale afwijkingen in een grote groep van IDH gemu-
teerde graad II gliomen. Trisomie van chromosoom 7 in IDH gemuteerde astrocytomen 
en een mutatie in het PTEN gen in oligodendrogliomen waren geassocieerd met een 
slechtere prognose. We konden dit echter niet bevestigen in een analyse gecorrigeerd 
voor andere prognostische factoren. Ook vonden we geen impact op de prognose van 
verlies van een deel van chromosoom 9, 9p21.3, wat regelmatig wordt gerapporteerd 
als marker van progressie in hooggradige gliomen. Langere follow-up is echter nodig 
voor definitieve conclusies.
In hoofdstuk 4 beschrijven we een grote groep van IDH- wildtype (geen mutatie in 
het IDH gen) laaggradige en anaplastische gliomen en toonden aan dat deze groep 
tumoren zowel moleculair als klinisch zeer heterogeen is. Slechts 52,7% van de pa-
tiënten bleek namelijk een fenotype met trisomie van chromosoom 7 en verlies van 
chromosom 10q te hebben, wat een moleculair kenmerk is van een glioblastoom (de 
meest aggresieve vorm van gliomen). Behoudens één patiënt hadden al deze pati-
enten ook een TERT promoter mutatie. 18,9% van de patiënten had alleen een TERT 
promoter mutatie en had zelfs een slechtere prognose dan patiënten met de klassieke 
moleculaire kenmerken van een glioblastoom (trisomie chromosoom 7 en verlies 10q) 
. Een belangrijke bevinding was dat ongeveer 20% van de patiënten geen van de onder-
zochte mutaties of chromosomale afwijkingen had, en dit was geassocieerd met een 
aanzienlijk langere overleving. Uit deze gegevens blijkt dat aanvullende moleculaire 
diagnostiek naast onderzoek naar het IDH1/2 gen noodzakelijk is voor een adequate 
inschatting van prognose en starten van een juiste behandeling.
In hoofdstuk 5 onderzochten we de mogelijke associatie tussen de uitgebreidheid 
van de operatieve resectie en de prognose bij laaggradige gliomen geclassificeerd 
volgens de WHO 2016 classificatie. De revisie van de WHO classificatie in 2016 maakte 
het noodzakelijk om de rol van chirurgie opnieuw te evalueren. We includeerden 228 
volwassen patiënten die een operatie hadden ondergaan voor een supratentorieel 
gelokaliseerd laaggradig glioom. We onderzochten de uitgebreidheid van de resectie 
door het pre- en postoperatief tumorvolume semi-automatisch te bepalen. In een 
multivariabele analyse was het postoperatieve tumorvolume omgekeerd evenredig 
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gecorreleerd met totale overleving (HR 1.01 per cm3 toename van het postoperatief 
volume; 95% CI 1.002-1.02; P = 0.016). Deze resultaten ondersteunen een maximale 
resectie als eerstelijnsbehandeling voor laaggradige gliomen. Het effect van posto-
peratieve tumorrest was met name sterkt in IDH gemuteerde astrocytomen, waarin 
zelfs zeer kleine postoperatieve tumorvolumes al een negatief effect hadden op de 
overleving.
hoofdstuk 6 richt zich op de timing van de operatie en het effect op de overleving bij 
tumoren die op beeldvorming verdacht zijn voor een laaggradig glioom. Middels een 
unieke studieopzet hebben we geprobeerd de indicatie- en selectiebias te voorkomen 
die aanwezig is in eerdere studies naar de timing van chirurgie. In een retrospectief 
cohort van patiënten in goede klinische conditie met een vermoedelijk laaggradig 
glioom op beeldvorming, en die in aanmerking kwamen voor een uitgebreide operatie, 
vergeleken we de resultaten tussen drie soorten behandelstrategieën: de zogenaamde 
wait-and-see benadering, een biopsie of een vroege resectie. We vonden geen ver-
schil in de totale overleving voor vroege resectie in vergelijking met de wait-and-see 
benadering (HR 0.92; 95% CI 0,43-2.01; p = 0.85). Biopsie als eerste behandelstrategie 
was geassocieerd met een aanzienlijk kortere totale overleving in vergelijking met 
wait-and-see (HR 2,69; 95% CI 1.19-6.06; P = 0,02).
In hoofdstuk 7 geven we inzicht in de anatomische locatie van de door de WHO 
2016 erkende subtypen van laaggradige gliomen. Dit door middel van het genereren 
van heatmaps van de anatomische locatie per WHO 2016 subgroep van de patiënten 
beschreven in hoofdstuk 5. We toonden dat elk subtype een verschillend patroon van 
anatomische verdeling heeft, maar ook dat er overlap bestaat tussen subtypen. IDH 
gemuteerde laaggradige gliomen komen vaker voor anterieur van de laterale hersen-
kamers, en IDH wildtype laaggradige gliomen zijn significant vaker gelokaliseerd in de 
basale kernen van de rechter hemisfeer.
Ten slotte bespreken we de belangrijkste bevindingen van hoofdstukken 2 tot en 
met 7 en plaatsen deze in perspectief met recente literatuur in hoofdstuk 8.
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